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SUMMARY
The effects of pharmacological and pathological manipulations of excitatory 
amino acid receptor-mediated events in the rat brain were investigated using 
quantitative in vivo autoradiographic procedures. [u C]-2-Deoxyglucose in vivo 
autoradiography was used to measure local rates of cerebral glucose utilisation 
in discrete brain regions, following systemic administration of agents acting at 
AMPA and NMDA receptor subtypes, to assess physiological changes in cerebral 
metabolism occurring in response to pharmacological challenge. Secondly, in 
order to assess in vivo the effects of systemic administration of an agent which 
putatively modulates NMDA receptor activity, [1251]-MK-801 in vivo 
autoradiography was used to measure levels of NMDA receptor activation 
throughout the brain. Thirdly, [u C]-2-deoxyglucose in vivo autoradiography was 
used to assess the chronic and acute cerebral metabolic effects of manipulating 
discrete populations of neurones by microinjections of excitatory amino acid 
agonists into the basal forebrain.
AMPA Receptor Blockade
Local cerebral glucose utilisation was examined in 50 discrete CNS regions 
acutely after intravenous administration of the AMPA receptor antagonists 
NBQX (10, 30 and lOOmg/kg) and the novel agent LY-293558 (10, 30 and 
lOOmg/kg) to conscious rats. Both agents markedly depressed glucose use 
throughout the brain, producing anatomically widespread, dose-dependent 
reductions in glucose use in the majority of regions examined. No elevations in 
glucose use were seen in any of the regions examined following administration 
of either agent.
16
Following NBQX (lOOmg/kg), statistically significant decreases in glucose 
use were seen in 48 of the 50 regions investigated, while significant reductions 
following LY-293558 (lOOmg/kg) occurred in 43 regions. The magnitudes of 
the glucose use depression seen following both NBQX (lOOmg/kg) and LY-293558 
(lOOmg/kg) were as great as any previously reported with any pharmacological 
intervention. Rates of glucose utilisation were reduced by 50-68% in many 
auditory, cortical and limbic regions by the highest dose of the AMPA 
antagonists. For example, NBQX (lOOmg/kg) and LY-293558 (lOOmg/kg) reduced 
glucose use by -64% and -68% respectively in the inferior colliculus; -64% and 
-64% respectively in the posterior cingulate cortex; and -50% and -55% 
respectively in sensory motor cortex (layer IV).
The anatomical patterns of reduced glucose use following NBQX and 
LY-293558 were essentially similar. However, in a number of regions subtle 
anomalies were evident in the nature of the response to the two AMPA 
antagonists. For example, LY-293558 was more potent than NBQX by a factor 
of 2-3 in auditory structures, and in a number of limbic and cortical regions. 
In addition, LY-293558 at any dose failed to significantly affect glucose use in 
7 of the regions examined, whereas glucose use was unchanged in 2 regions 
following NBQX. In one of the CNS regions examined, the superficial layer of 
the superior colliculus, glucose utilisation was insensitive to both NBQX and LY- 
293558 within the dose ranges studied.
In this study, the advantages of using the [14C]-2-deoxyglucose 
autoradiography technique to map dynamic functional events in vivo are 
highlighted by its ability to discern subtle dissimilarities in the regional effects 
of the two AMPA antagonists. The glucose use depression produced by AMPA
17
receptor blockade is in marked contrast to the previously reported heterogeneous 
effects of competitive and non-competitive NMDA antagonists.
NMDA Receptor Manipulation
Local cerebral glucose utilisation was investigated in conscious rats acutely 
after intravenous administration of D-cycloserine (0.3, 3 and 30mg/kg), a partial 
agonist at the glycine regulatory site on the NMDA receptor complex. The 
concentration range employed was chosen on the basis of reported dose- 
dependent agonist and antagonist properties of D-cycloserine in vivo. 
D-Cycloserine failed to significantly alter glucose use in any of the 51 brain 
regions examined.
In a separate study, [125I]-MK-801 in vivo autoradiography was used to 
assess NMDA receptor potentiation in the brain by a putative agonist dose of 
D-cycloserine (3mg/kg, i.v.). Results were compared with levels of [125I]-MK- 
801 binding in conscious and anaesthetised rats following intravenous 
administration of vehicle. No significant differences in the concentrations of 
bound [125I]-MK-801 were found between D-cycloserine and vehicle-treated rats, 
in any of the 13 CNS regions investigated, including regions with high 
concentrations of NMDA receptors such as the hippocampus region CA1, and 
posterior cingulate cortex.
In view of the apparent lack of effect of D-cycloserine on cerebral glucose
1 0 Ruse and [ IJ-MK-801 binding in vivo, the effects of D-cycloserine on NMDA
receptor-mediated events were further investigated under pathological conditions 
in the rat brain. Two models of glutamate neurotoxicity were employed: the 
middle cerebral artery (MCA) occlusion model of focal cerebral ischaemia, and
18
a novel model of cortical neurotoxicity produced by intracortical glutamate 
perfusion. Intravenous administration of a putative agonist concentration of 
D-cycloserine (3mg/kg) had no significant affect on the extent of neuronal 
damage produced by MCA occlusion (lesion size: vehicle, 191 ± 30mm3; 
D-cycloserine, 189 ± 40mm3), or by cortical glutamate perfusion (lesion size: 
vehicle, 20.3 ± 1.3mm ; D-cycloserine, 20.3 ± 2.1mm ). The integrity of the 
cortical lesion model was verified by the demonstration of neuroprotection by 
pretreatment with the AMPA receptor antagonist NBQX (30mg/kg) (lesion size: 
vehicle, 14.4 ± 0.7mm3; NBQX, 11.1 ± 0.7mm3).
The results of these studies highlight a situation in which quantitative in 
vivo [14C]-2-deoxyglucose and [125I]-MK-801 autoradiography techniques fail to 
provide insight into the functional consequences of a pharmacological 
manipulation.
Basal Forebrain Manipulations
The chronic effects of excitotoxic basal forebrain lesions on local cerebral 
glucose utilisation were assessed in 49 brain regions chronically (3 weeks) after 
infusions of ibotenic acid, NMDA, quisqualic acid or AMPA into the nucleus 
basalis magnocellularis (NBM) region, which provides the major cholinergic 
innervation of the neocortex. No significant alterations in glucose utilisation 
were evident in any of the brain regions examined, including 11 cortical regions, 
following ibotenate, NMDA, quisqualate or AMPA-induced NBM lesions. Trends 
towards reduced glucose use in frontal cortical regions were evident following 
AMPA-induced lesions, most marked in medial prefrontal cortex (vehicle: 83 ± 
3, AMPA: 67 ± 6, mean ± SEM punol/lOOg/min). The lack of significant
19
alterations in cerebral glucose use levels 3 weeks post-lesion supports previous 
reports of compensatory functional adaptation following denervation in the brain, 
despite biochemical evidence of sustained deficiencies in other indices of 
functional activity (e.g. cholineacetyltransferase, ChAT activity).
In a separate series of experiments, the acute effects of basal forebrain 
neuronal stimulation on cerebral glucose use were investigated in conscious rats 
following excitatory amino acid agonist infusions into the NBM. Infusions of 
NMDA and AMPA resulted in significant alterations in glucose use in cortical 
regions innervated by NBM efferents. Glucose use was significantly reduced 
in 10 cortical regions following AMPA, (for example, by -27% in medial 
prefrontal cortex, -23% in sensory motor cortex (layer IV), and -25% in anterior 
cingulate cortex), and in two cortical regions following NMDA (for example, by - 
26% in prefrontal cortex). Both agents also induced heterogeneous alterations 
in glucose utilisation in a number of subcortical regions corresponding to primary 
and secondary striato/pallidal projection targets, including the substantia nigra 
(pars reticulata and pars compacta), the entopeduncular nucleus, subthalamic 
nucleus, and lateral habenular nucleus. The glucose use alterations in 
subcortical regions distal to the infusion site appear to be associated with the 
marked hypermetabolic effects of AMPA and NMDA in regions anatomically 
close to the infusion site, including striatum and globus pallidus. The effects 
of excitatory amino acid infusions were compared with the cerebral metabolic 
sequelae of infusion of the GABAa agonist muscimol into the NBM region. 
Muscimol did not significantly alter rates of glucose utilisation in neocortical 
regions, or in the vicinity of the infusion site. However, muscimol did induce 
heterogeneous alterations in glucose use in a number of subcortical nuclei,
20
including entopeduncular nucleus and substantia nigra.
The studies in this thesis serve to highlight both the strengths and 
weaknesses of using autoradiographic approaches to map functional events in 
vivo. In particular, it is evident that the unique opportunity afforded by the 
l14C]-2-deoxyglucose technique, to assess alterations in cerebral metabolic 
activity in terms of local cerebral glucose use, is optimally exploited in 
conditions of acute pharmacological or pathological challenge where dynamic 
functional changes are likely to occur.
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PREFACE AND DECLARATION
This thesis presents results from autoradiographic studies in rat brain, 
investigating the functional consequences of manipulating glutamatergic systems 
within the CNS. The principal technique used was quantitative [14C]-2- 
deoxyglucose autoradiography, to measure local cerebral glucose utilisation in 
vivo. [ I]-MK-801 autoradiography was used to assess NMDA receptor
activation in vivo. The effects of glutamatergic agents on glutamate-induced 
lesions were also assessed histologically.
Investigations were conducted in three broadly defined areas:
1. The effects of intravenous administration of AMPA receptor antagonists 
on local cerebral glucose use in the rat.
2. The effects of intravenous administration of the NMDA receptor glycine 
site partial agonist D-cycloserine on local cerebral glucose use, l125I]- 
MK-801 binding, and on glutamate-induced neuronal damage.
3. The chronic and acute effects of basal forebrain manipulations on local 
cerebral glucose use.
Results from these studies are presented and discussed separately. In 
the final overview I have attempted to highlight the advantages and limitations 
of using quantitative autoradiographic techniques to assess putative functional 
alterations in the CNS.
This thesis comprises my own original work and has not been presented 
previously as a thesis in any form.
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CHAPTER I 
INTRODUCTION
THE ROLES OF GLUTAMATE WITHIN THE CNS
Glutamate Is The Major Excitatory Neurotransmitter In The CNS.
Glutamate is a non-essential amino acid found in abundance in the 
central nervous system (CNS) where it subserves a number of different roles. 
For many years glutamate has been known to be intimately involved in 
intermediary metabolism in the CNS, with roles in the Krebs Cycle (Krebs, 
1935), in the detoxification of ammonia in the brain (Weil-Malherbe, 1950), 
as a precursor of the inhibitory neurotransmitter y-aminobutyric acid, GABA 
(Roberts and Frankel, 1950), and is involved in peptide and protein synthesis 
(Meister, 1979). However, an increasingly large body of physiological and 
biochemical evidence indicates that, in addition, glutamate is the major 
excitatory neurotransmitter within the CNS.
A transmitter role for endogenous amino acids including glutamate and 
aspartate was first proposed in the 1950s following observations that these 
compounds could activate CNS neurones. In 1954 Hayashi found that topical 
application of sodium-glutamate to neocortex of dogs, monkeys and humans 
resulted in "clonic convulsions", while in initial electrophysiological studies 
Curtis e t al., (1960) demonstrated that microiontophoretic application of 
glutamate to single spinal neurones increased their firing rate. Subsequent 
structure-activity relationship studies of glutamate analogues identified 
L-glutamate and l - aspartate as the leading candidates for endogenous 
excitatory neurotransmitters in the mammalian CNS (Curtis and Johnston, 
1974).
Evidence supporting the concept of glutamate as a neurotransmitter in 
the CNS has been extensively reviewed (Di Chiara and Gessa, 1981; Fonnum,
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1984; Collingridge and Lester, 1989; Monaghan et al. 1989; Headley and
Grillner, 1990). Briefly, there are four main criteria which compounds must
satisfy to warrant classification as a neurotransmitter. These are:-
a) Presynaptic localisation in specific neurones.
b) Release in response to physiological stimuli in concentrations high 
enough to evoke a post-synaptic response.
c) The existence of mechanisms to rapidly terminate transmitter activity.
d) Their actions must be compatible with those of the naturally occurring 
transmitter, for example in response to antagonists.
Glutamate satisfies these criteria to varying degrees, as is briefly described
below.
a) Presvnaotic Neuronal Location
Attempts to locate glutamate-releasing nerve terminals have been 
complicated by the diversity of glutamate-mediated functions within 
the CNS and the existence of multiple metabolic pools of glutamate. 
At present no precursors or synthetic enzymes are known to be specific 
for the transmitter pool of glutamate, and hence no reliable enzyme 
marker for glutamatergic terminals is yet available. However, support 
for a presynaptic localisation of glutamate in terminals has been 
provided by the demonstration of selective, adenosine triphosphate (ATP) 
- dependent uptake of exogenous glutamate into synaptic vesicles (Naito 
and Ueda, 1985). Further, the pattern of glutamate-like 
immunoreactivity in synaptic vesicles in neuronal terminals has been 
found to be similar to the previously reported distribution of high-
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affinity glutamate uptake sites in rat brain (Ottersen and Storm- 
Mathisen, 1984b; Fonnum, 1984). More recently, the identification of 
carrier-mediated glutamate uptake mechanisms in neuronal terminals has 
further supported a presynaptic localisation of glutamate. A Na+- 
dependent glutamate uptake carrier has been identified in presynaptic 
neuronal (and glial) plasma membranes, while the discovery of a Na+- 
independent vesicular glutamate transporter has demonstrated
I compartmentalisation of a presumed transmitter pool of glutamate into 
synaptic vesicles within the presynaptic terminal, from where exocytotic 
vesicular release occurs (Nicholls and Attwell, 1990; see also b) and c) 
below).
b) Glutamate Release from Neurones bv Physiological Stimuli
Substantial evidence is available that glutamate is released from 
neurone terminals in response to physiological stimuli (Fonnum, 1984; 
Greenamyre, 1986; Headley and Grillner, 1992; for review see Nicholls, 
1993). Membrane depolarisation, by means of electrical or 
pharmacological stimulation, has been demonstrated to induce calcium 
(Ca2+) -dependent glutamate release in brain slice preparations 
(Potashner, 1978), in isolated neurone terminal (synaptosome) 
preparations (for review see Nicholls and Attwell, 1990; McMahon and 
Nicholls, 1991), and in vivo by means of microdialysis techniques 
(Hamberger et al., 1983).
There are several examples of synaptic aspartate/glutamate release 
following stimulation of specific nerve pathways in vitro. For example,
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exogenously added D-aspartate or L-glutamate is released in hippocampal 
slice preparations by stimulation of the Schaffer collateral pathway or 
the commissural pathway, and from the lateral septum in the septum- 
fimbria preparation (for review see Fonnum, 1984). In addition, Collins 
(1980) demonstrated release of endogenous amino acids after stimulation 
of the lateral olfactory tract in the olfactory cortical slice preparation. 
Glutamate release in a number of anatomical pathways has also been 
demonstrated in vivo. For example, Abdul-Ghani et al., (1979) reported 
glutamate release from the sensorimotor cortex after stimulation of the 
contralateral bronchial plexus, while Granata and Reis (1983) found that 
vagus nerve stimulation induced glutamate and aspartate release in the 
nucleus tractus solitarius region.
Early studies suggested that the amino acid transmitters were 
released directly from cytoplasm in nerve terminals (for review see 
Fonnum, 1984). However recent advances have identified a vesicular 
release mechanism. In 1989 Nicholls reported that prolonged
depolarisation of cortical or hippocampal guinea-pig synaptosome
2+preparations, by KC1 application, resulted in Ca -dependent release of 
15% of the total synaptosomal glutamate content. Further studies 
indicated that this release occurred from a vesicular compartment by 
means of exocytosis, probably triggered by a high cytoplasmic calcium
A
concentration, [Ca ]i (Nicholls and Attwell, 1990). However, there is 
also evidence of carrier-mediated Ca2+-independent release of 
cytoplasmic glutamate occurring in circumstances of chronic plasma 
membrane depolarisation. Although this carrier-mediated glutamate
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release, putatively due to reversal of the plasma membrane glutamate 
uptake carrier, is negligible during the millisecond time-course of normal 
physiological depolarisation, it does appear to contribute to the massive 
release of glutamate occurring in excitotoxic situations such as 
ischaemia (for review see Nicholls and Attwell, 1990; Nicholls, 1993).
There is also evidence from in vitro studies that a number of 
endogenous neurotransmitter systems may be involved in the regulation 
of glutamate release. For example, phorbol esters have been found to 
increase glutamate release from synaptosomes by 30% (Diaz-Guerra et 
al., 1988), while other agents including GABAb, adenosine and muscarinic 
receptor agonists have been shown to reduce glutamate release in 
synaptosome preparations (Burke and Nadler, 1988; Marchi et al., 
1989).
c) Rapid Termination of Neurotransmitter Activity
Mechanisms for rapid termination of transmitter activity, by 
removal of the excitatory amino acids from the synaptic cleft, are vital 
to maintain normal physiological extracellular glutamate concentrations 
(approximately I jjlM )  and hence avoid the excitotoxic effects of sustained 
high concentrations of glutamate. A sodium-dependent high-affinity 
uptake carrier is responsible for transport of L-glutamate and d-  and l -  
aspartate, against a concentration gradient, into both presynaptic 
neuronal terminals and glial cells (Nicholls and Attwell, 1990; Schousboe 
et al., 1992). Glutamate uptake into glial cells has also been shown to 
be K+-dependent, reduced intracellular K+ or raised extracellular K+
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levels inhibiting uptake (Barbour et al., 1988). Neuronal glutamate 
uptake can be inhibited by membrane depolarisation, while glial uptake 
can be blocked by arachidonic acid (Barbour et al., 1989). The latter 
may be an important observation since there is evidence of arachidonic 
acid release into the extracellular space following activation of post- 
synaptic NMD A receptors (Dumuis et al., 1988) which could contribute 
to the high extracellular levels of glutamate seen in ischaemia. 
Inhibition of the sodium-dependent high affinity uptake system 
for glutamate, prolongs the excitatory action of L-glutamate (Johnston 
et al. 1980), confirming the importance of this uptake system in 
terminating glutamate’s synaptic activity.
Glutamate taken up into astrocytes is converted into glutamine by 
glutamine synthetase (for review see Schousboe et al., 1992). Glutamine 
is then released from the glial cells into the extracellular space from 
where it is taken up into the presynaptic terminal by a low affinity Na+- 
dependent pathway (McMahon and Nicholls, 1990). It has been 
postulated that glutamine is converted to cytoplasmic glutamate by 
mitochondrial glutaminase, although this step has yet to be confirmed. 
Glutamate is then transported into synaptic vesicles by a Na+- 
independent, glutamate-specific transport system, reliant on an internal 
positive membrane potential which is maintained by an ATP-ase pump 
moving protons into the vesicle (Nicholls and Attwell, 1990).
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d) Compatible Action With Endogenous Neurotransmitter
The synthesis of a number of specific agonists and antagonists has 
been an important factor in the identification and characterisation of 
glutamate receptors and glutamatergic pathways. In particular, the 
employment of excitatory amino acid receptor antagonists in a great 
number of studies has provided unequivocal support for glutamate’s 
neurotransmitter role, by blocking post-synaptic responses to both 
exogenous glutamate, and the endogenous transmitter in vivo. As a 
consequence, multiple distinct post-synaptic receptor types have been 
identified (which will be discussed in detail in Section 1.2). Briefly, 
these are the ionotropic (ion channel-associated) NMDA, AMPA and 
kainate (KA) receptors, and the metabotropic receptor. At present, 
the most potent and specific antagonists have been developed for the 
NMDA receptor subtype. NMDA antagonists have been shown to block 
excitation of corticofugal fibres in the cuneate nucleus, caudate nucleus 
and cerebral cortex following cortical stimulation (Stone, 1979). In 
addition, Cotman e t al. (1981) have demonstrated the existence of a 
number of glutamatergic pathways in the hippocampus which are 
differentially susceptible to blockade by different classes of glutamate 
receptor antagonists. Studies employing NMDA antagonists have also 
indicated that NMDA receptor activation is necessary for the induction 
and maintenance of long term potentiation (LTP), the mechanism of 
enhanced synaptic activity which is thought to be a critical component 
of learning and memory processes (Collingridge and Bliss, 1987; Ben- 
Ari et al., 1992).
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Taken together these observations have led to glutamate being accepted 
as the major excitatory neurotransmitter in the mammalian CNS. In addition, 
evidence of the effects of lesions on high-affinity uptake and release have 
been useful in identifying the components of glutamatergic pathways, although 
the necessity of glutamate uptake for metabolic processes makes 
interpretation of such studies difficult (for review see Headley and Grillner, 
1990).
There is still the possibility that L-aspartate and other amino acids may 
also contribute to excitatory transmission in the CNS. Ca+-dependent 
release of endogenous L-aspartate from isolated terminal preparations has 
previously been demonstrated, although it constitutes at most only 10% of the 
amount of Ca2+-dependent glutamate release (McMahon and Nicholls, 1990), 
which would be consistent with the observed specificity of the synaptic 
vesicle uptake carrier for L-glutamate alone (Nicholls and Attwell, 1990). 
Three other agents also partially fulfil the criteria for transmitters at 
synapses mediated by excitatory amino acid receptors. For instance, 
N-Acetyl-aspartylglutamate (NAAG) has been found to be selectively 
distributed in the CNS, with highest levels found in the spinal cord and hind 
brain, and lower levels in the forebrain. Evidence suggests that NAAG may 
be localised in presynaptic terminals, it has been shown to displace [3H] 
glutamate binding in some CNS regions, and it also has identity of action with 
the endogenous transmitter in several pathways. In particular, NAAG has 
been implicated as the transmitter at the lateral olfactory tract - piriform 
cortex synapse, where evidence suggests glutamate and aspartate are not the 
principle transmitters (Ffrench-Mullen et al., 1985). Secondly, quinolinate, an
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endogenous kynurenene acting primarily on NMDA receptors, also fulfils many 
of the criteria for neurotransmitter status, but has not yet been shown to be 
released by physiological stimuli (Stone and Burton, 1988). In addition, l- 
homocysteate has been postulated to have a neurotransmitter role on the basis 
that it can be released from many brain regions by veratridine-induced 
depolarisation (Do et al., 1986).
1.2 Glutamate Receptor Subtype Classification
The recent development of a large number of excitatory amino acid 
antagonists has led to the discovery that several distinct receptor types 
mediate excitatory synaptic transmission induced by glutamate and its 
congeners (for reviews see Collingridge and Lester, 1989; Monaghan et al., 
1989; Watkins et al., 1990). To date five receptor classes have been 
identified, of which three are ion-channel-linked (ionotropic) receptors, named 
after their preferred agonists:- N-methyl-D-aspartate (NMDA), kainate (KA), 
and a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA). The
fourth is the metabotropic receptor, which is linked to a second messenger 
system, and is preferentially activated by quisqualate and trans-1- 
aminocyclopentane-l,3-dicarboxylic acid (tra/is-ACPD). Finally, a putative 
presynaptic autoreceptor sensitive to L-2-amino-5-phosphonobutyrate (l-AP4) 
has been described although this receptor is the least well characterised at
present. (For summary see Table 1, page 50.)
The identification of NMDA, KA and AMPA receptors arose largely 
from two lines of evidence:- differential sensitivity analysis (rank 
ordering of agonist potency in different neuronal types) and studies of
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FIGURE 1: SCHEMATIC REPRESENTATION OF THE NMDA 
RECEPTOR-CHANNEL COMPLEX
pharmacological antagonism. The endogenous amino acids L-glutamate 
and L-aspartate have mixed agonist activity, glutamate acting at all receptor 
subtypes whereas L-aspartate is relatively selective for the NMDA receptor 
(for review see Mayer and Westbrook, 1987a). Stimulation of KA and AMPA 
receptor subtypes induces generation of fast excitatory post-synaptic 
potentials (EPSPs), whereas the NMDA receptor can only be activated after 
depolarisation and appears to be involved in amplification of excitatory 
responses (MacDermott and Dale, 1987). This property has led to the 
proposal of critical roles for NMDA receptors in the mechanisms of synaptic 
plasticity and induction and maintenance long-term potentiation (LTP), 
involvement in burst firing such as that seen in epilepsy, and a role in the 
induction of neuronal degeneration in certain pathological conditions.
1.2.1 The NMDA Receptor
The availability of high affinity agonists and antagonists, and the use of 
radioligand binding assays, has meant that NMDA receptors are to date the 
most fully characterised of the glutamate receptor subtypes (for review see 
Cotman and Iversen, 1987). The signal transduction and pathophysiological 
properties of the NMDA receptor-channel complex depend on three major 
characteristics of the complex:- its voltage-dependence, Ca2+ permeability, 
and the existence of a number of functional domains at which receptor 
activity can be modulated (see Figure 1).
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Channel Properties
NMDA receptor activation by glutamate, aspartate and related amino 
acids evokes a voltage-dependent conductance in neurones by opening the 
receptor complex-associated cation-permeable ion channel. Under 
physiological conditions NMDA receptor agonists induce an inward current, 
carried by an influx of Na+ ions and balanced by an efflux of K+ ions (Mayer 
and Westbrook, 1987a; Ascher and Nowak, 1987).
At resting membrane potentials the channel is voltage-dependently 
blocked by Mg2+ which binds to a site within the channel (Mayer and 
Westbrook, 1987b; Ascher and Nowak, 1987; Bekkers and Stevens, 1993). This 
phenomenon is thought to underlie the voltage-dependency of NMDA-mediated 
firing (for review see MacDonald and Nowak, 1990). In vitro studies have 
demonstrated that addition of physiological concentrations of Mg2+ to 
hippocampal cells in magnesium-free solutions prevents NMDA-evoked 
neuronal firing, unless the cell membrane is depolarised sufficiently to remove
A ,
the Mg ion channel blockade (Ascher and Nowak, 1987).
The NMDA receptor channel is permeable to Ca2+, hence linking NMDA 
receptor activation to a number of physiological and pathological events 
(MacDermott et al., 1986; Mayer and Westbrook, 1987b; Ascher and Nowak, 
1988b). Ca2+ mediates activity in a variety of intracellular biochemical
A  ,
processes, and Ca influx via the NMDA receptor channel (rather than 
through voltage-sensitive Ca2+ channels) has been proposed to contribute to 
the induction of long-term potentiation (LTP) (Malenka e t al., 1988), and to 
excitotoxic neuronal degeneration (Choi, 1987; Abele e t al., 1990; see also 
Section 2.1).
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Recent in vitro studies have indicated that channel activity may also be 
regulated by pH. Electrophysiological recordings from hippocampal neurones 
suggest that H+ can attenuate NMDA receptor-mediated ion influx (Morad et 
al., 1988), while mild acidosis has been shown to abolish NMDA-activated 
Ca2+ currents, and to attenuate glutamate neurotoxicity and hypoxic neuronal 
injury in neuronal cultures (Giffard e t al., 1990; Tombaugh and Sapolsky, 
1990). Consequently, the voltage-independent nature of the H+ blockade has 
led to the proposal of a putative H+ site near the external membrane surface 
of the NMDA receptor complex.
NMDA receptor-induced synaptic currents are characteristically slow in 
onset and of long duration, decaying over several hundred milliseconds. It 
has been speculated that this long time-course is due to constant reactivation 
of the receptor by residual glutamate (D*Angelo et al., 1990), however a 
recent study by Lester and colleagues (1990) suggests that this is not the 
case. Lester et al., found that the long-lasting NMDA channel activity 
(induced in membrane patches from cultured hippocampal neurones by 
application of pulses of glutamate) could be terminated instantaneously by 
addition of Mg2+ but was unaltered by application of the NMDA recognition 
site antagonist 2-amino-5-phosphonopentanoate (AP5). These results suggest 
that glutamate does not constantly unbind and rebind to the recognition site, 
but that the long duration is directly related to the slow dissociation rate of 
glutamate from the receptor (Lester et al., 1990; Pan et al., 1993). Thus 
agonists with lower affinity for the recognition site, such as aspartate, evoke 
shorter duration NMDA-mediated synaptic currents. This observation may 
have some bearing on the understanding of pathophysiological events mediated
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by EAA receptors under conditions in which the proportions of glutamate and 
aspartate may be disturbed (Burke and Nadler, 1988).
Pharmacological/Regula tory Domains
Five distinct sites with potential for pharmacological or regulatory 
functions have so far been identified on the NMDA receptor complex.
a) The transmitter recognition site: NMDA receptors are defined by their 
high selectivity for a number of ligands including NMDA, NMLA, 
aspartate and ibotenate (Collingridge and Lester, 1989; see Watkins et 
al., 1990), and Gs-2,4-methanoglutamate which is the most potent and 
selective NMDA receptor agonist known to date (Lanthorn et al., 1990). 
Competitive NMDA receptor antagonists such as 3-(2-carboxypiperazin- 
4-yl)propenyl-l-phosphonate (CPP-ene) and 2-amino-4-methyl-5- 
phosphono-3-pentanoic acid (CGP-37849) exert their inhibitory action via 
blockade of the transmitter recognition site (Aebischer et al., 1989; 
Watkins et al., 1990).
b) The glycine regulatory site: NMDA receptor action is enhanced by
glycine, an inhibitory neurotransmitter in the CNS (for review see Foster 
and Kemp, 1989; Kemp and Leeson, 1993). Johnson and Ascher (1987) 
first showed that glycine increased the frequency of NMDA-induced 
channel opening in cultured neurones and suggested a mechanism of 
allosteric regulation of the NMDA receptor complex through a distinct 
glycine binding site. This co-agonist action of glycine has been shown
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to be strychnine-insensitive and thus unrelated to its established role as 
an inhibitory neurotransmitter in the brainstem and spinal cord, which 
is mediated by a strychnine sensitive chloride conductance. The idea 
that the glycine site is an integral part of the NMDA receptor complex 
is supported by evidence from in vitro autoradiographic ligand binding 
studies of a high degree of co-localisation of strychnine-insensitive [3H]- 
glycine binding sites with NMDA receptors (Monaghan and Cotman, 1985; 
Bristow et al., 1986), as well as with NMDA receptor channel-associated 
PCP binding sites labelled by [3H]-MK-801 and [3H]-TCP, in rat brain 
(Bowery et al., 1988; Maragos et al., 1988) and in human hippocampus 
and neocortex (Jansen et al., 1989 a and b). Following the cloning of 
a functional NMDA receptor subunit, Moriyoshi et al., (1991) have 
subsequently shown that both the transmitter- and glycine-recognition 
sites are colocalized on the same protein. D-Serine and o-alanine also 
bind with high affinity to this strychnine-insensitive glycine binding site. 
D-serine has subsequently become the agonist of choice in 
pharmacological studies of the glycine site due to its lack of affinity for 
both the glycine uptake system and the strychnine-sensitive glycine 
receptor (Johnson and Ascher, 1987).
It has recently been demonstrated that glycine binding is an absolute 
requirement for NMDA receptor activation. Kleckner and Dingledine 
(1988) found that while glycine potentiated the responses of NMDA 
receptors expressed in Xenopus oocytes, no NMDA receptor current 
could be elicited in the absence of glycine. Glycine enhancement of 
glutamate-induced synaptic responses has been further supported by
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biochemical, electrophysiological and autoradiographical studies both in 
vitro and in vivo (Bonhaus et al., 1987; Snell et al., 1987; Wong et al., 
1987; Salt et al., 1989; Thomson et al., 1989; Lester et al., 1993), and 
evidence from radioligand binding studies which implicates reciprocal 
enhancement of glutamate and glycine binding (Fadda e t al., 1988; 
Monaghan et al., 1988; Hood et al., 1990). It has also been proposed 
that glycine may exert its potentiating action on NMDA receptor 
activity by preventing receptor desensitization during prolonged agonist 
exposure, via a mechanism accelerating the receptor’s recovery from 
it desensitized state (Mayer et al., 1989).
As a consequence of the interdependence of the glycine and 
glutamate co-agonist sites, modulation of the glycine site has been used 
experimentally to manipulate NMDA receptor activity. A number of 
ligands which bind at the glycine site are currently available, including 
the broad spectrum excitatory amino acid receptor antagonists 
kynurenate and 7-chlorokynurenate. (+)-HA-966 (3-amino-1-
hydroxypyrolid-2-one), (+)-c/s-4-methyl-HA-966, and D-cycloserine are 
partial agonists at the glycine modulatory site, exhibiting dose-dependent 
agonist and antagonist properties (Watson et al., 1990; Emmett et al., 
1991; for review see Kemp and Leeson, 1993).
c) The PCP channel binding site: A number of chemically dissimilar
compounds have been classified as non-competitive NMDA antagonists, 
acting at a site functionally distinct from the transmitter recognition 
site. These include "dissociative anaesthetics" such as ketamine
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and TCP (N-[I-thienyl]-cyclohexyl-3,4-piperidine), PCP (N-[I- 
phenylcyclohexyll-piperidine; phencyclidine), and benzomorphan sigma 
opiates such as SKF 10047 (N-allyl-normetazocine) (Kemp et al., 1987; 
Lodge and Johnson, 1990). The most potent of this class of compounds 
is MK-801 ((+)-5-methyl-10,l 1-dihydro-5H-dibenzo[a,d]cyclohepten- 
5,10-imine maleate, dizocilpine; Clineschmidt et al., 1982; Kemp et al., 
1987). Antagonism of NMDA-receptor mediated responses by these 
agents is voltage- and use-dependent, i.e. the receptor must first be 
activated by an agonist before antagonism can occur. It therefore 
follows that antagonism is induced by agents binding at a site inside the 
open NMDA receptor-associated ion channel, resulting in blockade of 
transmembrane ion fluxes (Honey et al., 1985; Huettner and Bean, 1988; 
MacDonald and Nowak, 1990).
d) The polyamine modulatory site: The modulatory action of polyamines 
on NMDA receptor activity was first identified when polyamines were 
found to increase the level of [3H]-MK-801 binding induced by glutamate 
and glycine (Ransom and Stec, 1988). Subsequent studies have suggested 
the existence of a specific site in the NMDA receptor complex at which 
the polyamines spermine and spermidine act as agonists, and putrescine 
and arcaine are antagonists (for review see Scott e t al., 1993). Further 
in vitro studies have shown that spermidine enhances NMDA-induced 
currents in cultured neurones (Sprosen and Woodruff, 1990), while the 
competitive inhibition of NMDA-evoked release of [3H]-noradrenaline 
from brain slices induced by arcaine can be overcome by spermidine
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application (Sacaan and Johnson, 1990). Spermidine has also been found 
to potentiate NMDA-evoked seizures in vivo (Singh et al. 1990). In 
addition, the neuroprotective drug ifenprodil appears to be a non­
competitive antagonist at this polyamine site (Reynolds and Miller, 
1989).
  « a
e) The Zn binding site: Zn , a cation which is present in high
concentrations in the CNS and which has been shown to be released 
from synaptic terminals upon excitation, non-competitively inhibits 
NMDA receptor activation in hippocampal and cortical neurones 
(Westbrook and Mayer, 1987). As a consequence of the voltage- 
dependent nature of Zn2+ blockade, and the observations that Zn2+ 
reduces the dissociation rates of [3H]-TCP and [3H]-MK-801 binding in 
rat cortical membranes (opposite to the effects of Mg2+), a Zn2+ binding 
site has been proposed, putatively situated within the NMDA receptor- 
associated channel near the extracellular surface, but distinct from the
Mg2+ site (Reynolds and Miller, 1988). However, both voltage-dependent
2+and -independent properties of Zn action have been identified, 
suggesting that Zn2+-induced blockade may involve a reduction in the 
frequency of channel opening (Mayer and Vyklicky, 1989). In addition, 
Yeh and colleagues (1990) found that Zn2+ non-competitively inhibited 
[3H]-glycine binding, and speculated that Zn2+ may have a physiological 
role to reduce tonic activation of the NMDA receptor by glycine, thus 
reducing channel opening frequency. Therefore, although the exact 
nature of its receptor interaction is still unclear, Zn2+ may play a role
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in the regulation of NMDA receptor-mediated processes in the CNS.
Protein phosphorylation of NMDA receptors has also been implicated as 
an important component of modulatory control of receptor activity (for 
review see Raymond et al., 1993). Protein kinase-catalysed phosphorylation, 
at sites on the cytoplasmic domain of the receptor complex, are proposed to 
result in alterations in the charge and/or conformation of the receptor. 
Involvement of phosphorylation processes in the mechanism of synaptic 
plasticity underlying LTP has been proposed, on the basis of observations that 
protein kinase inhibitors block the induction and maintenance of LTP while, 
conversely, phorbol esters enhance synaptic transmission in hippocampal CA1 
region (Ben-Ari et al., 1992).
Molecular Biology o f NMDA Receptors
Molecular biological techniques have only recently yielded information 
on the subunit structure of NMDA receptors (for review see Seeburg, 1993). 
Within the last two years two subunit types have been cloned, the NRI subunit 
(Moriyoshi et al., 1991) which occurs in different splice forms with different 
pharmacological properties and the NR2 type of which four subunits (NR2A - 
NR2D) are known to date (Kutswada et al., 1992; Monyer, 1992; also see 
Seeburg, 1993). Homomeric expression of NRI forms ion channels which 
exhibit characteristic NMDA receptor channel properties. These include a 
requirement for both glycine and a transmitter site agonist (glutamate or
A
NMDA) to activate the channel, Ca permeability, voltage-dependent 
sensitivity to Mg2+, and channel blockade by MK-801. NR2 subunits do not
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appear to form receptor channels by themselves, but seem to have a 
modulatory role, since heteromeric NMDA receptors display different 
properties depending on which of the NR2 subunits is co-expressed with NRI. 
These effects of NR2 subunits include differences in receptor sensitivity to 
glycine, the strength of Mg2+ blockade, and deactivation kinetics (Monyer et 
al., 1992).
Examination of the expression patterns of mRNAs encoding the NMDA 
receptor subunits indicates that NRI mRNA is present in most neurones in 
the brain (Moriyoshi et al., 1991). In contrast, the NR2 mRNAs show distinct 
expression profiles, which have been suggested to underlie the differences in 
NMDA receptor properties in different neuronal populations (Monyer et al., 
1992; Sugihara e t al., 1992).
1.2.2 The AMPA Receptor
This ionotropic glutamate receptor subtype was originally known as the 
"quisqualate” receptor, since it was initially identified on the basis of 
excitatory neuronal responses to quisqualate and L-glutamate, which are 
selectively blocked by L-glutamic acid diethyl ester, GDEE (Haldeman and 
McLennan, 1972). Subsequently, the GDEE-sensitive excitant a-amino-3- 
hydroxy-5-methyl-4-isoxazole propionic acid, AMPA, has superseded 
quisqualate due to its much greater selectivity for this receptor (Krogsgaard- 
Larsen et al., 1980; Honor6 et al., 1982). Characterisation of the AMPA 
receptor was initially hampered by the lack of selective antagonists, until the 
recent development of the quinoxalinediones, a class of potent non-NMDA 
receptor antagonists (Honore et al., 1988). 2,3-Dihydroxy-6-nitro-7-
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sulfamoyl-benzo(F)quinoxaline (NBQX) is the most potent centrally active 
AMPA antagonist of this class known to date (Sheardown et al., 1990). 
NBQX exhibits 30-fold higher affinity for AMPA receptors than for kainate 
receptors in the CNS, and has no affinity for NMDA receptor binding sites. 
Other quinoxalinediones such as 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) 
and 6,7-dichloroquinoxaline-2,3-dione (DNQX) also antagonise AMPA receptor- 
evoked responses (Honore et al., 1988). However, these agents exhibit a much 
lower degree of selectivity between AMPA and kainate receptors than NBQX, 
being only 4-5 fold more potent inhibitors of [3H]-AMPA binding than of 
[3H]-kainate binding. In addition, CNQX and DNQX bind with low affinity at 
the glycine modulatory site on the NMDA receptor complex. The utility of 
CNQX and DNQX to block AMPA-mediated responses in vivo is further 
limited by the observation that these agents are not centrally active following 
systemic administration (Honore e t al., 1988).
Channel Properties
AMPA receptor agonists activate conductance channels which exhibit 
little voltage-dependence, are permeable to Na+ and K+, and which may be 
either permeable or impermeable to Ca2+ (Mayer and Westbrook, 1987 a and 
b; Ascher and Nowak, 1988a; lino et al., 1990; Miller et al., 1992; see also 
Section 1.2.3). Electrophysiological evidence that fast synaptic responses are 
blocked primarily by non-NMDA antagonists and that AMPA receptor 
stimulation desensitises rapidly (<lms) suggests that AMPA receptors mediate 
fast depolarising responses at the majority of excitatory synapses in the CNS 
(for review see MacDermott and Dale, 1987; Collingridge and Lester, 1989).
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Pharmacological Regulation
As well as the ligands already described which act at the transmitter 
recognition site, a number of other agents can modulate AMPA receptor 
activity. These include receptor antagonism by barbiturates (Simmonds and 
Horne, 1988), and potentiation by Zn2+ (Koh and Choi, 1988). Recently the 
benzodiazepine compound GYKI-52466 (l-(4-aminophenyl)-4-methyl-7,8- 
methylendioxy-5H-2,3-benzodiazepine) has been shown to have non­
competitive AMPA receptor antagonist properties; i.e. blockade of excitatory 
responses evoked by glutamate and quisqualate (but not NMDA or KA) in 
electrophysiological studies in the rat, and selective blockade of AMPA- and 
KA- (but not NMDA-) induced seizures in mice (Tarnawa, 1990; Zorumski et 
al., 1993; for review see Rogawski, 1993). The sites of action of these agents 
at the AMPA receptor complex have yet to be elucidated.
1.2.3 The Kainate Receptor
A third class of ionotropic glutamate receptors, preferentially activated 
by kainate (KA), was initially proposed on the basis that kainate-induced 
excitatory responses in cat spinal cord were found to be relatively insensitive 
to NMDA antagonists or the AMPA/quisqualate antagonist GDEE (McLennan 
and Lodge, 1979). Kainate and domoate are potent agonists a t the 
transmitter recognition site, while glutamate and AMPA show only moderate 
activity. Receptor activation opens a cation channel permeable to Na+, K+ 
and in some circumstances Ca2+ (Miller e t al., 1992). However there is some 
controversy surrounding the existence of a physiologically distinct KA 
receptor, some investigators suggesting that KA-evoked responses are
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mediated by activation of the AMPA receptor. Briefly, evidence supporting
this view includes:-
a) In autoradiographic binding studies, [3H]-KA binds to high and low 
affinity sites in rat brain membranes (Monaghan and Cotman, 1982). 
However, irradiation inactivation studies suggest that low affinity KA 
sites are identical to AMPA binding sites (Honors e t al., 1986).
b) In order to elicit an excitatory response, low micromolar KA 
concentrations are required, at which level KA interacts with the 
AMPA binding site (Mayer and Westbrook, 1987a).
c) The non-NMDA antagonists CNQX and DNQX are equipotent as 
antagonists of KA-, AMPA- and quisqualate-evoked increases in neuronal 
firing rates, suggesting that all three agonists elicit excitatory responses 
by activation of the same neuronal receptor (Honore et al., 1988).
However there is also evidence that at least some KA-induced neuronal
responses are independent of the AMPA receptor, including:-
d) In the rat cortical wedge, the AMPA antagonist NBQX has been reported 
to antagonise quisqualate- and KA-induced depolarisations differentially 
(Honore et al., 1988).
e) The non-NMDA antagonists NBQX, CNQX and DNQX are more potent 
as inhibitors of [3H]-AMPA than of [3H]-KA binding in rat brain 
membranes (30-fold, and 4-5-fold, respectively) (Honor6 et al., 1988).
f) In neuronal cultures, KA and quisqualate activate channels which show 
different conductance and desensitization properties (Mayer and 
Westbrook, 1987a; Collingridge and Lester, 1989).
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g) The concentration of KA required to depolarise spinal C-fibre afferents 
is of the same order of magnitude as that shown to label high affinity 
[3H]-KA binding sites in rat brain membranes (as opposed to 
concentrations which label the low affinity [3HJ-KA binding sites which 
have been suggested to be identical to AMPA binding sites) (see Agrawal 
and Evans, 1986).
h) In autoradiographic studies, the regional distribution pattern of high 
affinity [3H]-KA binding sites is unlike those of either AMPA or NMDA 
receptors. In addition, the pattern of [3H]-KA binding corresponds well 
with the brain regions which are particularly susceptible to the 
neurotoxic actions of KA, such as the cortex, lateral septum, and area 
CA3 of the hippocampus (Monaghan and Cotman, 1982; Foster and Fagg, 
1984; Monaghan et al., 1989).
Molecular Biology o f Non-NMDA Receptors
Increased insight into the characterisation of AMPA and KA receptors 
has been gained by recent advances in protein purification and molecular 
biology techniques (for review see Sommer and Seeburg, 1992; Seeburg, 1993). 
As a result, a number of non-NMDA receptor subunits have been cloned: 
GluRl - GluR7, KAI and KAII (Hollmann et al., 1989; Keinenan et al., 1990; 
Bettler e t al., 1992). From combinations of these subunits it is evident that 
multiple non-NMDA receptor subtypes exist which show differential responses 
to AMPA and KA, and at least one subtype appears to respond to both AMPA 
and KA.
46
High affinity AMPA, low affinity kainate receptors can be reconstituted 
in vitro by expression of one, or co-expression of any two of the four subunits 
termed GluRl - GluR4, or GluRA-D. In heteromeric subunit assemblies the 
GluR2 subunit dictates the conductance and permeability properties of the 
channel, inferring channel impermeability to divalent cations including Ca2+ 
(Verdoorn et al., 1991; Burnashev et al., 1992; Hollman et al., 1992). Thus, 
in cells expressing AMPA receptors which lack the GluR2 subunit, glutamate 
can activate Ca2+ currents through AMPA receptor channels (Burnashev et al., 
1992).
High-affinity kainate receptors can be generated from subunits 
GluR5-7, and KA1 or KA2 (Bettler e t al., 1992). Homomeric configurations 
of GluR5 and GluR6, but not GluR7, KA1 or KA2, can form functional 
channels in vitro. However, in combination with GluR5 or GluR6, KA2 
channels can be activated by AMPA as well as KA.
.2.4 The Metabotropic Receptor
Agonist activation of metabotropic glutamate receptors (mGluRs) 
stimulates intracellular second messenger systems, via a G-protein linked 
receptor transduction system, which leads to inositol-triphosphate (IP3)- 
mediated mobilisation of intracellular Ca stores (Sugiyama e t al., 1987; 
for review see Schoepp and Conn, 1993). Quisqualate, glutamate and 
ibotenate are agonists at this site, while NMDA, AMPA and KA are not. 
Recently another glutamate analogue, d l - 1 -amino-1,3-cyclopentane-trans- 
dicarboxylic acid (trans-ACPD), has been found to be a more selective, 
though less potent, agonist at this site. 2-Amino-3-phosphonopropionic acid
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(AP3) and AP4 appear to be weak antagonists at the metabotropic receptor.
Molecular Biology o f Metabotropic Receptors
Within the last two years molecular biological studies have characterised 
a family of mGluRs consisting of at least 8 cloned receptor subtypes 
(mGluRla, p, c, and mGluR2-6) (for review see Schoepp and Conn, 1993). 
These receptors exhibit heterogeneous functions and are coupled to multiple 
second messenger systems, including activation of phosphoinositide hydrolysis, 
activation of phospholipase C, both increases and decreases in cAMP 
formation, and modulation of ion channel activity. However, little is known 
to date about which of the cloned mGluRs mediates which second messenger 
response, although in situ localisation of mRNAs encoding different mGluRs 
shows contrasting distributions of the mGluR subtypes in the brain. For 
example, mGluR 1 mRNA is concentrated in most neuronal cells throughout 
the CA2, CA3 and CA4 hippocampal regions and in the dentate gyrus, while 
mGluR5 mRNA is specifically localised in pyramidal cells of areas CA1-CA4 
and granule cells of the dentate gyrus (Abe e t al., 1992; Shigemoto et al., 
1992). These differential distribution patterns suggest that the different 
mGluRs may have highly specialised cellular functions related to the specific 
signal-transduction mechanism they are coupled to. In general terms, 
mGluRs appear to be involved in acute modulation of synaptic transmission, 
as well as playing a role in the induction of long-lasting changes in synaptic 
function. For example, mGluRs have been implicated in the induction of LTP 
in hippocampus area CA1 (putatively by enhancing NMDA receptor currents 
via activation of protein kinase C, PKC; Bashir et al., 1993), and in the
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lateral septal nucleus (putatively by facilitating Ca2+ release from 
intracellular stores; Zheng and Gallagher, 1992).
1.2.5 The L-AP4 Receptor
The finding that the glutamate analogue L-2-amino-5-phosphonobutyrate 
(l-AP4) was a potent antagonist at subpopulations of excitatory synapses, 
but had no inhibitory action against the depolarising actions of glutamate, 
NMDA, quisqualate or KA, led to the proposal of a presynaptic L-AP4 
autoreceptor (Lanthorn et al., 1984; Cotman et al., 1986). It has been 
hypothesised that antagonism of excitatory responses by L-AP4 results from 
receptor-mediated inhibition of excitatory neurotransmitter release. 
However, no membrane binding site for L-AP4 has as yet been identified, and 
the exact mechanism of L-AP4 antagonism is still to be elucidated.
1.2.6 The Anatomical Distribution of Excitatory Amino Acid Receptors in the CNS
Most of the information about receptor distributions in the CNS has 
come from ligand binding studies and, more recently, from in situ 
hybridization studies. While such methods identify the location of binding 
sites selective for certain ligands, it must be noted that these procedures 
allow no measure of functional receptor activity. However 
electrophysiological studies have generally supported a role for glutamate 
receptor activation in regions coincident with the reported distributions of 
excitatory amino acid binding sites. The anatomical patterns of excitatory 
amino acid ionotropic receptor distributions in the rat brain, based on 
evidence from in vitro autoradiographic ligand binding studies, are summarised
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TABLE 1
EXCITATORY AMINO ACID RECEPTORS
R E C E P T O R
C L A S S E S  A G O N I S T S  A N T A G O N I S T S  R A D I O L I G A N D S
N M D A
Transm itter
S i te
Channel
N M D A
L - G l u t m a t e
M e t h a n o g l u t a m a t e
L - A s p a r t a t e
I b o t e n a t e
C P P
C p p - e n e
D - A P 5  
C G S - 1 9 7 5 5
P C P
M K - 8 0 1
T C P
K e t a m i n e  
S K F  1 0 0 4 7
l -  [ ?H  ] - G l u t a m a t e  
D - [ H ] - A P 5
[ 3 H ] - C P P  
[ H ] - C G S - 1 9 7 5 5
[ ? f t J - MK- e o i
[ 1  I ] - M K - 8 0 1  
[ 3 H ] - T C P
G lycine
S i te
Polyamine
S ite
G l y c i n e
D - S e r i n e
D - A l a n i n e
D - C y c l o s e r i n e
S p e r m i n e
S p e r m i d i n e
(P)
H A - 9 6 6  ( P )  
K y n u r e n a t e  
7 - C l - K y n u r e n a t e
I f e n p r o d i l
[ H ] - G l y c i n e
A M P A
AMPA
L-Glutamate
Quisqualate
N B Q X
C N Q X
D N Q X
L Y - 2 9 3 5 5 8
G Y K I - 5 2 4 6 6
G D E E
[3H]-AMPA 
[,H]-CNQX 
[ H ] -L-Glutamate
K A
K A
L - G l u t a m a t e
D o m o a t e
Q u i s q u a l a t e
C N Q X
D N Q X
[,H]-KA
[ H ]-L-Glutamate
M E T A B O T R O P I C
tran s-ACPD 
L - G l u t a m a t e  
Q u i s q u a l a t e  
I b o t e n a t e
A P 3
A P 4
L - A P 4
L - A P 4
L - G l u t a m a t e
A  s u m m a r y  o f  r e p r e s e n t a t i v e  a g o n i s t s ,  a n t a g o n i s t s  a n d  r a d i o l i g a n d s  f o r  e a c h  o f  
t h e  e x c i t a t o r y  a m i n o  a c i d  r e c e p t o r  c l a s s e s .  A g e n t s  a r e  n o t  n e c e s s a r i l y  r a n k e d  
i n  o r d e r  o f  p h a r m a c o l o g i c a l  p o t e n c y .  ( P ) : P a r t i a l  a g o n i s t .
A b b r e v i a t i o n s :
A C P D ,  1 - a m i n o - c y c l o p e n t y l - 1 , 3 - d i c a r b o x y l a t e ;  A M P A , a - a m i n o - 3 - h y d r o x y - 5 -
m e t h y l i s o x a z o l e  p r o p i o n a t e ;  A P 3 ,  2 - a m i n o - p h o s p h o n o b u t y r a t e ;  A P 4 ,  2 - a m i n o -  
p h o s p h o n o v a l e r a t e ;  C N Q X , 6 - c y a n o - 7 - n i t r o - q u i n o x a l i n e - 2 , 3 - d i o n e ;  C P P ,  3 - 3 ( 2 -  
c a r b o x y p i p e r a z i n - 4 - y l ) p r o p y l - 1 - p h o s p h a t e ;  C P P - e n e ,  3 - ( 2 - c a r b o x y p i p e r a z i n - 4 -
y l ) p r o p e n y l - 1 - p h o s p h o n o a t e ; D N Q X , 6 , 7 - d i n i t r o - q u i n o x a l i n e - 2 , 3 - d i o n e ;  G D E E ,  
g l u t a m i c  a c i d  d i e t h y l  e s t e r ;  K A , K a i n a t e ;  M K - 8 0 1 ,  d i b e n z o c y c l o h e p t e n e i m i n e ;  
N M D A , i Y - m e t h y l - D - a s p a r t a t e ;  P C P ,  p h e n c y l i d i n e ;  T C P ,  1 - ( 1 - t h i e n y l -  
c y c l o h e x y 1 ) p i p e r i d i n e .
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below (for review see Cotman e t al., 1987; Young and Fagg, 1990).
NMDA-displaceable [3H]-glutamate binding sites are found throughout 
the brain, but predominantly in the telencephalon (Monaghan and Cotman,
1985). The general distribution of NMDA receptors in rat CNS has been 
confirmed by mapping the binding patterns of radiolabelled NMDA antagonists 
which bind at the transmitter recognition site, such as [3H]-CPP and [ 3 H ] - d-  
AP5 (Monaghan et al., 1984b; Olverman et al., 1986). Highest levels of 
NMDA binding sites in the brain are found in strata oriens and radiatum of 
the hippocampal CA1 region, while moderate levels exist in area CA3 and the 
dentate gyrus. These observations correlate with the proposed involvement 
of NMDA receptors in long term potentiation in area CA1 (Collingridge and 
Bliss, 1987). In cortex, highest densities of NMDA binding sites are found 
in frontal, anterior cingulate and pyriform cortices. In neocortical areas such 
as parietal cortex a laminar pattern of binding sites exists, consisting of two 
dense bands of NMDA binding sites corresponding to cortical layers I-II1 
and V. In sub-cortical regions high levels of NMDA sites are found in the 
dorsal lateral septum, amygdala, and the basal ganglia (particularly striatum 
and nucleus accumbens). Other brain regions which are frequently associated 
with sensory functions contain moderate levels of NMDA receptors. These 
include visual structures such as the superior colliculus superficial layer and 
dorsal lateral geniculate body, auditory regions including the medial 
geniculate body and cochlear nucleus, and the plexiform layer of the olfactory 
bulb and anterior olfactory nuclei. Low levels of NMDA sites are found in 
regions associated with motor function including the cerebellar molecular 
layer, p o n t i n e  n u c l e u s  a n d  t h e  r e d  n u c l e u s .  F u r t h e r ,  a u t o r a d i o g r a p h i c  s t u d i e s
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jshow a high degree of co-localisation in the anatomical distribution patterns 
of NMDA-displaceable binding sites, and of ligands binding at regulatory 
domains on the NMDA receptor-channel complex. These include PCP site 
[ligands (e.g. [3H]-TCP and [3H]-MK-801), and [3H]-glycine binding to the 
I strychnine-insensitive glycine recognition site (Bristow et al., 1986; Bowery 
et al., 1988; Maragos et al., 1988; Sakurai et al., 1991).
[3H]-AMPA binding sites show a high degree of colocalisation with 
NMDA sites throughout the CNS, highest levels being found in the 
hippocampal complex, and in particular in strata radiatum and oriens of area 
CA1 (Monaghan et al., 1984a; Rainbow et al., 1984; Cotman et ai., 1987). 
In the cortex AMPA sites are concentrated in the outer layers, and high levels 
are also found in striatum, nucleus accumbens, lateral septum, amygdala, 
anterior olfactory nuclei and the olfactory tubercle. In a few areas AMPA 
binding sites are more abundant than NMDA binding sites, for example in the 
cerebellar molecular layer and stratum pyramidale of the hippocampus. The 
general pattern of NMDA and AMPA receptor colocalization supports 
electrophysiological evidence that NMDA and AMPA receptors work in 
concert in mediating post-synaptic excitation, AMPA receptors being 
responsible for the stimulatory fast EPSP while NMDA receptors mediate a 
slower conductance which appears to play a modulatory role in neuronal 
activation, contributing to synaptic responses only under special conditions 
(Collingridge and Bliss, 1987; MacDermott and Dale, 1987).
Kainate binding sites, in contrast, generally do not complement NMDA 
distribution (Monaghan and Cotman, 1982; Unnerstall and Walmsley, 1983; 
Cotman et al., 1987). Kainate sites tend to predominate in regions of low
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NMDA site density such as the termination zone of the mossy fibre pathway 
in the hippocampus (stratum lucidum). In cortex, the highest densities of 
kainate binding sites are found in layers V and VI. In thalamic areas, kainate 
sites are concentrated in the reticular nucleus and hypothalamus, whereas 
NMDA binding site densities are low in these regions relative to other 
thalamic areas. In striatum, kainate and NMDA binding site densities are 
similar, but NADPH-diaphorase histochemistry suggests that they are located 
on different cell types within the striatum (Beal et al., 1986). However, 
there is evidence of co-localisation of kainate and NMDA binding sites in 
the dentate gyrus and cerebellum.
1.2.7 Glutamatergic Pathways in the CNS
Evidence obtained from the distribution profiles of presynaptic markers 
for glutamate-containing terminals, in conjunction with observed patterns of 
post-synaptic excitatory amino acid receptors within the brain, indicate that 
endogenous excitatory amino acids, and in particular glutamate, are the major 
excitatory neurotransmitters in corticocortical, corticofugal and sensory 
systems (for review see Fonnum, 1984; Cotman et al., 1987).
Neuronal terminals employing a given transmitter can often be identified 
by their ability to synthesise, store, release, take up, or inactivate the 
transmitter. Therefore, potential markers for glutamate-secreting terminals 
include transmitter content, presence of the catabolic enzyme glutaminase, 
demonstration of Ca2+-dependent glutamate release, and the presence of the 
high affinity uptake mechanism for glutamate. Histological visualisation of 
presynaptic markers, for example using glutamate immunocytochemistry, has
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facilitated the demonstration of Ca2+-dependent glutamate release from 
hippocampal neurones in response to depolarisation (see Ottersen and Storm- 
Mathisen, 1987). Autoradiographic mapping of the distribution of high- 
affinity glutamate uptake sites in the brain has also been widely used to 
localise glutamate-containing terminals, employing the metabolically inert 
glutamate analogue [3H]-aspartate to label the glutamate uptake site. 
[3H]-Aspartate autoradiography in the rat brain has demonstrated that the 
pattern of glutamate uptake sites is strikingly similar to the sum of the 
distributions of excitatory amino acid receptor subtypes throughout the CNS, 
with particularly high levels of uptake evident in hippocampus area CA1, 
strata radiatum and oriens (Ottersen and Storm-Mathisen, 1984; Taxt et al., 
1984). In addition, high levels of [3H]-aspartate binding are seen in the outer 
layers of the cerebral cortex, while slightly lower levels are seen in striatum, 
basal forebrain, nucleus accumbens, lateral septum, olfactory tubercles, and 
dorsal lateral geniculate body (Ottersen and Storm-Mathisen, 1984). Further 
insight into the terminal location of high-affinity glutamate uptake sites has 
been gained from the demonstration of down-regulation of [3H]-aspartate 
binding in certain brain regions following deafferentation. However, the 
interpretation of [3H]-aspartate binding as a selective marker for neuronal 
glutamate uptake sites should be treated with caution, following the recent 
demonstration that lesioning the major [3H]-glutamatergic input to the 
superior colliculus superficial layer from the retina had no effect on levels 
of [3H]-aspartate binding in this region. As a consequence, it was postulated 
that [3H]-aspartate binding is not restricted solely to binding sites on 
presynaptic neuronal terminals, but may also label binding sites on glial cell
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membranes (Browne et al., 1991).
By comparing the anatomical distribution patterns of presynaptic 
markers and post-synaptic receptors, and investigation of the sequelae of 
pathway manipulations, a number of pathways have been proposed to employ 
excitatory amino acids as neurotransmitters. In addition to corticocortical 
association fibres, linking cortical pyramidal neurones (Peinada et al., 1986), 
and corticofugal projections (Fonnum, 1984; Ottersen and Storm-Mathisen,
1986), sensory pathways including retinofugal projections, mossy fibre synapses 
in the cerebellum, and certain auditory, olfactory and somatosensory pathways 
have been proposed to employ glutamate as the major excitatory 
neurotransmitter. Evidence implicating glutamate’s involvement in a number 
of pathways is summarised in Table 2. Further, a combination of evidence 
from autoradiographical, biochemical and physiological studies has indicated 
functional heterogeneity between two hippocampal pathways which fulfil the 
criteria for glutamate as a neurotransmitter. Uptake, storage and release 
of glutamate have been demonstrated in both the mossy fibre and Schaffer 
collateral pathways, while excitatory amino acid receptor antagonists have 
been shown to block synaptic transmission in both pathways (Cotman et al., 
1986, 1987). However, autoradographic studies have revealed that the 
Schaffer collateral terminal field contains the highest density of NMDA 
receptors in the brain (which is implicated in the process of LTP in this 
pathway), whereas mossy fibre terminals innervate a region with the highest 
levels of KA receptors in the brain (Monaghan and Cotman, 1982, 1985). In 
addition, presynaptic L-AP4 receptors have been demonstrated on mossy fibre 
terminals (Cotman et al., 1986).
55
TABLE 2
MAJOR GLUTAMATERGIC PATHWAYS IN THE CNS
Cortex:
Cortico - Cortical
Cortico - Striatal
Cortico - Thalamic
Hippocampus:
Schaffer Collateral-Commissural 
Mossy Fiber
Retino-Fugal Projections
(Pricipally to superior colliculus 
and lateral geniculate body).
Ottersen and Storm-Mathisen (1984) 
Fonnum et al. (1981)
Fonnum et al. (1981)
Cotman et al. (1986)
Taxt et al. (1984)
Lund-Karlsen and Fonnum (1978) 
Miller and Slaughter (1986)
Sillito et al. (1990)
Selected examples from the literature of glutamatergic excitatory pathways 
in the CNS. For reviews, see also Fonnum (1984), Cotman et al. (1987), 
Collingridge and Lester (1989).
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2. THE ROLE OF GLUTAMATE IN NEURODEGENERATION
2.1 Glutamate-Mediated Excitotoxicity in Neurodegeneration
Glutamate’s potential toxicity to CNS neurones was first reported in 
1957 when Lucas and Newhouse discovered that systemic glutamate injections 
led to degeneration of retinal neurones in neonatal mice. Subsequently Van 
Harreveld (1959) demonstrated that cortical application of glutamate in 
rabbits induced cortical spreading depression, and went on to propose that this 
effect was associated with neuronal hypoxia. These observations were 
supported further by investigations in which Olney (1969, 1971) showed that 
following systemic administration to immature rats, glutamate induced 
neuronal degeneration in the mature animals in areas of the brain which lack 
protection by the blood-brain barrier, such as the arcuate nucleus of the 
hypothalamus. Structure-activity studies subsequently revealed a strong 
correlation between the excitatory and neurotoxic potencies of different 
excitatory amino acid analogues, while glutamate analogues lacking excitatory 
activity were found to also lack neurotoxic effects. These observations 
suggested a convergence in the mechanisms underlying these two actions. 
This theory was further supported by findings that specific antagonists of 
glutamate-type excitation also effectively protected against glutamate-type 
neurotoxicity, suggesting the two events were receptor-mediated.
The neuropathological state produced acutely by glutamate and its 
analogues is characterised by rapid cellular swelling, most marked in dendrites 
(consistent with the predominantly dendritic localisation of excitatory amino 
acid receptors) while perikarya initially show swollen mitochondria and 
dilatation of endoplasmic reticulum. Subsequently, nuclear pyknosis is seen
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and the cytoplasm becomes vacuolated (Olney, 1971; Olney and de Gubbareff, 
1978; Olney et al., 1979).
In combination, these observations led Olney to propose the "excitotoxic" 
hypothesis of cell death, which states that:-
prolonged neuronal depolarisation underlies glutamate-induced 
neurotoxicity, and that the toxic action of glutamate is mediated 
through dendrosomal synaptic receptors specialised for 
glutamatergic (or aspartergic) transmission.
This process is assumed to involve pathologic changes in neuronal membrane 
permeability and impaired ion homeostasis. Since neuronal axons, presynaptic 
terminals and non-neuronal cells survive a glutamatergic insult, the 
excitotoxic process is often termed "axon sparing".
The first direct evidence of excitotoxicity in the adult rat brain came 
from studies in which injections of kainic acid into striatum were found to 
result in neuronal death characterised by the pathological neuronal 
alterations described by Olney (Coyle and Schwarcz, 1976; McGeer and 
McGeer, 1976). Experimentally, chronic infusions of high concentrations of 
glutamate are required to elicit neuronal degeneration due to the attenuating 
effect of the high affinity uptake system for glutamate. Application of 
uptake inhibitors, or removal of glutamate uptake sites by axotomy have 
consequently been shown to enhance glutamate toxicity. Other excitotoxins 
which are not substrates for glutamate’s uptake carrier, such as kainate, 
ibotenate or quisqualate, are therefore generally used experimentally.
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2.1.1 Mechanisms of Excitotoxic Neuronal Death
The exact mechanism of glutamate-induced excitotoxic neuronal death 
is not yet fully understood, although evidence indicates that it is ultimately 
dependent on abnormally high intracellular free calcium concentrations, 
[Ca2+]i (Siesjo et al., 1991; Miller et al., 1992).
Excitatory amino acid receptor activation induces elevations in [Ca2+]i 
via a number of different pathways. These include Ca2+ influx through 
voltage-sensitive calcium channels (VSCCs) and/or agonist-operated calcium 
channels (AOCCs), including channels associated with glutamate receptor 
subtypes; by mobilisation of intracellular Ca2+ stores following metabotropic 
receptor-mediated activation of inositoltrisphosphate (IP3); or alternatively 
by Ca2+-induced Ca2+ release (Siesjo, 1991; Brorson et al., 1991). Under 
normal physiological conditions this increase is tightly regulated by means 
of Ca2+ extrusion from neurones by an ATP-dependent Ca2+/Na+ exchange 
mechanism (Mayer and Miller, 1990). These normal increases in [Ca ]i 
underlie basal neuronal physiological processes, such as post-synaptic 
excitability, membrane permeability and synaptic plasticity, and are also 
thought to contribute to the initiation of long-term potentiation, since <Da2+ 
regulates Ca2+-activated K+ and Cl" channels in the cell membrane and can 
therefore directly control the membrane’s electrical properties. Ca2+ may 
also act as a trigger for neurotransmitter release, and is involved in 
regulation of gene expression. In addition, Ca2+ activates second messenger 
systems within neurones and modulates the activities of various enzymes 
including Ca2+-dependent phosphatases, protein kinases, proteases and lipases. 
Hence, Ca2+-dependent reactions contribute to the maintenance of cell
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structural elements (for review see Siesjo, 1988).
In pathological situations such as ischaemia, trauma or status 
epilepticus, excessive glutamate release and impaired re-uptake mechanisms 
result in prolonged exposure of post-synaptic receptors to the excitatory 
agonist, which can lead to excessive intracellular accumulation of Ca2+. Such 
loss of Ca2+ homeostasis results in ’’overloading” of cells with Ca2+ and the 
subsequent activation of a wide range of subcellular components, which may 
ultimately lead to disruption of normal cellular processes. High levels of 
nuclear Ca2+ activate nucleases, resulting in DNA fragmentation. Activation 
of proteases by high cytosolic Ca2+ levels leads to destruction of cytoskeletal 
components and mitochondrial dysfunction, while alterations in the activities 
of other enzymes, such as lipases, results in membrane damage and the 
production of free radicals. The ultimate consequence of these sequelae is 
cell death (Siesjo, 1988; Siesjd and Bengtsson, 1989).
Over the last four years a substantial body of evidence has emerged 
implicating nitric oxide (NO) as a mediator of glutamate-induced 
neurotoxicity in the CNS. In addition to its numerous physiological 
functions, including mediation of smooth muscle relaxation in peristalsis and 
vasodilatation, NO is an intracellular messenger in the brain and the 
peripheral nervous system (Garthwaite, 1991; Snyder and Bredt, 1991; Dawson 
et al., 1993).
NO is synthesised in post-synaptic neurones in response to increased 
[Ca2+]1. Ca2+ binding to calmodulin associated with the enzyme nitric oxide 
synthase (NOS), activates the enzyme to catalyse the synthesis of NO from 
L-arginine. Hence agonist activation of glutamate receptors, and in
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particular NMDA receptors, triggers NO synthesis via the associated influx 
of Ca2+ ions. The target for NO action is the soluble enzyme guanylyl 
cyclase which catalyses cyclic guanosine monophosphate (cGMP) production 
within the cell. Consequently NMDA receptor activation has been shown to 
increase intracellular cGMP levels (Bredt and Snyder, 1989) which in turn has 
an impact on various cellular functions, including regulation of protein 
kinases, phosphodiesterases, and ion channel activities.
The proposition that NO plays a role in mediating glutamate 
excitotoxicity is supported by evidence from in vitro studies that NOS 
inhibitors block the neurotoxic actions of glutamate and NMDA in neuronal 
cultures and brain slices, and that NOS blockade is reversible by the addition 
of L-arginine (Dawson et al., 1993). In addition, sodium nitroprusside (SNP), 
which induces spontaneous release of NO, produces cell death in neuronal 
cultures in a dose-dependent manner which parallels observed increases in 
cGMP levels, while haemoglobin (which complexes NO) and calmodulin 
inhibitors prevent the neurotoxic effects of both NMDA and SNP (Dawson et 
al., 1991, 1993). NO has also been implicated in processes of neuronal injury 
in vivo. For example, in experimental models of focal ischaemia in the rat, 
in which neuronal death is thought to be induced by raised extracellular 
glutamate levels, the NOS inhibitor N-arginine has been found to reduce or 
completely abolish neuronal damage (Nowicki e t al., 1991; Trifiletti, 1992). 
Further, SNP has been found to elicit neuronal injury when injected directly 
into the hippocampus (Loiacona and Beart, 1992). The exact mechanism by 
which NO kills neurones is still unclear, although a number of reports 
implicate the involvement of free radicals and in particular superoxide anions
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(02‘”). Superoxide and NO can combine to form peroxynitrite (ONOO”), 
which in turn decomposes into the highly reactive free radicals OH' and 
N02', which may be the ultimate common mediators of NO toxicity. 
Evidence for the participation of superoxide anions in neurotoxicity elicited 
by NMDA, and by NO produced by SNP, is provided by the neuroprotective 
effects of superoxide dismutase, an enzyme that scavenges the superoxide 
anion (Dawson et al., 1993; Lafon-Cazal, 1993).
Paradoxically, under certain circumstances NO has been demonstrated 
to have neuroprotective properties against glutamate-induced neurotoxicity, 
putatively due to the ability of NO to nitrosylate the NMDA receptor 
complex, effectively blocking glutamatergic neurotransmission (Vige et al., 
1993). Further, NOS-containing neurones have been shown to correspond to 
neurones that stain positively for nicotinamide adenine dinucleotide phosphate 
(NADPH) diaphorase (Dawson e t al., 1991; Snyder and Bredt, 1991), and which 
have been found to be resistant to degeneration in diseases such as 
Alzheimer’s and Huntington’s diseases, to NMDA toxicity in cortical culture, 
and to hypoxic-ischaemic brain injury (Koh and Choi, 1988; Snyder and Bredt,
1991).
A recent report by Lipton et al. (1993), indicating that NO can exist in 
two distinct redox states, may provide a means of reconciling the neurotoxic 
and neuroprotective properties of NO. Lipton and colleagues have 
demonstrated that the reduced ion, nitrogen monoxide (NO”) is responsible for 
the neurotoxic actions of NO via a reaction with superoxide anions, while the 
oxidized nitrosonium ion (NO+) reacts with the thiol group of the NMDA 
receptor complex to block neurotransmission. This apparent dichotomy in
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the actions of NO ions may help explain the observed resistance of NOS- 
containing neurones.
The proposed pathways mediating the transduction of glutamate-induced 
excitotoxic processes are summarised in Figure 2.
2.1.2 Glutamate Receptors and Excitotoxicitv 
NMDA Receptor-Mediated Toxicity
Until recently the NMDA receptor complex was thought to be the only 
glutamate receptor subtype involved in agonist-operated calcium channel 
(AOCC)-mediated Ca2+ influx, since its associated cation channel is highly 
permeable to Ca2+, Na+ and K+ ions (Mayer and Westbrook, 1987b). NMDA 
receptor activation has also been implicated in the mediation of glutamate- 
induced excitotoxicity in both in vitro (Rothman and Olney, 1987; Regan and 
Choi, 1991) and in vivo models of ischaemia and trauma (Faden and Simon, 
1988; Park et al., 1988a).
a) Acute Toxicity
Garthwaite and Garthwaite (1990) used electron microscopy in rat 
brain studies to assess whether neurones become overloaded with Ca2+ 
during NMDA receptor-mediated excitotoxic challenge. They 
demonstrated, in both cerebellar and hippocampal slice preparations, 
that the intracellular sites of Ca2+ accumulation correlated well with 
the loci of the cytopathological changes occurring in the progression 
towards irreversible cell damage. The stages of neuronal damage are 
described thus:-
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FIGURE 2: PUTATIVE MECHANISM OF GLUTAMATE EXCITOTOXICITY
(i) Ca2+ is amassed in the Golgi apparatus, corresponding with 
swelling of these organelles.
(ii) Ca2+ begins to accumulate in the nucleus, coinciding with
aggregation of chromatin. If the agonist stimulation is removed
2+at this stage cells can recover. There is insufficient Ca in 
cytoplasm to be detected by electron microscopy.
o  ,
(iii) The onset of irreversible damage is signalled by Ca 
accumulation in mitochondria, which subsequently begin to swell. 
Large quantities of free Ca2+ can be seen in the cytoplasm 
(100]jlM +). Removal of the agonist at this stage will not prevent 
neuronal necrosis.
Although the precise mechanisms elicited by high intracellular 
calcium levels are still unclear, the importance of its presence is 
illustrated by the fact that exposure of slices to NMDA in the absence 
of Ca2+ prevents pathological changes occurring in the Golgi apparatus, 
nucleus and mitochondria, and prevents irreversible neuronal damage. 
Since the ionic and metabolic changes associated with NMDA receptor- 
mediated depolarisation still persist in these conditions, these structural 
alterations appear to be Ca2+-dependent. Evidence suggests that the 
major route of Ca2+ influx in the circumstances described is via AOCCs, 
and chiefly via the NMDA associated channel which has high Ca2+ 
conductance (Mayer and Westbrook, 1987b; for review see Mayer and 
Miller, 1990). Stimulation of VSCCs alone, by using K+ to depolarise 
the neurones, induced insufficient Ca2+ influx to produce toxicity. Also
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the toxicity produced in the presence of NMDA was potentiated in 
Mg2+- free medium, or by simultaneously depolarising neurones with K+ 
or kainate to overcome Mg2+ voltage-dependent channel blockade, 
further suggesting the involvement of an NMDA receptor channel 
mediated event.
b) Delayed Toxicity
Following injection of NMDA into rat striatum or hippocampus in 
vivo, in amounts which are not immediately toxic, neurodegeneration 
occurs gradually over several hours. This delayed cell death can be 
inhibited by delayed administration of NMDA receptor antagonists 
(Foster et al., 1988).
Non-NMDA Receptor-Mediated Toxicity
AMPA and kainate receptor-associated ionophores have conventionally 
been thought to be Ca2+-impermeable (Mayer and Westbrook, 1987a; Mayer 
and Miller, 1990). Ca influx has been observed after non-NMDA receptor 
stimulation, but in the past this Ca2+ influx has been attributed to activation 
of voltage-sensitive calcium channels (VSCCs) by the membrane 
depolarisation which results from Na+ influx through non-NMDA receptor 
channels (Murphy and Miller, 1989). However, an increasing body of 
evidence indicates that some AMPA and kainate receptor ionophores are 
permeable to Ca2+.
In 1989, Murphy and Miller demonstrated that the Ca2+ influx induced 
by KA in cultured striatal neurones could not be completely blocked by VSCC
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blockers. In electrophysiological studies, lino e t al., (1990) and Ozawa et 
al. (1991) showed that a fraction of cultured hippocampal neurones expressed 
glutamate receptors which were permeable to Ca2+ after stimulation by KA. 
They termed these receptors "type-II KA receptors”, as opposed to the 
typical "type-I KA receptors” which are Na+-permeable and Ca2+- 
impermeable. Further, in vitro studies have identified the existence of Ca2+- 
permeable non-NMDA receptors in ra t cerebellar granule cells (Holopainen 
et al., 1989), rat hippocampal neurones (Ogura e t al., 1990) and glial cells 
(Linn and Christensen, 1992).
In order to elucidate whether this non-NMDA receptor mediated Ca2+ 
influx was due solely to VSCC activation, Miller and colleagues (1992) 
investigated the KA-induced increase in [Ca2+]1 in cultured cerebellar 
Purkinje cells in a Na+-free medium (replacing Na+ with the impermeant
o ,
cation N-methyl-D-glucamine, NMDG). In some cells Ca influx was found 
to be dependent on cell depolarisation, but in the majority of cells 
investigated a substantial Ca2+ influx occurred in Na*-free conditions (Brorson 
et al., 1992; Miller et al., 1992). AMPA also induced Na+-independent Ca2+ 
influx, and both AMPA- and KA-induced [Ca2+]i increases were found to be 
completely blocked by the non-NMDA receptor antagonist CNQX, but 
unaffected by the NMDA antagonist APV. In addition, administration of the 
non-specific organic VSCC blocker TA-3090, at doses sufficient to inhibit 
both depolarisation- and K+-induced Ca2+ influxes, was ineffective in blocking 
the Na+-independent increase in [Ca2+]i following KA stimulation ((Bleakman 
et al., 1991). Further, in voltage-clamped conditions KA-induced inward 
Ca2+ currents were found to be unaffected by TA-3090 or the inorganic VSCC
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blocker Co2+ (Miller et al., 1992).
2+Further evidence of the existence of Ca -permeable non-NMDA 
receptor-associated ionophores has come from the recent cloning of a number 
of non-NMDA receptor subunits, GluRl - GluR7. Studies have revealed that 
when expressed in certain combinations these proteins yield glutamate 
receptors which are permeable to Ca2+, as discussed in Section 2.2.3 
(Keinenan et al., 1990; Hollman et al., 1992).
2.2 Acute Neuronal Death
Following observations that the patterns of necrosis induced by 
excitatory amino acid injections into discrete brain regions mimic the 
neuronal degeneration seen in cerebral ischaemia, it was speculated that 
excitatory amino acid receptors may be intrinsically involved in the acute 
processes of ischaemic neuronal death.
2.2.1 Cerebral Ischaemia
The term "cerebral ischaemia" encompasses a number of clinical 
situations including thrombotic stroke, which produces an irreversible focal 
ischaemia involving brain regions supplied by end arteries and territories with 
collateral supply; cardiac arrest which induces transient global ischaemia; and 
asphyxia which produces hypoxia and global reductions in cerebral blood flow. 
Interrupting the cerebral circulation prevents supply of the metabolic 
substrates glucose and oxygen to brain regions, which can result in neuronal 
death. Although neuronal viability in most parts of the brain may be 
reinstated if circulation is restored within a few minutes, selective neuronal
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necrosis may still occur in specific brain regions (Brierley and Graham, 1984).
The etiology of the neuronal death resulting from ischaemic episodes, 
and other insults secondarily involving ischaemia, such as cerebral trauma 
and subarachnoid haemorrhage, is still not fully understood. However, it is 
well established that excitotoxic mechanisms are involved in ischaemic 
neuronal death (for review see Rothman and Olney, 1986, 1987; Siesjo, 1992). 
In vivo, microdialysis studies have demonstrated marked increases in 
extracellular levels of glutamate and other excitatory amino acids during 
global and focal ischaemic episodes (Benveniste e t al., 1984; Drejer et al. 
1985; Hagberg et al., 1985; Butcher et al., 1990). In vitro experiments 
suggest that increased excitatory amino acid concentrations arise from both 
enhanced synaptic release and from impaired reuptake of glutamate and 
aspartate ((Bosley et al., 1983; Drejer e t al., 1985). Choi (1987) has 
subsequently demonstrated that the level of extracellular glutamate present 
after 10-30 min of ischaemia is comparable with the glutamate concentration 
which is toxic to neurones in culture following brief exposure (60-500y.M).
Further evidence of a crucial role for excitatory amino acids in 
ischaemic pathology is provided by the similarity in the acute cytopathology 
seen following excitotoxic lesions with the changes occurring during 
reperfusion after transient forebrain ischaemia in the rat. The early 
morphology of excitotoxicity - focal dendritic swelling and mitochondrial 
dilatation in dendrites and perikarya - has been widely reported to be evident 
acutely following an ischaemic insult (Brown and Brierley, 1972; Simon et al., 
1984). In addition, evidence of a role for excitatory synaptic activity in 
ischaemic processes is provided by the results of hippocampal deafferentation
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studies. Delayed neuronal loss occurs in the CA1 zone of the hippocampus 
following transient global ischaemia in the rat or gerbil. However, lesioning 
hippocampal input pathways such as the Schaffer collateral or perforant 
pathways, prior to the ischaemic insult, provides partial protection against 
this cell loss (Wieloch et al., 1985; Onodera et al., 1986; Jorgensen et al., 
1987; Buchan and Pulsinelli, 1990). In addition, evidence of the 
neuroprotective effects of excitatory amino acid receptor antagonists, such 
as MK-801 and NBQX, in animal models of focal and global ischaemia have 
further supported an intrinsic role for glutamate in ischaemic neuronal death 
(Park et al., 1988a, b; Sheardown et al., 1990; see also Section 2.2.3).
2.2.2 Animal Models of Cerebral Ischaemia
a) Focal Ischaemia
An experimental model of stroke may be achieved by permanent 
occlusion of the middle cerebral artery (MCA), which is the vessel most 
often occluded in stroke in man (Brierley and Graham, 1984).
In the rat, permanent MCA occlusion results in severely reduced 
blood flow in the centre of the vascular territory supplied by the MCA, 
in which ischaemic cell death may ultimately occur. At the periphery 
of this region is an area with sub-critically reduced blood flow, (the 
"penumbral” zone) (for review see Tamura et al., 1981b; Nedergaard, 
1988; Siesjo, 1992). The MCA supplies most of the caudate nucleus and 
putamen, the lateral segment of the globus pallidus, much of the 
cerebral cortex, the insula, superior regions of the internal capsule, and 
adjacent white matter. Permanent MCA occlusion induces infarction
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in the ischaemic core, generally involving cortical and subcortical 
structures supplied by the MCA. Cerebral infarction has been defined 
by Nedergaard (1988) as necrosis of all tissue elements within a given 
region, including both neuronal and glial cells, nerve fibres, and all 
blood vessels. Within a few hours of MCA occlusion cells at the core 
of the MCA territory are swollen or already lysed, chromatin is 
dispersed away from the nucleus and cells appear pale under light 
microscopic examination of stained sections, due to their inability to 
take up histological dyes. In the surrounding tissue with reduced blood 
flow, shrunken and pyknotic neurones are visible after approximately 4h. 
Some or all of this territory may become infarcted within 24h (Graham 
et al., 1993). After 24-48h most of the swollen cells will have 
disappeared, and small eosinophilic cells will be visible in the penumbra. 
At this stage the infarcted area is sharply demarcated in histologically 
stained sections, the transitional zone of the penumbra often being only 
a few millimetres wide. The nature of the lesion produced by 24h 
permanent MCA occlusion is illustrated in Figure 8 (Methods). 
However, in experimental animals eosinophilic neurones are occasionally 
found sporadically distributed outside the infarcted zone and penumbra. 
For example such cells have been identified in ra t cortical mantle 
>lmm from the infarct following MCA occlusion (see Nedegaard, 1988).
Following transient MCA occlusion scattered areas of selective 
neuronal damage may be induced in the caudate/putamen. Selective 
neuronal injury has been defined as irreversible damage to some 
neurones whilst sparing other cells and preserving tissue structure
70
(Nedergaard, 1988). The size and distribution of neuronal damage varies 
with the duration of occlusion, but occlusion of 6h or more produces 
infarction to the same extent as permanent occlusion.
b) Global Ischaemia
Models of global ischaemia have been described principally in the 
gerbil and rat. These usually involve clamping the common carotid 
arteries for 5-30 min, (i.e. two- or four-vessel occlusion models; 2VO or 
4VO). Transient forebrain ischaemia results in delayed degeneration of 
pyramidal neurones in the CA1 region of the hippocampal complex. One 
to 2h after the ischaemic insult acute changes such as focal dendritic 
swelling and mitochondrial ballooning are seen in CA1 pyramidal and 
other hippocampal neurones, accompanied by hypermetabolism and an 
increase in blood flow to this region (for review see Ginsberg, 1990). 
The neurones then appear to recover transiently before finally 
degenerating, generally 24 to 72h after the ischaemic event (Pulsinelli, 
1982).
It is important to note that processes of infarction and selective 
neuronal injury take time to evolve. Therefore, for light microscopic 
histological analysis of the lesion in models of focal and global ischaemia, a 
sufficiently long recovery period should be allowed before quantification of 
infarct volume: at least 24h in cryostat-processed sections following focal 
ischaemia; 2-4 days following transient global ischaemia to allow for the 
evolution of delayed CA1 cell death.
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2.2.3 Neuroprotection bv Excitatory Amino Acid Antagonists
Excessive stimulation of glutamate receptors, due to massive increases 
in extracellular glutamate concentrations, appears to underlie the sequence 
of cellular events which lead ultimately to neuronal damage following 
cerebral ischaemia and traumatic head injury (Benveniste et al., 1984; 
Butcher et al., 1990; Bullock et al., 1992). Consequently a number of 
pharmacological strategies have been proposed as possible mechanisms for 
attenuating glutamate’s neurotoxic actions. These include reduction of 
synthesis and release of transmitter glutamate; reducing neuronal firing 
rates; enhancing transmitter reuptake from the synaptic cleft; or 
alternatively inhibiting the post-synaptic sequelae of glutamate receptor 
activation, for example by inhibition of Ca2+ influx by ion channel blockers 
(for review see Choi, 1990). Most notably, however, pharmacological 
blockade of glutamate activity at post-synaptic excitatory amino acid 
receptors has been found to provide marked protection against neuronal 
damage in models of excitotoxic and ischaemic cell death in vitro, and in 
vivo (including in vivo models of focal and global ischaemia, head injury and 
hypoxia) (for review see Mel drum, 1990).
The NMDA receptor subtype, in particular, has been implicated in the 
pathogenesis of neuronal damage, supported by a number of studies reporting 
the beneficial effects of NMDA receptor antagonists on the outcome of 
traumatic brain or spinal cord injury (Faden and Simon, 1988; for review see 
Bullock et al., 1992), and in ameliorating the neurochemical and behavioural 
deficits produced by excitotoxic lesions of discrete pathways within the brain 
(see Dunnett et al., 1991). However, the majority of studies demonstrating
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the neuroprotective actions of excitatory amino acid antagonists in vivo to 
date have employed experimental models of focal or global ischaemia, which 
are briefly reviewed below.
Investigations of the effects of different excitatory amino acid receptor 
antagonists in experimental models of ischaemia have been complicated by 
many extrinsic factors which can affect the outcome of the ischaemic insult, 
including the animal’s species, strain, sex and age; the nature of the 
ischaemic event (global or focal; temporary or permanent), severity and 
reproducibility of the experimental model used; physiological variables 
including temperature and cardiovascular parameters; lipophilicity of the 
antagonist; and the dose and route of administration of the antagonist (for 
review see Meldrum, 1990). As a consequence, different groups have in some 
cases reported contrasting effects of glutamate receptor antagonists. 
However, in general, NMDA receptor antagonists markedly reduce neuronal 
damage in focal ischaemia in the cat and rat, while AMPA antagonists appear 
to be more potent neuroprotectants than NMDA antagonists against the 
delayed hippocampal damage occurring after global ischaemia.
Focal Cerebral Ischaemia
The neuroprotective actions of NMDA antagonists in experimental 
models of focal ischaemia have been demonstrated in primate, cat, rabbit, 
and in the rat (Park et al., 1988a, b; Chen et al. 1991; Gill e t al., 1991; for 
review see McCulloch, 1992). In the rat, non-competitive NMDA receptor 
antagonists such as PCP and MK-801 reduce ischaemic brain damage by more 
than 50% when administered prior to, or up to 2h after the onset of
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ischaemia (Park et al., 1988b; Gill e t al., 1991). In contrast, while 
competitive NMDA antagonists such as CPP-ene are equally effective in 
reducing ischaemic damage when administered prior to the ischaemic episode, 
most lack significant neuroprotective effects when administered lh or more 
after the onset of ischaemia, putatively because of their greater 
hydrophilicity (and thus impaired ability to cross the blood-brain barrier) 
compared to non-competitive antagonists (Simon and Shiraishi, 1990; Park et 
al., 1991). In addition, agents acting at other modulatory sites on the NMDA 
receptor complex have also been found to be neuroprotective against focal 
ischaemia in the rat, including the glycine antagonist HA-966, the polyamine 
site antagonist ifenprodil and systemic administration of Mg (see McCulloch 
and Iversen, 1991).
A reduction in the volume of ischaemic damage induced by focal 
ischaemia has also been demonstrated following AMPA receptor blockade. 
Systemic administration of the AMPA antagonist NBQX (prior to, and after 
onset of ischaemia) has been shown to protect neurones against ischaemic 
damage in the rat, although the volume of salvaged tissue is less 
(approximately 30%) than that protected by NMDA antagonists (Gill e t al.,
1992). In addition, preliminary evidence indicates that the novel AMPA 
antagonist LY-293558 is neuroprotective following MCA occlusion in the cat 
(Bullock et al., 1993). A recent study has also indicated that the 
benzodiazepine non-NMDA receptor antagonist GYKI 52466 is neuro­
protective against focal ischaemia in the ra t (Smith and Meldrum, 1993).
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Global Cerebral Ischaemia
In studies of global ischaemia in large animals (primates, dogs and cats) 
NMDA receptor antagonists are ineffective in attenuating ischaemic damage 
(for review see McCulloch, 1992). However, in rodents (rat and gerbil) 
NMDA antagonists such as MK-801 and CGS 19755 appear, in general, to 
reduce delayed damage to hippocampal CA1 pyramidal neurones following 
transient global ischaemia, although this view remains controversial as some 
groups have reported NMDA antagonists to be ineffective in global ischaemia 
models (Gill et al., 1987, 1989; Buchan et al., 1991b). Subsequently it has 
been suggested that the neuroprotective actions of NMDA antagonists may 
be due to indirect drug actions, such as hypothermia, or anticonvulsant 
actions (Buchan and Pulsinelli, 1990).
In contrast, the AMPA antagonist NBQX markedly reduces neuronal 
damage following global ischaemia in the rat and gerbil. Most notably, 
NBQX protects hippocampal CA1 neurones against delayed damage even when 
administered up to 24h after the onset of ischaemia (Sheardown et al., 1990, 
1993; Buchan et al., 1991a; Diemer et al., 1992; Nellgard and Wieloch, 1992).
The reason for the different effects of NMDA and AMPA antagonists 
on delayed hippocampal damage following global ischaemia is not 
immediately apparent, especially as the CA1 region of the hippocampus is the 
site of highest NMDA and AMPA receptor densities in the entire brain 
(Cotman et al., 1987). However, following findings from molecular 
biological studies of different non-NMDA receptor subunits which impart 
different receptor characteristics, it has been suggested that the process of 
ischaemia might influence protein synthesis within cells, leading to a
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modification in AMPA receptor structure.
Pellegrini-Giampietro and colleagues (1992) demonstrated that following 
transient severe ischaemia mRNA transcription in CA1 hippocampal neurones 
is altered, resulting in reduced production of the GLuR2 AMPA receptor 
subunit which maintains channel impermeability to Ca2+. It has been 
postulated that if new AMPA receptor/channel complexes are synthesised in 
the CA1 region 12h or more after the ischaemic event, these new channels 
may lack the GLuR2 subunit and would therefore be permeable to Ca2+ 
(Pellegrini-Giampietro et al., 1992; Pulsinelli e t al., 1992). This putative 
modulation of mRNA may explain the unique delay in the onset of injury to 
CA1 neurones following transient global ischaemia, and the neuroprotective 
efficacy of delayed AMPA antagonist administration. The proposed changes 
in AMPA receptor subunit expression would precede both the histological 
signs of CA1 injury and the late increase in Ca2+ uptake by CA1 neurones 
which has previously been demonstrated using 45Ca autoradiography (Dienel, 
1984). However further studies are required to determine if these 
alterations in mRNA expression are translated into functional AMPA 
receptors in the hippocampus following transient global ischaemia.
2.2.4 Cortical Glutamate Perfusion: A Novel In Vivo Model of Glutamate 
Excitotoxicitv
Although animal models of cerebral ischaemia have proved to be 
valuable in determining the anti-ischaemic effects of agents which putatively 
ameliorate glutamate-mediated excitotoxicity, the nature of the 
experimental procedures involved means that multiple cerebrovascular and 
neurochemical mechanisms are disturbed in addition to the presumed primary
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insult of elevated extracellular glutamate levels. Evidence suggests that 
these mechanisms will not only contribute to the outcome of the ischaemic 
insult, but will also influence anti-ischaemic drug action. For example, 
following MCA or carotid artery occlusion in experimental models, cerebral 
blood flow is reduced in the penumbral ischaemic zone, leading to impaired 
delivery of the metabolic substrates oxygen and glucose, reduced tissue 
oxygen tension, and hence disturbed energy generation. Under such 
circumstances the neuroprotective effects of drugs whose actions are 
mediated by energy-dependent mechanisms may be attenuated, while agents 
which improve tissue perfusion in marginal areas may reduce neuronal 
damage without having any direct effect on the excitotoxic process.
In an attempt to circumvent these potentially complicating factors, a 
novel model involving production of a glutamate-induced cortical lesion has 
been developed to facilitate investigations of the effects of putative 
neuroprotective agents against pure glutamate-induced neurotoxicity in vivo 
(Fujisawa et al., 1993a and b; Landolt et al., 1993). This method employs 
retrograde dialysis of glutamate into the cerebral cortex of rats to produce 
excitotoxic lesions in a less invasive manner than cerebral ischaemia models. 
The cortical lesions produced have previously been characterised and show 
histological alterations consistent with excitotoxic cell damage (i.e. 
mitochondrial and cytoplasmic swelling, pyknosis). The nature of the lesion 
produced by cortical glutamate perfusion is illustrated in Figure 9 (Methods).
In the past, selective excitatory amino acid receptor agonists have been 
widely used to produce excitotoxic lesions in the CNS rather than glutamate 
itself, due to their lack of affinity for the glutamate uptake carrier, and
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because unlike glutamate they are not involved in CNS metabolic processes. 
However, in the studies of excitotoxic cortical lesions outlined in this thesis, 
glutamate was selected as the exogenous exci to toxin due to the apparent 
intrinsic involvement of endogenous glutamate in pathological processes of 
neuronal injury. Consequently, in an ischaemic insult, for example, the 
broad spectrum of glutamate-mediated actions within the CNS (including 
actions at all excitatory amino acid receptor subtypes and as a substrate for 
uptake mechanisms) potentially contribute to the overall outcome of the 
pathological episode (e.g. ischaemic insult).
2.3 Excitotoxic Cell Death in Chronic Neurodegenerative Diseases
The capacity of glutamate to induce excitotoxic lesions reminiscent of 
those occurring in human neurodegenerative disorders has led to the 
proposition that glutamate is involved in the pathogenesis of the neuronal cell 
death occurring in chronic diseases, such as Alzheimer’s and Huntington’s 
diseases and olivopontocerebellar atrophy. This brief analysis will 
concentrate on the evidence supporting a role for glutamate-mediated 
neurotoxicity in the neurodegenerative processes occurring in Alzheimer’s 
Disease (AD).
2.3.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a dementing disorder manifest clinically as 
a progressive deterioration in memory, learning capacity, language and 
intellect. AD is characterised neuropathologically by the presence of large 
numbers of senile or neuritic plaques and neurofibrillary tangles, in
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conjunction with neuronal degeneration and/or atrophy in certain brain 
regions, principally in associational cortex, entorhinal cortex, hippocampus 
and basal forebrain regions including the nucleus basal is of Meynert (nbM). 
In general the distribution of the histopathological markers coincides with 
areas of neuronal loss, high densities of plaques often being found in 
association areas of neocortex, hippocampus and amygdala, while high 
densities of tangles are similarly found in cortex, as well as in subcortical 
regions including the nbM, locus coeruleus and the dorsal raphe nuclei (Mann, 
1988). Similarly, the psychological deficits observed in AD patients are 
compatible with the consequences of cortical disconnection, and dysfunction 
in a number of hippocampal pathways such as the entorhinal cortex - 
perforant pathway, thus showing some degree of correlation with the 
neuropathological sequelae of the disease.
Despite enormous interest in AD which has fuelled intensive research 
in recent years, and the subsequent proposal of numerous hypotheses 
concerning the etiology of this disorder, no theory has yet been able to 
satisfactorily explain all the facets of Alzheimer symptomatology. However, 
consistent abnormalities in cholinergic and glutamatergic systems within the 
brain have been observed in Alzheimer postmortem tissue, which has led to 
the proposition of two hypotheses of selective vulnerability of these 
neurotransmitter systems. The "cholinergic hypothesis" argues that the 
syndrome of dementia, the fundamental feature of this disorder, is 
attributable to cortical cholinergic dysfunction resulting from loss of cortical 
cholinergic innervation from neurones in the nbM, and cholinergic dysfunction 
in the hippocampus. This theory is supported by findings of reduced
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cholineacetyltransferase (ChAT) and acetylcholinesterase (AChE) activities 
in Alzheimer hippocampus and cortex in post-mortem and biopsy studies (for 
review see Bartus et al., 1982; Fibiger, 1991). Additionally, neuronal loss 
and atrophy has been observed in cortical-projecting cholinergic 
magnocellular neurones of the nbM in AD patients. However recent 
observations of glutamatergic deficits in Alzheimer cortex and hippocampus 
have led to an alternative glutamate hypothesis of AD, which implicates the 
involvement of excitotoxic mechanisms in the pathogenesis of the disease, as 
is described below.
2.3.2 Glutamate Dysfunction in Alzheimer’s Disease
Various lines of evidence indicate that glutamate-mediated excitotoxic 
processes are involved in the chronic neurodegeneration seen in Alzheimer’s 
disease (AD) (for review see Greenamyre, 1986; Maragos e t al., 1987; Procter 
et al., 1988). The neuropathology of AD includes neuronal loss in cortex and 
hippocampus. Glutamate is putatively the major excitatory neurotransmitter 
in pyramidal neurones which constitute approximately 70% of the total 
neuronal population of mammalian cerebral cortex and mediate cortico- 
cortical and cortico-fugal neurotransmission (Peinado et al., 1986). Loss of 
cortical pyramidal cells is a prominent feature of AD leading to suggestions 
that cortical glutamate dysfunction may contribute to the pathophysiological 
progression of the disease. Subsequently, histological studies have also 
demonstrated disruption of cortico-cortical association pathways and cortico- 
hippocampal pathways which employ glutamate as a pre-synaptic 
neurotransmitter in AD (Rogers and Morrison, 1985; Hymen et al., 1987).
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Autoradiographic investigations of high-affinity glutamate uptake site 
distributions have shown marked reductions in uptake site densities in 
cortical and hippocampal regions (Cowburn et al., 1988) suggesting that 
glutamatergic presynaptic elements are severely reduced in AD. In addition, 
recent studies have indicated that many pyramidal neurones which contain 
neurofibrillary tangles also show glutamate-like immunoreactivity (see 
Maragos et al., 1987), while exposure of human neuronal cultures to 
glutamate can induce formation of paired helical filaments, which are 
constituents of neurofibrillary tangles suggesting a link between glutamate 
and cytoskeletal change in AD (De Boni and Crapper-McLachlan, 1985).
Supporting the hypothesis of glutamatergic disruption in AD there is 
also evidence from in vitro radioligand binding studies of loss of post-synaptic 
excitatory amino acid receptors in regions showing the neuropathological 
hallmarks of AD most notably in cortical and hippocampal regions 
(Greenamyre, 1986; Greenamyre et al. 1985, 1987; Chalmers e t al., 1990; 
Dewar et al., 1991). Greenamyre et al., (1985) found total glutamate 
binding to be reduced by 34-45% in the cerebral cortex of brains from AD 
patients compared to levels in age-matched controls. Subsequent ligand 
binding studies of glutamate subtype alterations in AD postmortem tissue 
have in general indicated down-regulation of excitatory amino acid receptor 
subtypes in cortex and hippocampus. However, the diverse etiology of the 
disease, and the variability of the extent of progression of the disease when 
AD patients come to postmortem, means that the overall pattern of receptor 
changes is not as yet clear. For instance, while a number of groups have 
reported reduced NMDA receptor levels in cortical and hipppocampal regions
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(Greenamyre 1986; Greenamyre et al., 1987; Chalmers et al., 1990), others 
have reported NMDA levels to be unaltered (Geddes e t al., 1986; Cowburn et 
al., 1988). [3H]-TCP binding to the NMDA receptor-associated ion channel 
has been reported to be reduced in frontal cortex and hippocampus of AD 
patients. In contrast, Procter et al. (1989) reported no change in [3H]-MK- 
801 binding in the cortex of AD patients, but demonstrated a possible 
dissociation of the coupling between the regulatory glycine site and the PCP 
binding site on the NMDA receptor channel.
AMPA and KA receptor binding has been shown to be unaltered in 
cortical regions of AD patients relative to levels in age-matched controls 
(Chalmers et al., 1990). In hippocampal regions, quisqualate/AMPA binding 
site deficits have been reported in the CA1 region, dentate gyrus and 
subiculum (Greenamyre et al., 1987; Dewar et al., 1991). Down-regulation 
of KA receptors in the CA1 region, and reductions in metabotropic receptor 
levels in subiculum and CA1 have also been reported in subiculum and CA1 
(Dewar et al., 1991). In conjunction with reports of the integrity of other 
receptor systems in these regions, including muscarinic cholinergic, 
benzodiazepine and GABAa binding sites, and the maintenance of normal 
glutamate binding levels in other brain areas, the observations from 
autoradiographical studies of excitatory amino acid receptor distributions in 
AD suggest that the pathogenesis of AD may involve regionally-specific, 
selective degeneration of structures innervated by glutamatergic projections.
The clinical manifestations of the disease include memory and learning 
impairments, processes in which glutamatergic systems are heavily 
implicated. For example, the hippocampus is the site of long-term
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potentiation, a phenomenon mediated by NMDA receptor activity in which 
brief, high frequency stimulation of glutamatergic afferents leads to a long- 
lasting enhancement in the synaptic response, which is putatively associated 
with memory (Collingridge and Bliss, 1987). Thus the profound loss of 
glutamate receptors in cortical and hippocampal regions may explain the 
learning and memory deficits which are prominent in AD. In addition, 
behavioural studies employing lesions of glutamatergic hippocampal pathways 
have demonstrated learning and memory deficits in experimental animals 
(Morris et al., 1986; Everitt e t al., 1987), thus supporting a role for 
glutamatergic hypofunction in the cognitive impairments characteristic of 
AD.
As a result of the observed role of NMDA receptors in long-term 
potentiation it has been suggested that positive modulation of NMDA 
receptor activity in AD patients may ameliorate the learning and memory 
impairments concomitant to the disease. Due to its well documented role 
in excitotoxicity, the potential of the NMDA receptor complex as a 
therapeutic site must be treated with caution. Therefore, manipulating 
the glycine co-agonist site with a partial agonist such as D-cycloserine, 
has been proposed as a possible route for modulating NMDA receptor activity 
in AD while avoiding the problems of excitotoxicity associated with excessive 
stimulation of the transmitter recognition site (Hood et al., 1989; Monahan 
et al., 1989b; Watson et al., 1990; Emmett et al., 1991; Chessell et al., 1991).
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2.3.3 Excitotoxic Basal Forebrain Lesions - A Model of Alzheimer’s Disease?
As a corollary of the observations of reduced cortical ChAT activity 
and concomitant loss or atrophy of neurones in the nucleus basalis of Meynert 
(nbM) of AD patients, it has been proposed that lesions of cholinergic basal 
forebrain - cortical projections in the ra t might constitute an animal model 
of AD. Subsequently, numerous studies in the ra t have reported evidence of 
cortical cholinergic dysfunction and impairment of performance in a variety 
of behavioural tests of learning and memory following both electrolytic and 
neurotoxic lesions of the nucleus basalis magnocellularis (NBM) basal 
forebrain region (for review see Dunnett e t al., 1991).
The nucleus basalis magnocellularis (NBM) region in the rat, believed to 
be homologous with the nbM in man, consists of a group of large 
acetylcholinesterase (AChE) positive neurones distributed diffusely amongst 
cells of the ventromedial globus pallidus. NBM efferents provide the major 
extrinsic cholinergic innervation of cortex, contributing up to 70% of the 
cholinergic content of neocortex (Johnston et al., 1981). While NBM lesions 
induce massive cholinergic denervation in the cortex (as demonstrated by 
decreases in cortical ChAT and AChE activities, choline uptake and ACh 
release), cortical ablation or neurotoxic cortical lesions reciprocally induce 
retrograde degeneration of cholinesterase-positive NBM neurones (Sofroniew 
and Pearson, 1985) raising the possibility that in some cases the histological 
changes seen in AD nbM may result from retrograde degeneration.
Experimental attempts to determine the functional role of NBM 
neurones have to date focused primarily on the consequences of destruction 
of NBM efferents on performance in behavioural tasks designed to assess
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different facets of cognitive function. In the absence of a selective 
cholinergic neurotoxin, and given the gross and non-specific nature of the cell 
destruction elicited by electrolytic lesions, axon-sparing excitotoxic amino 
acid lesions have been widely used to destroy cell bodies in the basal 
forebrain, including cholinergic neurones of the NBM. To this end, ibotenic 
acid, kainate acid (KA), quisqualic acid, AMPA and NMDA have all been 
employed to lesion NBM efferents (London et al., 1984; Orzi et al., 1987; 
Robbins et al., 1989a and b; Page et al., 1991). However, while such basal 
forebrain lesions have been found to impair performance in a variety of 
behavioural tasks which have been widely interpreted to reflect disturbances 
in learning and memory processes, Dunnett and colleagues have identified a 
dissociation in the effects of different excitatory amino acids, both in terms 
of cognitive deficits and accompanying cholinergic dysfunction (for review 
see Dunnett et al., 1991). Of the five excitotoxins cited above, AMPA and 
quisqualic acid appear to be the toxins of choice to lesion cholinergic NBM 
neurones, since they yield the greatest depletions in cortical ChAT activity 
while also sparing dorsal pallidal and non-cholinergic basal forebrain 
neurones. In the hands of different investigators, AMPA and quisqualate 
basal forebrain lesions have been shown to reduce cortical ChAT activity by 
approximately 40-70%, compared to 15-40% depletions seen following NMDA, 
KA and ibotenic acid lesions (Etherington et al., 1987; Dunnett e t al., 1987; 
Robbins et al., 1989 a and b; Page et al., 1991). AMPA appears to be the 
most cholinergic-selective of these neurotoxins, reducing cortical ChAT 
activity by more than 70%, which represents near total destruction of the 
extrinsic cholinergic innervation of neocortex (Page e t al., 1991). These
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observations suggest that the excitatory amino acid input to cholinergic NBM 
neurones is mediated largely through AMPA receptors.
Following from these observations, doubt has been cast upon the 
assumption that cognitive deficits seen following excitotoxic NBM lesions are 
due solely to loss of cholinergic neurones since different excitatory amino 
acid agonists have been found to have different effects on behavioural tests 
of learning, memory and attention (for review see Dunnett et al., 1991). 
Studies have revealed that whereas ibotenic acid and NMDA lesions impair 
performance in tests of cognitive and mnemonic function (such as acquisition 
of a visual discrimination task) quisqualic acid and AMPA fail to induce 
deficits in the same tasks despite producing far greater reductions in cortical 
ChAT activity, as illustrated in Table 3. It has therefore been suggested 
that the functional deficits induced by ibotenic acid basal forebrain lesions 
in these tasks cannot be attributed to the destruction of cholinergic neurones 
in the NBM. Instead, these apparent "cognitive" impairments may be due to 
disruption of other cognitive or non-cognitive processes within the basal 
forebrain, arising from non-specific destruction of non-cholinergic neuronal 
populations. However, Robbins and colleagues (1989b) have also 
demonstrated that basal forebrain lesions induced by ibotenic acid, 
quisqualate and AMPA all impair attentional function, as assessed by a 5- 
choice serial reaction time task. Supporting the involvement of cholinergic 
systems in the attentional task examined, comparable attentional deficits 
have subsequently been observed in the same test paradigm following 
intracerebroventricular administration of the high-affinity choline uptake 
inhibitor hemicholinium, the effects of which can be reversed by co-
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TABLE 3
EFFECTS OF EXCITOTOXIC BASAL FOREBRAIN LESIONS 
ON CORTICAL ChAT LEVELS AND COGNITIVE FUNCTION
IBOTENATE QUISQUALATE WDA AMPA
Dunnett e t  a l . 1987 0.06M (2x0.5|jl) 0.12M (2x0.5pl) 0.12M (2x0.5pl)
ChAT Depletion 41% 50% 39%
Water Maze +++
Passive Avoidance +++ +++ +++
Etherington e t  a l .  1987 0.06M (0 .4p l) 0.12M (2x0.5pl)
ChAT Depletion 17% 41%
Operant Delayed Matching ++
Wenk e t  a l .  1989 0.025M (0 .5p l) 0 .12M (0 .5p l)
ChAT Depletion 41% 73%
T-maze Discrimination ++ +
Robbins e t  a l .  1989a 0.06M (0 .4p l) 0.12M (2x0.5pl)
ChAT Depletion 31% 50%
Visual A ttention ++ ++
Robbins e t  a l .  1989b 0.06M (0 .4p l) 0 .12M (2x0.5pl)
ChAT Depletion 27% 44%
Conditional Learning ++
Riekkinen e t  a l .  1991 0.07M (2x0.3pl) 0.10M (2x0.3pl)
ChAT Depletion 51% 65%
Water Maze +++
Passive Avoidance ++ ++
Page e t  a l .  1991 0.09M (0 .5p l) 0.015M (0 .5p l)
ChAT Depletion 49% 70%
Water Maze +++
Passive Avoidance ++ ++
S e l e c t e d  e x a m p l e s  f r o m  t h e  l i t e r a t u r e  o f  d i f f e r e n t i a l  e f f e c t s  o f  b a s a l  f o r e b r a i n  
l e s i o n s  i n d u c e d  b y  i b o t e n a t e ,  q u i s q u a l a t e ,  N M D A  a n d  A M P A  o n  c o r t i c a l  
c h o l i n e a c e t y l t r a n s f e r a s e  ( C h A T )  a c t i v i t y ,  a n d  o n  v a r i o u s  t e s t s  o f  c o g n i t i v e  a n d  
a t t e n t i o n a l  f u n c t i o n .  W a t e r  m a z e ,  p a s s i v e  a v o i d a n c e ,  o p e r a n t  d e l a y e d  m a t c h i n g ,  
c o n d i t i o n a l  l e a r n i n g  a n d  T - m a z e  d i s c r i m i n a t i o n  t a s k s  a r e  t e s t s  o f  l e a r n i n g  a n d  
m e m o r y .  V i s u a l  a t t e n t i o n a l  t a s k s  a s s e s s  a t t e n t i o n a l  f u n c t i o n .
+ + +  m a j o r  d e f i c i t ;  + +  m o d e r a t e  d e f i c i t ;  +  m i l d  d e f i c i t ;  -  n o  d e f i c i t .
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administration of the anticholinesterase physostigmine (Muir et al., 1992a). 
These results are therefore consistent with the hypothesis that at least some 
of the deficits obtained on this attentional task may be attributable to 
disruption of cholinergic NBM-cortical projects.
As a consequence of the use of excitatory amino acids to lesion basal 
forebrain-cortex projections in these experiments, it appears that NBM- 
cortical cholinergic neurones do not play an essential role in learning and 
short-term memory processes, but may be involved in attentional function. 
Thus, studies employing the excitotoxic properties of glutamate congeners 
have further challenged the "cholinergic hypothesis" of memory dysfunction 
in dementia and aging.
These studies serve to highlight the problems surrounding putative 
animal models of the deficits seen in AD patients. While it is widely 
accepted that the diverse symptomatology of AD generally precludes the 
utility of animal models such as NBM lesions, except in attempting to mimic 
discrete lesions which might contribute to Alzheimer pathology, 
investigations of NBM neurotoxic lesions have identified a mismatch between 
biochemical ChAT deficits and functional cognitive deficits which were 
previously thought to be representative of the deficits underlying dementia. 
In addition, such studies illustrate the utility of using excitatory amino acids 
to manipulate neuronal activity, and give insight into the functional 
organisation of anatomical pathways within the CNS.
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3. IMAGING FUNCTIONAL ACTIVITY IN THE CNS
The development of autoradiographic radioligand binding techniques in 
the 1970s revolutionised experimental approaches for identifying and 
localising components of functional systems within the CNS (for review see 
Young and Fagg, 1990; London, 1993). In the past, investigations of 
neurotransmitter systems and functional pathways within the brain relied on 
biochemical, histochemical and electrophysiological techniques, such as 
mapping the transport of dyes or radiolabelled, fluorescent or 
immunofluorescent markers, measurement of the effects of discrete 
intracerebral interventions on levels of biochemical markers, and 
electrophysiological studies into the localisation of evoked electrical 
responses. However, the utility of these approaches is restricted by a 
number of fundamental drawbacks. Due to the nature of the experimental 
protocols involved, these procedures generally only permit investigation of 
isolated neuronal populations or pathways decided on a priori, and often 
necessitate the use of dissected brain tissue, therefore limiting the degree 
of anatomical localisation obtainable and giving little scope to evaluate the 
repercussions of manipulations on integrated activity throughout the CNS as 
a whole. In addition, while these methods may demonstrate pathways with 
a potential for function, they give no insight into their contribution to normal 
CNS activity. In contrast, in vitro and in vivo isotope labelling 
autoradiographic techniques allow mapping of CNS elements and functional 
activity, allowing visualisation and quantitation of specific radiolabelled 
ligand distributions in discrete structures throughout the CNS with high 
degrees of spatial resolution, in both normal and pathological conditions, and
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with no requirement for a priori determination of the regions to be examined. 
Quantitative autoradiographic procedures have now been adapted to assess 
many different components of integrated cerebral functional activity both in 
vitro and in vivot discussed in brief below, and provide a valuable tool to 
complement histochemical, biochemical and electrophysiological 
investigations of neurotransmitter-mediated events in the CNS (see London 
et al., 1993).
In vitro autoradiographic procedures have been applied to image the 
distributions of pre- and post-synaptic neuronal elements including binding 
sites, transmitter uptake sites and second messenger systems. For example, 
tritiated ligands have been widely used to map constituents of glutamatergic 
systems within the brain including distributions of NMDA, AMPA, kainate and 
metabotropic receptor-associated transmitter binding sites, receptor- 
associated ion channels, and high-affinity glutamate/aspartate uptake sites 
in both homogenate and tissue section preparations (Cotman et al., 1987; 
Young and Fagg, 1990; see also Section 1.1.6). Radiolabelled ligands also 
have a number of applications to map functional activity in vivo. 
Isotopically labelled orthograde and retrograde axoplasmic transport markers 
are used to map specific neuronal projections; labelled peptide substrates 
such as [3H]-leucine and [3H]-valine localise sites of protein synthesis; the 
distribution of activated receptor complexes may be mapped in vivo by 
radiolabelled tracers, such as the localisation of active NMDA receptors by 
[,25I]-MK-801 (McCulloch et al., 1992).
Initial investigations of cerebral energy metabolism in vivo employed 
the nitrous oxide method of Kety and Schmidt (1948) or adaptations of this
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procedure (for review see Sokoloff, 1981). However, these procedures only 
measure average rates of energy metabolism throughout the brain as a whole, 
and consequently, while these techniques have demonstrated changes in 
cerebral metabolic rate following gross or diffuse changes in cerebral 
function (for example during anaesthesia) they are relatively insensitive to 
subtle or localised changes in cerebral metabolism (Sokoloff, 1981). 
Quantitative autoradiographic in vivo imaging procedures have enabled 
assessment of local rates of cerebral blood flow and energy metabolism in 
discrete brain regions, allowing non-prejudicial measurement of dynamic 
events simultaneously throughout the CNS.
Local rates of cerebral blood flow may be measured using [14I]- 
antipyrine (Sakurada et al., 1978); and cerebral energy metabolism can be 
assessed in terms of local rates of cerebral glucose use (LCGU) by measuring 
[14C]-2-deoxyglucose uptake in discrete brain regions (Sokoloff et al., 1977).
In addition, the 2-deoxyglucose method has been modified to allow 
local measurement of glucose utilisation in man. Radiolabelling the 
2 -deoxyglucose molecule with the y-em itter 18F allows non-invasive detection 
of local levels of 2 -deoxyglucose in the brain using computerised positron- 
emission tomography (PET).
In the present thesis, the indices of cerebral functional activity in the 
rat, under both normal and pathological conditions, have been investigated in 
vivo using principally two quantitative autoradiographic techniques, which are 
described in detail below. The [1 4C]-2-deoxyglucose procedure, which 
facilitates the measurement of cerebral metabolic rates for glucose in vivo, 
has been characterised in great detail over the last 15 years since its
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development by Sokoloff and colleagues (1977). In contrast the [1 2 5I]-MK- 
801 technique which maps the distribution of activated NMDA receptors in 
vivo was developed relatively recently and has yet to be extensively 
investigated.
3.1 [14C]-2-Deoxyglucose Autoradiography Maps Cerebral Glucose Use In Vivo 
[u C]-2-Deoxyglucose autoradiography (Sokoloff e t al., 1977) provides a 
unique opportunity to gain insight into functional activity within the brain as 
it is reflected by local rates of cerebral glucose utilisation. This 
autoradiographic technique permits in vivo localisation and quantitation of 
glucose use in discrete anatomical regions throughout the CNS.
The conceptual basis of the method is that, under normal physiologic 
conditions, aerobic catabolism of glucose constitutes the major energy- 
generating pathway for cerebral tissue. Since the functional activity of any 
CNS region is intrinsically linked directly with energy consumption within 
that region, and as the CNS has only a minimal capacity to store 
carbohydrate, then function-related energy requirements must be met by 
oxidative catabolism of glucose extracted from the circulating blood 
(Sokoloff et al., 1977; Siesjo, 1978; McCulloch, 1982).
The use of isotopically labelled 2-deoxyglucose to determine rates of 
cerebral glucose utilisation takes advantage of the biochemical 
characteristics produced by the simple modification of glucose to 2 - 
deoxyglucose. Both molecules are transported into brain cells from the 
blood by the same uptake carrier at the same rate, where both undergo 
phosphorylation by hexokinase. However at this stage the metabolic
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pathways of the two molecules diverge. While glucose-6 -phosphate is further 
metabolised, deoxyglucose-6 -phosphate metabolism ceases (at least for the 
45 min duration of the experiment) and the molecule becomes essentially 
trapped within the neurones (Sokoloff e t al. 1977). Therefore, by 
isotopically labelling 2-deoxyglucose with 1 4C, the amount of 2-deoxyglucose 
taken up into discrete brain structures can be measured densitometrically. 
By using the operational equation developed by Sokoloff and colleagues 
(1977), a mathematical model which takes into consideration the 
biochemical properties of glucose and 2 -deoxyglucose, the local rate of 
glucose utilisation in a given structure can be calculated from the levels of 
glucose and [u C]-2-deoxyglucose in the circulating arterial blood, and the 
autoradiographically determined level of [u C]-2-deoxyglucose in the structure 
(see Methods, Section 1.1). It is therefore possible to identify structures 
and pathways throughout the entire CNS in which metabolic activity is 
altered.
Many different energy-dependent processes contribute to the rate of 
glucose utilisation within neurones, including transmitter synthesis, release 
and reuptake; the biosynthesis of macromolecules; and the maintenance of 
ionic gradients by ionic pumping. In addition, the different structural 
elements of cerebral tissue, such as the neuronal perikarya, terminals, axons 
and dendrites, and glial cells, will differentially contribute to glucose use 
within a region. It has been estimated that neurones account for 
approximately 75% of the total oxygen consumption in the CNS (Siesjd, 1978), 
while electrical activity in neuronal terminals is thought to provide the major 
contribution to dynamic alterations in cerebral glucose use (see Sokoloff,
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1981; Kadekaro e t al., 1987; Dewar and McCulloch, 1992). Studies also 
indicate that most of the energy generated by the brain is used for ion 
transport. This is based on findings that induction of an isoelectric 
encephalogram (EEG) by barbiturate anaesthesia reduces cerebral glucose 
catabolism to about 40% of its normal level (Crane et al., 1978), while 
concomitant inhibition of the Na+, K+-ATPase electrogenic pump further 
reduces cerebral glucose use to approximately 2 0 % of its normal level 
(Astrup et al., 1981).
It should also be noted that the local rate of glucose utilisation 
measured in a discrete region of the brain represents the average glucose use 
in a heterogenous population of cell types within that structure (including 
afferent neurones, interneurones and glia). Hence, if different cell types 
within the same structure exhibit opposite alterations in [1 4C]-2-deoxyglucose 
uptake, no overall change in deoxyglucose uptake may result, despite radical 
alterations in functional activity at the cellular level. In addition, increases 
and decreases in glucose use cannot be equated simply with neuronal 
excitation and inhibition, respectively. There is no evidence to suggest that 
the energetic requirements of post-synaptic inhibition are any different than 
those of excitation, particularly when reflecting that the largest component 
of glucose use is apparently associated with terminal activity. This view 
receives support from studies by Ackerman and colleagues (1984) which 
demonstrated increased glucose use during long-duration recurrent inhibition 
in the hippocampus. Thus, changes in glucose use may be used to define 
regions in which neuronal activity is altered. However, in pharmacological 
investigations these regions will not represent solely the primary sites of
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drug-receptor interaction, but will reflect polysynaptic circuits in which 
activity is influenced by the consequences of the receptor manipulation.
A number of alternative approaches to determine local cerebral 
metabolic rate have previously been investigated, for example, measuring the 
local tissue concentrations of inert, diffusable radioactive tracers (based on 
methods used to determine local rates of cerebral blood flow; Landau e t al., 
1955; Kety, 1960), or using I3!!]- and [1 4C]-deoxyglucose (Crane e t al., 1978) 
or [1 4C]-glucose (Hawkins et al., 1974) as tracer molecules. However these 
methods have proved unsatisfactory compared to the [1 4C]-2-deoxyglucose 
technique of Sokoloff et al., (1977) for a number of reasons. Firstly, the use 
of inert radioisotopes is handicapped by the unsuitability of the radiolabelled 
species of the normal substrates for cerebral energy metabolism, oxygen and 
glucose, for measurement in vivo. Both oxygen and glucose are rapidly 
converted to carbon dioxide, which is subsequently cleared from the cerebral 
tissues too rapidly for accurate measurements (for review see Sokoloff e t al., 
1977; Sokoloff, 1981). In contrast, the method of Crane et al., (1978) 
measures the accumulation of deoxyglucose-6 -phosphate over a brief period 
(4 minutes) after rapid inactivation of hexokinase. Although the short time 
constant makes this approach attractive, the requirement of gross tissue 
dissection and chromatographic detection of deoxyglucose-6 -phosphate levels 
restrict its utility due to the limited neuroanatomical localisation possible 
compared with autoradiographic approaches. In addition, doubts surround 
the constancy of the phosphorylation coefficient in this method and it has 
been suggested that glucose use measures may be influenced by transient 
changes in local cerebral blood flow (for review see McCulloch, 1982).
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Thirdly, the method described by Hawkins et al. (1974) employing 
radiolabelled glucose has proved to be untenable since one of the central 
assumptions of the technique - that isotopic equilibrium exists between 
glucose pools in the CNS and in arterial plasma - has been shown to be 
invalid (see McCulloch, 1982).
The use of the [1 4C]-2-deoxyglucose in vivo autoradiography technique 
of Sokoloff and colleagues (1977) has a number of advantages over the 
procedures outlined above, most notably that it allows the quantification of 
local rates of cerebral glucose utilisation simultaneously in all components 
of the CNS, in conscious animals. This approach is non-prejudicial, allowing 
the identification of brain regions involved in functional events which may 
not have been predicted a priori. The method also attains a high degree of 
spatial resolution of 14C distribution, while the use of cryostat-processed 
brain sections allows the [1 4C]-2-deoxyglucose method to be combined with 
ligand binding autoradiography in consecutive sections, to enable investigation 
of any receptor alterations in functionally altered regions. The [1 4C]-2- 
deoxyglucose technique can therefore give novel insight into cerebral 
metabolic alterations occurring during physiological, pathophysiological or 
pharmacological challenge. A small number of the many diverse applications 
of this technique are reviewed briefly below.
3.1.1 Applications of f1 4Cl-2-Deoxvglucose Autoradiography 
Physiological Applications
Simple sensory stimulation and deprivation experiments provide strong 
support for the utility of the [1 4C]-2-deoxyglucose method for measuring local
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cerebral function. Deprivation of visual stimuli, for example by orbital 
enucleation in the rat, results in markedly reduced glucose use in both 
primary neuroanatomical components of the visual system (the superior 
colliculus superficial layer and the dorsal lateral geniculate body) and in 
secondary regions (area 17 of neocortex) (Toga and Collins, 1981; Chalmers 
and McCulloch, 1991). In contrast, visual stimulation by diffuse light 
induces intensity-dependent increases in glucose use in these regions (Miyaoka 
e t al., 1979; Toga and Collins, 1981). In addition, similar studies in monkeys 
have identified and characterised ocular dominance columns in striate cortex 
of monkeys (Kennedy et al., 1975). Thus, the [1 4C]-2-deoxyglucose technique 
has demonstrated that altered functional activity of photoreceptors in the 
retina results in metabolic changes not only in the region containing the 
photoreceptors, but also in components of the polysynaptic pathway involved 
in processing visual information in the CNS.
Similarly, alterations in glucose use within polysynaptic circuits are also 
seen following modulation of other sensory systems. For example, electrical 
stimulation of the sciatic nerve in rats results in pronounced increases in 
glucose use in the ipsilateral dorsal horn of the lumbar spinal cord, 
corresponding to a local increase in terminal activity (Kadekaro e t al., 1987). 
Auditory stimulation increases glucose use throughout the primary auditory 
pathway, from the cochlear nucleus to auditory cortex, while occlusion of the 
external auditory canals reduces glucose use in these regions (Sokoloff e t al., 
1977). Olfactory stimulation with various odours has also been shown to 
enhance glucose utilisation in certain regions of the olfactory bulb (Kauer and 
Cinelli, 1993). In addition, Ginsberg et al., (1987) have demonstrated in the
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ra t that movement of a single whisker increases glucose use in a discrete 
column of the somatosensory cortex. Further, marked focal increases in 
glucose use occur in brain areas involved in cardiovascular regulation, such 
as the paraventricular and supraoptic nuclei of the hypothalamus and the 
nucleus of the tractus solitarus, following moderate hypotension (Savaki et 
al., 1982). Studies like these reflect a close coupling between local 
functional activity and energy metabolism in the CNS. In addition, results 
demonstrate that metabolic responses may be used to identify CNS regions 
involved in specific responses to physiological stimuli.
Pathological Manipulations
The utility of the [1 4C]-2-deoxyglucose technique to assess alterations 
in glucose use in pathological states is restricted in conditions involving 
structural damage within the CNS, such as cerebral ischaemia, due to a 
number of factors which will influence the viability of the measurement. 
These include the possibility of impeded delivery of glucose and deoxyglucose 
to the brain as a result of critically reduced cerebral blood flow, altered 
plasma glucose levels, alterations in the values of the rate constants and/or 
lumped constant of the model, or the establishment of non-steady state 
kinetics for either glucose metabolism or tissue levels of glucose and its 
metabolites (for review see Ginsberg, 1990). The effects of ischaemia on 
2-deoxyglucose uptake are discussed further in Section 3.1.2.
In some pathophysiological convulsive states where no structural tissue 
damage occurs, the [1 4C]-2-deoxyglucose procedure has been employed to map 
seizure-propagation, demonstrating massively increased glucose use in CNS
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areas activated by seizures (for review see Sokoloff, 1981). It should be 
noted that in some seizure states such as status epilepticus, fluctuations in 
presumed experimental constants (such as plasma glucose levels) and neuronal 
damage may occur, which will have a bearing on the accuracy of glucose use 
calculations.
Pharmacological Applications
[1 4C]-2-deoxyglucose autoradiography has been used in conjunction with 
manipulations of almost all known neurotransmitter systems within the CNS 
to gain insight into central drug actions. This technique is optimally 
exploited when investigating function-related changes in glucose use 
associated with receptor stimulation or blockade, when comparing the actions 
of agents putatively acting at the same receptor, or when contrasting the 
mechanisms of action of different drugs. Alternatively, the method allows 
different routes of drug administration to be compared, for example systemic 
versus direct intracerebral administration, or to investigate the temporal 
progression of functional events after lesioning or stimulating specific 
pathways within the CNS. There have been many such studies into 
transmitter/drug action, which have previously been extensively reviewed (see 
McCulloch, 1982; Kurumaji et al., 1993). A number of glucose use studies 
are briefly reviewed below in an attempt to highlight the many diverse, novel 
insights into the functional consequences of drug/receptor interactions which 
[14C]-2-deoxyglucose autoradiography can provide.
Manipulations of dopaminergic systems within the CNS, after either 
systemic administration of dopamine agonists and antagonists or stereotaxic
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lesions of dopaminergic pathways, have shown that glucose use alterations 
after any of these manipulations are restricted in their anatomical 
distribution, emphasising the selective nature of functional events which are 
influenced by dopaminergic activity (Brown and Wolfson, 1978; McCulloch et 
al., 1982a; for review see McCulloch, 1982). Systemic administration of the 
dopamine agonists apomorphine or amphetamine increased glucose use in 
regions containing dopamine receptors, including the striatum, globus pallidus, 
substantia nigra pars compacta and reticulata, and the subthalamic nucleus 
However, glucose use changes were not restricted to areas rich in dopamine 
receptors. Other regions devoid of dopamine receptors, but influenced by 
activity in extrapyramidal regions, also showed glucose use elevations (e.g. 
in the cerebellar hemisphere, inferior olivary nucleus, motor cortex, motor 
relay thalamic nuclei, and the red nucleus). Glucose use increases in all 
these regions were eliminated by prior administration of the dopaminergic 
antagonist haloperidol (McCulloch et al., 1982b).
Direct intracerebral approaches to manipulate neuronal activity within 
the brain, for example by lesioning dopaminergic pathways or injecting 
dopaminergic agents directly into discrete brain regions, have also proved 
useful for characterising the involvement of specific brain regions in 
dopaminergic activity. For example, both systemic and local striatal 
injection of apomorphine result in enhanced glucose use in the subthalamic 
nucleus (Kozlowski and Marshall, 1980). The observation that the 
consequences of systemic apomorphine administration in this region could be 
inhibited by lesioning striatal efferents suggested that activation of a striato- 
pallidal-subthalamic pathway is the primary cause of increased subthalamic
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glucose use, rather than activation of dopaminergic receptors intrinsic to this 
region (Kelly e t al. 1982). Similarly, the combination of systemic 
administration of apomorphine and lesioning of the retinal input to primary 
visual structures in [14C]-2-deoxyglucose studies has aided characterisation 
of the involvement of retinal dopaminergic receptor activation in visual 
processes (Miyaoka et al., 1979; McCulloch et al., 1980). In general, 
procedures resulting in decreased dopaminergic activation result in glucose 
use reductions, whereas activating dopamine receptors (for example by 
apomorphine or amphetamine administration) leads to increases in glucose use 
(McCulloch, 1982).
In contrast, activation of receptors specific for the major inhibitory 
neurotransmitter, y-aminobutyric acid (GABA), by GABAa agonists muscimol 
or 4,5,6,7-tetrahydroisoxazole[5,4-c]pyridin-3-ol (THIP), results in glucose 
use depression throughout the CNS (Kelly and McCulloch, 1982, 1984; Kelly 
et al., 1986). However, investigation of log dose-response curves for glucose 
use changes following muscimol and THIP emphasises a regional 
heterogeneity in the susceptibility of structures to glucose utilisation 
modification by these GABAa agonists (Kelly e t al., 1986). In addition, the 
route of administration of muscimol influences the glucose use response seen. 
In contrast to the widespread functional depression seen following systemic 
administration, local activation of GABAergic mechanisms by intrastriatal 
injection of muscimol evokes both increases and decreases in glucose use: 
glucose use being reduced in the ipsilateral striatum, but elevated in striatal 
efferent projection targets such as the globus pallidus and substantia nigra 
pars reticulata (Kelly and McCulloch, 1984).
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A further example of how studies of the effects of GABA agonists on 
cerebral glucose use have enhanced understanding of GABAergic systems in 
the CNS arose from the observation that systemic administration of 
muscimol evoked significant alterations in glucose use in the substantia nigra 
pars reticulata, despite this putatively being a site of essential GABA 
activity within the brain. Kelly and McCulloch (1987) suggested that this 
occurred because inhibitory striatal efferent activity in this region was 
already near maximal in normal conscious animals, and hence GABAa agonists 
would be ineffective unless the influence of this pathway was removed or 
reduced, for example by lesioning striatal efferents.
The contributions of excitatory neurotransmitter systems to functional 
activity have also been investigated, such as 5-hydroxytryptamine (5-HT2, 
serotonin), acetylcholine and glutamate. While studies involving lesion 
paradigms have shed little light on 5-HT mechanisms (Cudennec et al., 
1988a), electrical stimulation of serotonergic pathways has facilitated 
mapping of 5-HT-dependent systems (Cudennec et al., 1988b). The use of 
cholinergic agonists and antagonists in functional mapping investigations has 
highlighted the involvement of cholinergic mechanisms in pathways thought 
to be involved in learning and memory paradigms in the CNS (Hel6 n and 
London, 1984; Kurumaji et al., 1993). Manipulations of excitatory amino 
acid receptor systems are reviewed below.
3.1.2 Glutamate and Cerebral Glucose Use
Since glutamate is the major excitatory neurotransmitter in the CNS, 
and its excitotoxic action is implicated in the pathogenesis of several
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neurodegenerative disorders, the effects of glutamate receptor manipulations 
on cerebral function in both normal and pathologic conditions are of great 
interest. Hence the [u C]-2-deoxyglucose autoradiography technique has 
been widely used to determine the cerebral metabolic consequences of 
glutamate receptor-mediated events in experimental animals, for example by 
pharmacological manipulations of excitatory amino acid receptors and in 
pathologic conditions associated with elevated extracellular glutamate levels 
such as cerebral ischaemia, subdural haematoma and excitotoxic lesions (for 
review see Ginsberg, 1990).
Pharmacological Manipulations
Due to the wide ranging metabolic and transmitter actions of glutamate 
in the CNS, analysis of the effects of systemic glutamate administration on 
glucose use presents numerous interpretational problems. However, 
intravenous administration of the glutamate analogue kainic acid, a t a dose 
previously demonstrated to be neurotoxic to specific hippocampal neurones 
when administered systemically, has been found to massively increase glucose 
use in a limited number of limbic structures (in particular in hippocampal 
regions CA1 and CA3, the lateral septal nucleus and amygdala), whereas 
glucose use in other CNS regions was unaltered (Celik e t al., 1979).
Due to the fact that a number of selective NMD A receptor antagonists 
have been available for several years, the consequences of NMDA receptor 
blockade on cerebral glucose use have been intensively studied. Systemic 
administration of NMDA antagonists results in widespread heterogeneous 
alterations in glucose use throughout the CNS, with pronounced differences
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seen between the effects of competitive and non-competitive antagonist 
classes. These discrepancies are thought to reflect the different 
mechanisms of action of NMDA antagonists. For example, non-competitive 
NMDA antagonists such as MK-801 and phencyclidine (PCP) markedly 
increase glucose use in anatomical components of the limbic system (in 
particular posterior cingulate cortex and entorhinal, cortex, hippocampus, 
mamillary body, substantia nigra pars compacts and pars reticulata), while 
moderately reducing glucose use in neocortex and the inferior colliculus 
(Weissman et al., 1987; Nehls et al., 1988; Kurumaji et al., 1989; McCulloch 
and Iversen, 1991; Hargreaves et al., 1993b). The hypermetabolic sequelae 
of non-competitive NMDA antagonists, for instance in components of the 
Papez circuit, appear to reflect the use-dependent nature of NMDA receptor 
channel blockade in these areas (Kurumaji et al., 1989). It appears that 
presynaptic terminal activity is enhanced during non-competitive channel 
blockade in an attempt to overcome the blockade by elevating synaptic 
glutamate concentrations.
In contrast to the non-competitive NMDA antagonists, which generally 
produce similar patterns of glucose use alterations, competitive antagonists 
display heterogeneous effects on glucose use. For example, CPP and AP7 
induce few overt glucose use changes, but CPP-ene reduces glucose use in 
sensory regions including auditory and visual structures, while not markedly 
affecting glucose use in limbic regions (Chapman et al., 1989; Kurumaji et 
al., 1989). In addition, the AP7 analogue CGP-39551 (2-amino-4-methyl- 
5-phosphono-3-pentanoic acid 1 -ethyl ester), a potent orally active 
competitive NMDA antagonist, induces large increases in glucose use in
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limbic regions, the extrapyramidal system and olfactory regions, whilst not 
affecting sensory regions (Chapman et al., 1991). These heterogeneous 
patterns of glucose use changes evoked by competitive NMDA antagonists 
may represent some degree of affinity of these agents for other receptor 
classes, or alternatively may reflect the proposed existence of sub­
populations of NMDA receptors within the brain (Sakurai e t al., 1993; 
Seeburg, 1993). Selective, centrally active AMPA receptor antagonists have, 
in contrast, only recently become available. The consequences of AMPA 
receptor blockade on local rates of cerebral glucose utilisation are addressed 
in this thesis.
Pathologic Conditions
Following experimental focal ischaemia induced by MCA occlusion, 
glucose use is greatly diminished in the ischaemic core in the caudate 
nucleus, while a transient increase in glucose utilisation has been 
demonstrated in a zone around the periphery of the infarcted tissue (Shiraishi 
and Simon, 1990; for review see Ginsberg, 1990). This enhanced [1 4C]-2- 
deoxyglucose uptake in the ischaemic penumbra was previously speculated to 
be due to anaerobic glycolysis, since double-labelling studies of local cerebral 
glucose use and cerebral blood flow (CBF) have demonstrated that areas of 
increased glucose use coincided with regions in which local CBF was 
markedly depressed (Ginsberg, 1990). Thus, the cerebrometabolic sequelae 
of ischaemic damage are in marked contrast to the association between 
glucose use and CBF in normal, non-ischaemic brain, where local levels of 
metabolism and blood flow are generally tightly coupled. However, an
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increasing body of evidence supports the concept that this hypermetabolic 
response represents excitatory activity in penumbral neurones induced by 
abnormally high levels of glutamate release (Shiraishi and Simon, 1990). 
After global forebrain ischaemia, [1 4C]-2-deoxyglucose autoradiographic 
studies in rat and gerbil have demonstrated general glucose use depression lh 
post-ischaemia, (with the exception of the hippocampus) which persists for 
up to 48h in parietal cortex and caudate. In hippocampal regions (in 
particular, CA1), marked, though transient increases in glucose use are seen 
(Pulsinelli et al., 1982). This intense increase in the rate of 2-deoxyglucose 
uptake in the hippocampus coincides with the period of early postischaemic 
reperfusion and reported electrical hyperactivity in neurones, and is followed 
by delayed neuronal death in CA1 2-3 days later.
Subdural haematoma in the rat, which results in a zone of focal 
ischaemic damage in areas of cortex and striatum immediately underlying the 
haematoma, has also been shown to have a marked, but transient effect on 
cerebral metabolism around the lesion site (see Bullock et al., 1992). 
Glucose use is transiently increased in the periphery of the ischaemic zone, 
persisting for 2-4h after induction of the haematoma. However, the most 
striking change in functional activity occurs bilaterally in the hippocampi, 
where glucose use increases of approximately 142% have been detected in 
ipsilateral CA1 2h post-haematoma, disappearing by 4h post-lesion.
Excitotoxic lesions induced by direct intracerebral injections of 
excitatory amino acid agonists have been shown to result in reduced 2 - 
deoxyglucose uptake in the lesion core. However, it should be noted that in 
damaged tissue reduced uptake does not necessarily represent decreased
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metabolic rate (as discussed in Section 3.1.1). Nevertheless, decreases in 2- 
deoxyglucose uptake have been observed following a number of different 
interventions, including in the striatum following intra-striatal injections of 
kainic acid (Wooten and Collins, 1982; Kelly et al., 1982), in the amygdala 
following kainate lesions (Tremblay et al., 1983), and in the entorhinal cortex 
14 days after ibotenate lesions of this region (Kurumaji and McCulloch, 
1990a). In the latter study, the NMDA antagonist MK-801 was shown to 
profoundly alter the cerebral metabolic responses to entorhinal lesions in 
CNS regions innervated by the putatively glutamatergic projection arising 
from the entorhinal cortex. In contrast, intrahippocampal injections of the 
NMDA antagonist MK-801 result in elevated glucose utilisation in 
hippocampal regions 8-10 days post-lesion (Kurumaji and McCulloch, 
1990b).
3.2 Imaging NMDA Receptor Activation In Vivo With [125I]-MK-801
[125I]-MK-801 autoradiography maps the distribution of activated NMDA 
receptor-channel complexes throughout the CNS (McCulloch et al., 1992; also 
see Wallace et al., 1992). The theoretical basis for this technique is that 
the NMDA antagonist MK-801 binds non-competitively at a site within the 
NMDA receptor-associated cation channel. At resting membrane potentials 
this channel is voltage-dependently blocked by Mg2+. Therefore membrane 
depolarisation is required to remove this blockade, facilitating receptor 
activation by agonist binding at the cell surface recognition site, leading to 
channel opening. Thus, MK-801 binding within the channel only occurs when 
the NMDA receptor complex is activated (see Figure 1) (Kemp et al., 1987).
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Since MK-801 is highly lipophilic and readily crosses the blood-brain barrier, 
it is postulated that, following intravenous injection of tracer levels of [1 2 5I]- 
MK-801, subsequent autoradiographic detection and measurement of the [1 2 5I] 
radiolabel in discrete brain regions will allow quantitative mapping of [1 2 5I]- 
MK-801 binding, putatively reflecting the extent of NMDA receptor 
activation throughout the CNS. In order to take into account the degree of 
non-specific [125Il-MK-801 binding within the brain, densitometric measures 
of isotope levels in forebrain structures are compared with cerebellar isotope 
levels, which act as a measure of non-specific binding due to the paucity of 
NMDA receptors in this region (McCulloch et al., 1992).
The specificity of [1251]-MK-801 for the NMDA receptor ionophore has 
been investigated by co-administration of pharmacological doses of "cold" 
MK-801 and tracer doses of [125I]-MK-801 in experimental animal models of 
focal ischaemia following MCA occlusion (McCulloch et al., 1992). 
Compelling evidence implicates the involvement of NMDA receptors in the 
neuropathologic processes of ischaemic brain damage, since NMDA receptor 
antagonists ameliorate ischaemic damage in experimental models of focal 
cerebral ischaemia, brain trauma and subdural haematoma (see McCulloch 
and Iversen, 1992). McCulloch and colleagues (1992) demonstrated in the 
rat, following MCA occlusion, that cold MK-801 displaced [125I]-MK-801 
binding in pathologically damaged tissue within the ischaemic core. [1 2 5Il- 
MK-801 was not readily displaced in non-ischaemic tissue. It has previously 
been shown that extracellular levels of amino acids such as glutamate and 
aspartate are elevated during an ischaemic insult (Benveniste et al., 1984; 
Drejer e t al., 1985; Butcher e t al., 1990), and these elevations are thought to
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In previous studies assessing [125I]- and [3H]-MK-801 binding in vivo, non­
specific binding has been determined by displacem ent of the radioligand by! 
an excess of cold MK-801 (Wallace e t al., 1992; McCulloch e t al., 1992).
This approach was not used in the present study, which employed a tracer
1 1 dose of [ IJ-MK-801, since the required concentration of cold MK-801 would
be sufficient to be pharmacologically active in vivo , blocking the NMDA
recep tor ionophore s and would therefore in terfere  with the action of
D-cycloserine under investigation. As a consequence, levels of [125I]-MK-801
binding in the cerebellum were used in the present study as an estim ate of
non-specific binding since the cerebellum contains a low density of NMDA
receptors relative to forebrain structures. However, it is recognised that
this does not constitute an accurate m easure of non-specific binding. As a
consequence, in this thesis [125I]-MK-801 binding levels are referred  to as
" to ta l” binding in forebrain structures re la tive  to  cerebellar levels. In studies
employing displacement of radiolabelled MK-801, non-specific binding has
been found to constitute approximately 50% of to tal binding (Wallace e t al.,
1992). The differences in the ability of cold MK-801 to displace [125I]-MK-
801 binding in normal and damaged tissue reported by McCulloch e t al., (1992)
appear to re flec t the large signal to noise ratio  seen in [125I]-MK-801
autoradiograms.
underlie excitotoxic cell death in ischaemia. Thus, the observation of [1 2 5I]- 
MK-801 binding in conditions of increased glutamate-induced receptor 
stimulation, and therefore enhanced channel opening, suggests that [1 2 5I]-MK- 
801 is binding at abnormally activated NMDA receptors. These observations 
suggest that [125I]-MK-801 is mapping a dynamic process involved in the 
evolution of ischaemic brain injury in vivo, a view further supported by 
findings that [125I]-MK-801 binding in ischaemic tissue declines over time, 
reflecting the progression of the ischaemic pathology from reversible to 
irreversible neuronal changes. However, [125I]-MK-801 uptake was not 
reduced by cold MK-801 in non-ischaemic tissue where normal levels of 
NMDA activation exist, leading to uncertainty about the utility of using 
[125Il-MK-80l as an in vivo ligand in the normal CNS.
It has therefore been suggested that [125I]-MK-801 autoradiography may 
be valuable in elucidating the functional competency of NMDA receptors in 
vivo during a pathological challenge, such as ischaemia. This technique 
provides an opportunity to map dynamic activation of NMDA receptors both 
in animal models (McCulloch et al., 1992; Wallace e t al., 1992) and in man 
(McCulloch et al., 1991).
In the present thesis the [125I]-MK-801 in vivo binding technique has 
been used to try to elucidate whether NMDA receptor activation occurs in 
the CNS following putative stimulation of the NMDA receptor complex. 
Experiments are described which assess dynamic changes in NMDA receptors 
following administration of D-cycloserine, a ligand at the glycine modulatory 
site on the NMDA receptor complex at a putative agonist dose (see Section 
4.3).
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4. AIMS OF THESIS
This thesis will investigate what insight can be gained into the 
consequences of glutamate receptor manipulations on cerebral function by 
the use of quantitative autoradiographic techniques to map functional events 
in vivo.
The experiments described employ three different approaches to 
manipulate the activities of glutamate receptor subtypes, namely blockade 
of AMPA receptor activity, modulation of NMDA receptor activity by a 
glycine site partial agonist, and modification of neuronal activity in a 
circumscribed region of the CNS by direct intracerebral injections of 
excitatory amino acid receptor agonists. The analytical techniques used 
allow examination of aspects of the functional consequences of manipulations 
which putatively influence glutamate’s roles in the CNS as a 
neurotransmitter, and as a neurotoxin.
4.1 AMPA Receptor Blockade
Glutamate-induced neurotoxicity is implicated in the pathology of 
neurodegenerative disorders such as ischaemia. In the last ten years, much 
effort has been exerted in attempts to ameliorate the excitotoxic properties 
of glutamate by manipulating excitatory amino acid receptor activities. 
Most work, to date, has focused on modulation of the NMDA receptor due to 
the availability of potent NMDA receptor antagonists. However, while 
NMDA receptor antagonists such as MK-801 and CPP-ene are undoubtedly 
potent neuroprotectants, their clinical utility is restricted by their adverse 
effects on brain function. NMDA receptor antagonists have been found to
110
induce morphological cell changes including cytoplasmic swelling in certain
regions of the CNS, notably in the posterior cingulate cortex (Olney et al.,
1989, 1991; Hargreaves e t al. 1993). These changes, which are similar to
excitotoxic neuronal pathology, may progress to cell death. Previous [1 4C]-
2 -deoxyglucose autoradiography studies have highlighted hypermetabolic
sequelae of NMDA receptor blockade in regions associated with abnormal
morphometric cell changes and altered gene expression, (Park et al., 1988a
and b; Kurumaji et al., 1989; Hargreaves e t al., 1993). In addition NMDA
iGrotta (1994)
antagonists are associated with psychosis and memory loss. Therefore, it is 
important to identify alternative anti-ischaemic strategies which avoid the 
adverse metabolic effects of NMDA antagonists.
Attention has recently turned to trying to ameliorate excitotoxicity at 
non-NMDA receptors. In particular, AMPA receptor activity has come under 
increased scrutiny following reports that the fast excitatory post-synaptic 
potential (EPSP) mediated by AMPA receptors underlies neuronal excitation, 
and the identification of several mechanisms of AMPA receptor involvement
A
in Ca influx, (which are postulated to be the ultimate cause of cell death). 
Subsequently, various non-NMDA antagonists have been shown to be neuro- 
protective in both in vitro and in vivo models of excitotoxicity and 
ischaemia. To date, the most potent AMPA receptor antagonists described 
are NBQX and the novel agent LY-293558.
NBQX: A quinoxalinedione analogue, 2,3-dihydroxy-6-nitro-7-sulfamoyl- 
benzo(F)quinoxaline (NBQX) is the most potent AMPA antagonist of this class 
as yet reported. In binding studies in ra t cortical membranes NBQX
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competitively inhibited [ H]AMPA binding with an IC50 of 150nM compared 
to an IC5 0 of 4.8plM for displacement of [ H]-KA binding. In addition, NBQX 
has no affinity for the transmitter recognition site or the glycine regulatory 
site on the NMDA receptor complex (Sheardown et al., 1990). NBQX has 
been found to be neuroprotective in both in vitro (Sheardown et al., 1990), 
and in vivo models of global ischaemia in the gerbil (Sheardown et al., 1990) 
and the rat (Buchan et al., 1991a; Nellgard and Wieloch, 1992; Diemer et al., 
1993; Sheardown et al., 1993), and in a model of focal ischaemia in the rat 
(Gill et al., 1992). The potent neuroprotective action of NBQX against the 
delayed selective neuronal death seen in the hippocampus following transient 
global ischaemia contrasts markedly with the limited neuroprotection seen 
after NMDA antagonists (Buchan et al., 1991a and b; Sheardown et al. 1993).
LY-293558: Initial studies have demonstrated that the novel AMPA
antagonist (-)-6 -(2 -(lH -te trazo l-5 -y l)e thy l)-l,2 ,3 ,4 ,4a,5 ,6 ,7 ,8 ,8a- 
decahydroisoquinoline-3-carboxylate ((-)LY-293558) selectively displaces 
[3H]AMPA binding in rat cortical membranes with an IC50 of 1.35 >jlM. In 
electrophysiological studies in the cortical slice assay LY-293558 was found 
to reduce depolarisations due to 40yM AMPA with an IC50 of 1.78yM 
(Ornstein et al., 1993). Previous investigations into the racemic amino acid 
analogue, LY-215490, have revealed neuroprotective actions of this agent in 
vivo. LY-215490 is anticonvulsant in a maximal electroshock (MES) seizure 
assay in mice, and blocks rigidity in mice induced by the AMPA receptor 
agonist ATPA (see Ornstein et al., 1993). Observations that LY-215490 is 
less potent than its (-) isomer, LY-293558, in displacing [3H]AMPA binding in
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rat cortical membranes (ICgg of 4.8 lyM) and in antagonizing AMPA-induced 
depolarisations in a cortical slice assay (IC50 of 6 .0 )jlM) (Ornstein et al.,
1993) have led to the suggestion that LY-293558 will also have potent 
neuroprotective effects in vivo. Although investigations into the 
neuroprotective actions of LY-293558 are limited to date, initial studies in 
the MCA occlusion model of ischaemia in the cat (Bullock et al., 1993) 
support a neuroprotective role for LY-293558 in vivo.
AIM NUMBER 1: To assess the consequences of AMPA receptor blockade
on cerebral function in the conscious rat. The study will employ [1 4C]-2- 
deoxyglucose in vivo autoradiography to compare and contrast the effects of 
systemic administration of NBQX and LY-293558 on local cerebral glucose 
utilisation, and to determine whether AMPA receptor blockade at 
neuroprotective doses induces adverse metabolic alterations similar to those 
elicited by NMDA antagonists.
4.2 NMDA Receptor Manipulation by a Glycine Site Partial Agonist
It has been proposed that dysfunction in the mechanism of long-term 
potentiation (LTP) in hippocampal neurones may underlie the memory and 
learning impairments manifested in the dementia associated with Alzheimer’s 
disease (AD). Following reports that NMDA receptor activation is necessary 
for the induction of LTP in the hippocampus, and the detection of NMDA 
receptor deficits in hippocampal regions of AD brain, it has been postulated 
that positive modulation of NMDA receptors may ameliorate the cognitive 
deficits seen in this disease. One putative method of enhancing NMDA
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receptor activity is by agonist stimulation of the glycine modulatory site on 
the NMDA receptor complex. D-Cycloserine (D-4-amino-3-isoxaxoldione), a 
partial agonist at the glycine regulatory site on the NMDA receptor complex, 
has been proposed as a possible candidate to enhance NMDA receptor 
activation in situations of glutamatergic dysfunction. D-Cycloserine has been 
in clinical use for many years as an antimycobacterial agent, but a 
neurobiological action has only recently been recognised following 
observations that it readily crosses the blood-brain barrier. Subsequent 
studies have indicated that D-cycloserine exhibits partial agonist properties 
at the glycine co-agonist site on the NMDA receptor complex: D-cycloserine 
displaces strychnine-insensitive [3H]-glycine binding in both rodent and human 
brain tissue (Monahan et al., 1989b; Procter e t al., 1991), and has also been 
shown to dose-dependently enhance [3H]-TCP binding at the NMDA receptor- 
associated ionophore (Hood et al., 1989). However, the maximal extent of 
[3H]-TCP binding enhancement by D-cycloserine is less than that produced by 
pure glycine site agonists such as glycine and serine, while D-cycloserine 
actually antagonises glycine-induced enhancement of [3H]-TCP binding (Hood 
et al., 1989). In addition, partial agonist actions of D-cycloserine have been 
identified in its regulation of cGMP activity in Xenopus oocytes (Watson et 
al., 1990) and in mouse cerebellum (Emmett e t al., 1991) (see Figure 4). 
Further, putative agonist doses of D-cycloserine (0.1-10mg/kg) have been 
shown to positively modulate NMDA activity, enhancing performance in 
behavioural tests of learning in the rat (Monahan et al., 1989b).
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FIGURE 4: EFFECTS OF D-CYCLOSERINE ON CEREBELLAR cGMP LEVELS : 
PARTIAL AGONISM IN VIVO
Cyclic guanosine monophosphate (cGMP) levels were measured in mouse cerebellum 
30 min after parenteral injections of D-cycloserine (1.25 - 50 mg/kg), to assess 
NMDA receptor - mediated activity in vivo. D-Cycloserine produced biphasic 
dose-response effects on cGMP levels, low doses (1.25 - 10 mg/kg) augmenting 
NMDA receptor activity, while a higher dose (50 mg/kg) significantly reduced cGMP 
levels (*p < 0.05, t - test). In addition, the maximal in vivo agonist effects of 
D-cycloserine on cerebellar cGMP were approximately 40 - 50% of those of a full 
agonist such as D-serine (Wood et al., 1989). Thus, the observed effects of 
D-cycloserine on cerebellar cGMP levels are consistent with partial agonist 
modulation of NMDA receptor activity. (After Emmett et al.t 1991).
AIM NUMBER 2: To investigate the consequences of NMDA receptor
modulation by the glycine site partial agonist D-cycloserine on cerebral 
function in normal and pathologic states in the rat. Four approaches will be 
used to examine the effects of D-cycloserine on glutamatergic processes 
within the brain:-
(i) Local Cerebral Glucose Utilisation: [14C]-2-deoxyglucose 
autoradiography will be used to map any alterations in local rates of 
glucose metabolism in the CNS acutely after systemic administration 
of D-cycloserine (0.3, 3 and 30mg/kg). The dose range examined 
encompasses concentrations of D-cycloserine which have previously been 
reported to exhibit agonist and antagonists properties in vivo.
(ii) f 25I]-MK-801 Binding in Vivo: [125U-MK-801 in vivo autoradiography 
will be used to investigate the effects of a putative agonist dose of d-  
cycloserine (3mg/kg) on NMDA receptor activation in the conscious rat 
CNS. Results will be compared with levels of [125I]-MK-801 binding in 
conscious and halothane-anaesthetised controls.
(iii) Focal Cerebral Ischaemia: The effects of putative potentiation of 
NMDA receptor activity on the volume of ischaemic damage will be 
investigated in the MCA occlusion model following administration of a 
reported agonist dose of D-cycloserine (3mg/kg).
(iv) Cortical Glutamate Perfusion: The consequences of NMDA receptor 
modulation on excitotoxic cell death will be examined in the 
anaesthetised rat by investigating the effects of a putative agonist 
dose of D-cycloserine (3mg/kg) on the volume of neuronal damage 
produced by cortical glutamate perfusion. In order to validate this
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approach, the neuroprotective actions of the AMPA receptor antagonist 
NBQX will be investigated in the same model.
4.3 Intracerebral Manipulations of Basal Forebrain Activity
The cholinergic innervation of the neocortex arising from the basal 
forebrain can be manipulated by excitatory amino acid-induced activation of 
basal forebrain neurones, including magnocellular cholinergic neurones of the 
nucleus basalis magnocellularis (NBM).
Previous in vivo studies into the contribution of cholinergic NBM 
efferents to cerebral function, employing behavioural tests of cognitive 
function in conjunction with biochemical analyses of cholinergic markers 
following excitotoxic basal forebrain lesions, have indicated a separation in 
the effects of NMDA and non-NMDA receptor agonists (Dunnett e t al., 1987; 
Etherington et al., 1987; Robbins et al., 1989a,b; Page e t al., 1991; see also 
Table 3). Evidence suggests that AMPA and quisqualate are more selective 
for cholinergic neurones than ibotenate and NMDA (Page et al. 1991; for 
review see Dunnett et al., 1991). However, a number of factors limit the 
utility of behavioural paradigms to assess alterations in cerebral function, 
most notably that these studies allow examination of only one functional 
pathway within the brain, decided a priori.
Autoradiographic techniques have also been used previously to map the 
effects of basal forebrain lesions on cerebral function throughout the entire 
CNS. Such studies have included assessment of glucose use alterations by 
[14C]-2-deoxyglucose in vivo autoradiography in the ra t and [3 H]-2- 
deoxyglucose binding in rat brain homogenates following unilateral and
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bilateral excitotoxic NBM lesions, (Lamarca and Fibiger, 1984; London et al., 
1984; Orzi et al., 1988; Soncrant e t al., 1992), and positron emission 
tomography (PET) following electrolytic nbM lesions in the baboon (Kiyosawa 
et al., 1989). All investigators reported initial reductions in glucose 
utilisation in cortical areas which receive NBM projections 3-4 days after 
unilateral lesions, the extent of functional depression correlating with the 
degree of ChAT depletion in the cortex. Bilateral NBM lesions produced 
widespread metabolic depression throughout the CNS. However, within 4 
weeks of unilateral lesions (and 4 months of bilateral lesions) glucose use in 
cortical regions had returned back to basal levels, despite sustained 
depletions in presynaptic cholinergic markers in the cortex, and persistent 
impairment of conditioned behaviour. It should be noted that previously 
reported [1 4Cl-2-deoxyglucose studies have investigated only the effects of 
kainic acid (Lamarca and Fibiger, 1984) or ibotenic acid (London et al., 1984; 
Orzi et al., 1988; Soncrant et al., 1992) lesions of NBM efferents in the rat, 
whereas the consequences of AMPA- or quisqualic acid-induced lesions on 
cortical function, which are putatively more selective for cholinergic NBM 
neurones, have not previously been examined by in vivo autoradiographic 
methods.
The observations of metabolic recovery following excitotoxic basal 
forebrain lesions suggest that the [1 4C]-2-deoxyglucose autoradiography 
technique may not be a particularly sensitive method of distinguishing subtle 
differences in the effects of different excitatory amino acid agonists at 
chronic time points post-lesion. An alternative approach is to measure the 
effects on cerebral glucose use of neuronal stimulation directly after 
receptor activation by excitatory amino acid agonists.
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A complementary approach to manipulate the activity of basal forebrain 
cholinergic neurones is via modulation of the inhibitory GABAergic input to 
these neurones (Sarter et al., 1990). Glutamic acid decarboxylase (GAD)- 
immunoreactive terminals have been shown to synapse on magnocellular 
cholinergic neurones in the NBM (Zaborszky et al., 1986). Evidence indicates 
that these GABAergic projections arise from the nucleus accumbens (Page et 
al., 1991) and possibly also from neurones intrinsic to the basal forebrain 
(Zaborszky et al., 1986). This GABAergic innervation of cholinergic 
neurones appears to have a regulatory role, deduced from observations of 
altered cholinergic activity in the cortex following pharmacological 
manipulations of basal forebrain neuronal populations with GABAergic agents. 
Injections of the GABAa agonist muscimol directly into the basal forebrain 
have been found to decrease cortical ACh turnover (Wood, 1985), to reduce 
cortical ACh release (Casamenti e t al., 1986), and to decrease high affinity 
choline uptake in cortex (Wenk, 1984).
The consequences of manipulating GABAergic input to the basal 
forebrain on functional activity in the CNS have previously been assessed in 
vivo by using behavioral tests of cognition and attention (Muir et al., 1992b). 
The aims of these studies were to compare the acute sequelae of 
manipulating GABA-ergic input to the basal forebrain with those following 
excitatory amino acid-induced activation of basal forebrain neurones. The 
results demonstrated that muscimol infusion into the NBM region impaired 
animals’ responses in a five-choice serial reaction time task, indicating a 
deficit in attentional function reminiscent of the effects of AMPA, 
quisqualate and ibotenate infusions. This muscimol-induced deficit could 
be reversed by administration of the cholinomimetic agent physostigmine.
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However, like ibotenic acid, muscimol also impaired acquisition of a passive 
avoidance task, which is postulated not to be cholinergic in nature (Dunnett 
e t al., 1991). These results suggest that the functional consequences of 
GABAa receptor stimulation in the basal forebrain indicate non-selective 
actions on both cholinergic and non-cholinergic neuronal populations.
AIM NUMBER 3: To compare and contrast the effects of different
excitatory amino acids on functional activity within the basal forebrain. 
[1 4C]-2-deoxyglucose in vivo autoradiography will be used to map functional 
events in the CNS in conscious rats following manipulations of glutamatergic 
input to the NBM region of the basal forebrain by two different approaches:-
(i) Chronic: Local rates of cerebral glucose utilisation will be measured
approximately 3 weeks after unilateral infusions of ibotenate, NMDA, 
AMPA and quisqualate into the NBM basal forebrain region.
(ii) Acute: The consequences of agonist stimulation of different glutamate
receptor subtypes in the basal forebrain on cerebral function throughout 
the brain will be assessed acutely (15 min) after unilateral infusions of 
NMDA and AMPA into the NBM region. Results will be compared with
the effects of indirect manipulation of basal forebrain neuronal activity
by intracerebral administration of the GABAa agonist muscimol.
CHAPTER II 
METHODS
1. AUTORADIOGRAPHIC TECHNIQUES
In this section, the quantitative autoradiographic techniques employed 
in the present thesis will be described. The following sections, 2-4, will deal 
with the specific experimental investigations to which these techniques were 
applied.
1.1 In Vivo [14C]-2-Deoxyglucose Autoradiography
1.1.2 Theory
There are two basic principles which provide the conceptual basis for 
the utility of the [14C]-2-deoxyglucose technique as an experimental measure 
to give insight into cerebral function in vivo. Firstly, under normal 
physiological conditions the energy requirements of cerebral tissue are derived 
almost exclusively from the oxidative catabolism of glucose (Sokoloff e t al., 
1977; Siesjo, 1978). The CNS has a low capacity to store carbohydrates, and 
therefore functional energy requirements must be met by glucose supplied 
continuously from the cerebral circulation. Second, since functional activity 
is intimately related to cerebral metabolic rate (Sokoloff et al., 1977), 
regional measurement of local rates of glucose phosphorylation gives direct 
insight into local levels of functional activity within the CNS.
The [14C]-2-deoxyglucose autoradiography technique measures rates of 
cerebral energy metabolism in anatomically discrete regions of the CNS in 
vivo, in terms of local rates of cerebral glucose utilisation (LCGU; Sokoloff 
e t al., 1977). The technique takes advantage of the biochemical 
characteristics resulting from a simple modification of the glucose molecule, 
by replacement of a hydroxyl group on the second carbon atom of glucose with
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a hydrogen atom, to become 2 -deoxyglucose.
Glucose and 2-deoxyglucose are transported from blood into the CNS by 
the same saturable carrier. In cerebral tissue glucose and 2 -deoxyglucose 
compete for the hexokinase enzyme which phosphorylates both, or for the 
carrier molecule for transport back to plasma. At this point the two agents’ 
metabolic pathways diverge. Glucose-6 -phosphate is subsequently 
metabolised via the glycolytic and tricarboxylic acid pathways and therefore 
does not accumulate within cerebral tissues. In contrast, deoxyglucose-6 - 
phosphate is not a substrate for glucose-6 -phosphate isomerase or glucose- 
6 -phosphate dehydrogenase. Therefore its catabolism ceases at this point 
(at least within the 45 min experimental period; Sokoloff et al., 1977) and 
deoxyglucose-6 -phosphate becomes essentially ’’trapped" within the cerebral 
tissue. Thus the rate of deoxyglucose-6 -phosphate accumulation in any 
cerebral region over a given time is equivalent to the rate of 2 -deoxyglucose 
phosphorylation by hexokinase, and hence may be directly related to the rate 
of glucose phosphorylation since deoxyglucose is taken up and phosphorylated 
by cells at a definable rate relative to glucose.
Sokoloff and colleagues (1977) have developed a theoretical model 
(Figure 5) whereby the rate of cerebral glucose utilisation (Ri) can be 
calculated using an operational equation in terms of the concentration of 
[1 4C]-2-deoxyglucose (Cp*) and glucose (Cp) in arterial plasma during the 
experimental period, and the total concentration of 14C tracer (Ci) within a 
given cerebral region at the end of the experimental procedure (Figure 6 ). 
In deriving this equation the following assumptions are made:-
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FIGURE 5: THEORETICAL MODEL OF DEOXYGLUCOSE UPTAKE
IN THE BRAIN
Cp* and Cp represent the concentrations of [ 1 4  C] - deoxyglucose and glucose in 
arterial plasma, whilst C E* and C£ represent their respective concentrations in the 
tissue precursor pool. CM* represents the concentration of [1 4 C] - deoxyglucose- 
6 -phosphate in the tissue. The constants kj*, k 2* and k 3* represent the rate constants 
for carrier-mediated [ 1 4  C] - deoxyglucose uptake and its subsequent phosphorylation 
by hexokinase; kj, k 2  and k 3  are the equivalent rate constants for glucose. The 
possibility of glucose-6 -phosphate hydrolysis by glucose-6 -phosphatase is indicated by 
the curved arrow (after Sokoloff et a l 1977).
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FIGURE 6: THE OPERATIONAL EQUATION
The rate of glucose utilisation, Ri, in any region of cerebral tissue is calculated 
from the total tissue concentration of 14C in that region (Ci*) measured 
densitometrically at the end of the experiment (time T); from the concentrations of 
[1 4 C] -2-deoxyglucose and glucose in the plasma (Cp* and Cp respectively) at given 
times (t) throughout the experiment; from the rate constants for deoxyglucose 
transport to and from plasma and tissue precursor pools, and for phosphorylation of 
deoxyglucose by hexokinase (k j *, k 2* and k 3*); and from the lumped constant, 
K. K is composed of the ratio of tissue distribution volumes for deoxyglucose and 
glucose; the fraction of glucose which, once phosphorylated, will be further 
metabolised via the glycolytic pathway; and the Michaelis-Menten constants and 
maximal velocities of hexokinase for both deoxyglucose and glucose (Sokoloff et 
al., 1977).
1) Carbohydrate metabolism is in steady state, with a constant plasma 
glucose concentration and a constant rate of cerebral glucose 
consumption throughout the duration of the procedure.
2) Each tissue compartment where measurement is made is homogenous, 
where concentrations of [1 4C]-2-deoxyglucose and glucose are uniform 
and exchange directly with plasma at constant rates.
3) I1 4C]-2-Deoxyglucose and [1 4Cl-2-deoxyglucose-6-phosphate are present 
only in tracer concentrations and are pharmacologically inactive.
4) [1 4C]-2-Deoxyglucose-6-phosphate, and any metabolites, remain trapped 
within the cerebral tissue for the duration of the sampling period.
The rate constants K^*, K2* and K3* define the distribution of tracer 
between plasma and brain tissue compartments. The "lumped constant", K, 
"corrects" for the relative preference of the glucose transport and enzyme 
systems for glucose, as opposed to 2-deoxyglucose. The constants used are 
not measured in each experiment, but are those previously determined in the 
ra t by Sokoloff and colleagues in the original description of the technique 
(Sokoloff et al., 1977).
1.1.2 Methodological Considerations
The stability of the lumped constant, K, in the operational equation, 
which allows the rate of deoxyglucose phosphorylation to be converted to that
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of glucose, has been the subject of debate since it has been found to alter in 
certain extreme experimental circumstances such as seizure, ischaemia, 
tumours and severe hypoglycaemia and hyperglycaemia (for review see Gjedde, 
1982). However, in the vast majority of neuropharmacological applications 
of the [1 4C]-2-deoxyglucose technique it is very unlikely that local alterations 
in the lumped constant will complicate the interpretation of measured glucose 
utilisation rates (Sokoloff et al., 1977). In cases of hypoglycaemia, plasma 
glucose concentrations of less than 5mM have been found to result in an 
overestimation of the cerebral metabolic rate, while in hyperglycaemic 
animals glucose use may be underestimated (Schuier e t al., 1990). 
Consequently, in the experiments described in this thesis, plasma glucose 
concentrations were measured prior to initiating the procedure, and no animal 
was used if its pre-experiment glucose level was below 6 mM or exceeded 
15mM. In animals undergoing stereotactic surgery and subsequent recovery, 
an initial loss in body weight often followed surgery. Animals generally 
recovered body weight rapidly (within approximately 4 days), but no animal 
underwent subsequent [u C]-2-deoxyglucose autoradiography before its pre­
surgery body weight had been equalled or surpassed.
Potential errors in calculating glucose utilisation may arise from 
uncertainty of the rate constants K.,*, K2* and K3* which define the 
distribution of tracer between plasma and tissue compartments, and which 
may vary under different physiological conditions. Uncertainties are 
minimised by allowing sufficient time for [1 4C]-2-deoxyglucose clearance from 
plasma, so that the exponential terms containing the rate constants fall to 
levels too low to significantly influence the result (Mori et al., 1990).
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In designing the experimental protocol, it is also necessary to take into 
consideration the activity of another CNS enzyme, glucose-6 -phosphatase. 
Both glucose-6 -phosphate and deoxyglucose-6 -phosphate are substrates for 
hydrolysis by glucose-6 -phosphatase to yield glucose and deoxyglucose. Hence, 
if glucose-6 -phosphate activity were significant within the duration of the 
experiment, its action would seriously undermine the use of [14C]-2- 
deoxyglucose technique as a determinant of local cerebral glucose utilisation 
(Hawkins and Miller, 1987). However, neurochemical studies provide no 
evidence that glucose-6 -phosphatase is present in the CNS in concentrations 
sufficient to interfere with the use of I14C]-2-deoxyglucose as a tracer if the 
experimental period is limited to less than lh (Nelson et al., 1987).
A further limiting factor to the procedure is the restraint of animals 
which is necessary for blood sampling. The experimental period should be 
kept short to limit the effects of stress induced in the animal, such as 
elevated plasma glucose levels.
In order to minimise the impact of these potential complicating factors, 
an experimental period of 45 min was used in the studies of cerebral glucose 
use described in this thesis. This period has been deemed long enough to 
allow plasma and tissue glucose and [14C]-2-deoxyglucose levels to equilibrate, 
and hence minimise any uncertainties in the rate constants employed, while 
being short enough to minimise any [14C]-2-deoxyglucose-6-phosphate depletion 
from the cerebral tissue due to glucose-6 -phosphatase activity (Sokoloff et 
al., 1977; Mori e t al., 1990).
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1.1.3 Surgical Preparation of Animals for f14Cl-2-Deoxvglucose Measurement
Rats were placed in a perspex chamber and anaesthestised with 5% 
halothane in a nitrous oxide and oxygen gas mixture (70%/30%). Anaesthesia 
was subsequently maintained by administering 0.5 - 1% halothane in the gas 
mixture via a face mask. Femoral vessels were exposed bilaterally by blunt 
dissection through small incisions in the skin at each side of the animal’s 
groin. Polyethylene catheters (Portex: external diameter 0.96mm; internal 
diameter 0.58mm; 15cm long) containing heparinised saline (10 IU/ml) were 
inserted 2 cm into both femoral arteries and veins, and tied off using silk 
thread. The incision sites were infiltrated with a local anaesthetic gel 
(xylocaine, 2%) and sutured closed. The wounds were covered with gauze 
pads held in place by tape. Animals were then enveloped in a surgical 
stocking and a plaster of Paris bandage (Gypsona: 7.5cm side) applied around 
the pelvis and lower abdomen to immobilise the animals, taking care not to 
restrict thoracic movements. The plaster was taped to a lead brick to 
support the animal. With the rats thus restrained, halothane anaesthesia was 
discontinued and the rats allowed to recover for at least 2 h before further 
manipulation. One femoral artery was connected to a pressure transducer 
(P23ID Gould Stratham, Model 2202) to measure arterial pressure throughout 
the [1 4C]-2-deoxyglucose procedure. Core temperature was measured by 
means of a rectal temperature probe, rats being maintained normothermic by 
means of heating lamps.
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1.1.4 The [u Cl-2-Deoxvglucose Procedure
The local rates of cerebral glucose utilisation were measured in 
conscious rats using the [14C]-2-deoxyglucose technique in accordance with 
the previously published experimental procedures (Sokoloff et al., 1977), and 
the methodological considerations discussed above (Section 1.1.2).
The procedure was initiated by the intravenous administration of a pulse 
of [1 4C]-2-deoxyglucose (125p.Ci/kg in 0.7ml saline) injected at a constant rate 
over 30 sec. Over the subsequent 45 min, 14 timed arterial blood samples 
(approximately lOOjil) were taken and immediately centrifuged. Plasma 
aliquots were then assayed to determine 14C and glucose concentrations, by 
means of liquid scintillation analysis and by semi-automated glucose oxidase 
enzyme assay (Beckman), respectively. Further arterial blood samples were 
taken at predetermined intervals before and after isotope administration, for 
analysis of pC02, p0 2 and pH using a blood gas analyser (168pH/Blood Gas 
System, Corning). Forty-five min after isotope administration the rats were 
killed by decapitation and their brains removed, frozen in isopentane 
at -43°C and processed for quantitative autoradiography (see Section 1.4.2.).
1.2 In Vivo [125I]-MK-801 Autoradiography
1.2.1 Theory
[125I]-MK-801 autoradiography provides a means of measuring NMDA 
receptor activation in vivo (McCulloch et al., 1992). The basic principle for 
the technique is that the non-competitive NMDA receptor antagonist MK- 
801 can only gain access to its binding site within the receptor-associated 
channel when the NMDA receptor has been activated, since under resting
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conditions the channel is voltage-dependently blocked. It has been postulated
>1 A P
that autoradiographic analysis of the distribution of [ I]-labelled MK-801 
following intravenous injection will reflect the pattern of MK-801 binding 
within the brain and hence the pattern of activated NMDA receptors either 
in resting conditions, or following pathologic, physiologic or pharmacologic 
manipulations of glutamatergic activity within the CNS. Subsequently, 
altered levels of [125Il-MK-80l binding have been detected in the region of 
ischaemic infarct in experimental models of focal cerebral ischaemia in the 
ra t (McCulloch e t al., 1992).
1.2.2 Surgical Preparation of Animals for f125I1-MK-801 Measurement
Rats were placed in a perspex chamber and anaesthetised with 5% 
halothane in a nitrous oxide and oxygen gas mixture (70%/30%). Anaesthesia 
was subsequently maintained by administering 0.5 - 1 % halothane in the gas 
mixture via a face mask. Femoral vessels were exposed bilaterally by blunt 
dissection through small incisions through the skin in each side of the animal’s 
groin. Polyethylene catheters (Portex: external diameter 0.96mm; internal 
diameter 0.58mm; 15cm long) containing heparinised saline (10 IU/ml) were 
inserted 2 cm into both femoral arteries and veins, and tied off using silk 
thread. The incision sites were infiltrated with local anaesthetic gel 
(xylocaine, 2 %), sutured closed, and the wounds covered with gauze pads 
held in place by tape. Animals to be anaesthetised during the [ Ij-MK-801
procedure underwent no further manipulation. Animals to be conscious during 
the autoradiographic procedure were enveloped in a surgical stocking and a 
plaster of Paris bandage (Gypsona: 7.5cm side) applied around the pelvis and
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lower abdomen to immobilise the animals while not restricting thoracic 
movements, and the plaster taped to a lead brick for support. With the rats 
thus restrained, halothane anaesthesia was discontinued and the rats allowed 
to recover for at least 2h before further manipulation. In all animals, 
arterial blood pressure was measured throughout the procedure by a pressure 
transducer (P23ID Gould Stratham, Model 2202) connected to one femoral 
artery catheter. Core temperature was measured by means of a rectal 
temperature probe and rats maintained normothermic by heating lamps.
1.2.3 The f125Il-MK-801 Procedure
^  O p
[ U-MK-801 content in discrete brain regions was measured in conscious
and halothane-anaesthetised rats using a modification of the previously 
described [125IJ-MK-801 in vivo autoradiographical technique of McCulloch et 
al. (1992).
The procedure was initiated by the intravenous injection of a pulse of 
[125I]-MK-801 (500uCi/kg in 0.7ml saline) a t a constant rate over 30 sec. Over 
the subsequent 120 min, 15 timed arterial blood samples (approximately lOOp.1) 
were taken and immediately centrifuged. 20y.l Plasma aliquots were then 
assayed to determine [1 2 5I] and glucose concentrations, by means of liquid 
scintillation analysis and by semi-automated glucose oxidase enzyme assay 
(Beckman) respectively. Arterial blood samples were also taken at 
predetermined intervals before and after isotope administration for analysis 
of pC02, p0 2 and pH using a blood gas analyser (168pH/Blood Gas System, 
Corning). 120 min after isotope administration the rats were killed by 
decapitation and their brains processed for quantitative autoradiography as
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outlined in section 1.4.3).
1.3 In Vitro I3!!] Ligand Binding Autoradiography
1.3.1 Theory
In vitro ligand binding autoradiography is based on the principle that 
radiolabelled ligands, which are highly selective for particular recognition 
sites, emit energy which will produce a photographic image when placed in 
contact with radiation-sensitive film. The optical density of the image is 
related to the amount of radioligand bound, and hence to the density of 
binding sites in any given area, and can be quantified by reference to 
calibrated radioactive standards. Thus in vitro autoradiography techniques 
allow anatomical mapping of the distribution of ligand binding sites within the 
CNS with a high degree of spatial resolution, and sensitive quantification of 
ligand binding densities in discrete brain regions.
1.3.2 [3Hl-PK-11195 Autoradiography
The in vitro ligand binding experiment described in this thesis employed 
the tritiated ligand, [3H]-PK-11195. [3H]-PK-11195 binds with high affinity
to peripheral-type benzodiazepine binding sites (Benavides et al., 1983; 1987) 
which are located predominantly on glial cells within the CNS. Hence the 
pattern of [3H]-PK-11195 binding within the brain gives an indication of the 
distribution of glial cells. In the present thesis, [3H]-PK-11195 binding was 
carried out in rat brain sections taken from animals in which local cerebral 
glucose use had previously been measured using the [1 4C]-2-deoxyglucose 
technique.
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In vitro [3H]-PK-11195 binding was performed according to the technique 
of Benavides et al., (1983), and is summarised in Figure 7. Rats were killed 
by decapitation and their intact brains dissected out, frozen by immersion in 
isopentane at -43°C for 10 min, and cut into 20)im-thick coronal sections 
using a cryostat microtome. Triplicate tissue sections (2 for total, and 1 for 
non-specific ligand binding), taken at 200yM intervals throughout the CNS and 
adjacent to those sections used in contemporaneous [1 4C]-2-deoxyglucose 
studies, were thaw-mounted onto gelatin-subbed slides and stored at -20°C. 
Prior to ligand binding, sections were dried in air at room temperature. Since 
[ H]-PK-1195 in vitro autoradiography was carried out in brain sections which 
had previously been labelled in vivo by [u C]-2-deoxyglucose, it was essential 
that the [1 4C] was eluted from the slide-mounted sections prior to incubation 
with [3Hj-PK-1195. Therefore, sections were washed twice for 30 sec in 
Tris/HCl buffer (170mM, 24°C) prior to preincubation for [3Hl-PK-11195 
autoradiography (Chalmers and McCulloch, 1991a). Any low residual levels 
of [14Cl remaining in sections will contribute to the non-specific binding signal 
determined in the [3H]-ligand binding studies (Chalmers and McCulloch, 
1991a).
Sections were incubated in Tris/HCl buffer (170mM, pH 7.4) containing 
[3H]-PK-11195 (InM) for 30 min at 24°C (total binding). Non-specific binding 
(ligand binding to sites other than the desired recognition sites such as other 
tissue constituents, or glass) was determined by incubating adjacent sections 
with [3H]-PK-11195 (InM) under the same incubation conditions with the 
addition of an excess of unlabelled PK-11195 (3 jjlM ) to competitively displace 
the isotopically-labelled ligand. After incubation, sections were washed twice
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FIGURE 7: r3 Hl-PK-l 1195 BINDING PROTOCOL
for 5 sec in buffer (4°C) to remove any unbound isotope, dipped in distilled 
water (4°C), and then dried rapidly in a stream of air. Autoradiograms were 
generated according to the procedure outlined in section 1.4.4. In this thesis 
total [3H]-PK-11195 binding autoradiograms were used for qualitative 
assessment of the distribution of peripheral-type benzodiazepine receptors in 
the CNS after excitotoxic basal forebrain lesions.
Several extrinsic factors may influence the amount of ligand binding to 
sections. These include temperature of incubation and rinsing, differences 
in the buffer medium (such as pH or salt concentrations), or differences in 
the specific activity or concentration of the radiolabelled ligand in the 
incubation medium. In order to minimise the contributions of these factors, 
binding studies for all animals in the experimental series were carried out on 
the same day.
The concentration of [3H]-PK-11195 used was similar to the equilibrium 
dissociation constant (Benavides et al., 1983; KD ~ InM), allowing sensitive 
detection of small changes in the numbers of binding sites.
1.4 Experimental Analysis
1.4.1 Liouid Scintillation Analysis
Liquid scintillation analysis was an essential component of [1 4C]-2- 
deoxyglucose and [3H] ligand binding autoradiography protocols. To determine 
the plasma history of [1 4C]-2-deoxyglucose over the 45 min experimental 
period, for use in calculation of the plasma integral, a 2 0 pl plasma aliquot 
from each arterial sample was pipetted into a scintillation vial containing 1 ml 
distilled water. Pipettes were repeatedly flushed with water to expel any
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residual radioactivity. Prior to [3H] ligand binding procedures, the 
concentration of the radioligand in the incubation medium was determined 
by pipetting lOpd aliquots into 1ml distilled water in scintillation vials. The 
procedure was repeated in triplicate.
Scintillation fluid (lOmls; Ecoscint, National Diagnostics, New Jersey, 
U.S.A.) was added to each vial, and vials shaken thoroughly. Radioactivity 
was counted in a refrigerated scintillation counter (Packard Tricarb, 1900CA) 
using the external standards channel-ratio method (Peng, 1977) with a standard 
calibration curve for quench correction. Mean values for disintegrations per 
minute (dpm) were calculated from triplicate counts.
1.4.2 Preparation of [1 4Cl-2-Deoxyglucose Autoradiograms
At the end of the 45 min experimental period, rats were decapitated and 
their brains removed intact. Whole brains were frozen by immersion in 
isopentane pre-cooled to -43°C, for 10 min. The time from decapitation to 
brain freezing did not exceed 5 min. The frozen brains were mounted onto 
swivel headed microtome chucks with plastic embedding matrix (Lipshaw) 
over solid C02, and stored at -20°C for a maximum of 2  days (-80°C for 
longer periods if necessary), before being cut into 2 0 )im-thick coronal cryostat 
sections. Triplicate sections were collected at predetermined levels, 
routinely at 200jjin intervals throughout the brain. Cutting schedules varied 
in different experiments depending on regions of special interest. Sections 
were thaw-mounted onto heated glass coverslips and then dried rapidly on a 
hotplate at 60°C. The coverslips were then glued onto thin card. 
Autoradiograms were generated by exposing the brain sections along with
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precalibrated epoxy resin UC standards (concentration range 44-1880nCi/g 
tissue equivalents) to u C-sensitive X-ray plates (Kodak GRL), in light-tight 
cassettes for 16-24 days. The duration of exposure was estimated from the 
calculated plasma integral value for each animal in order to optimise the 
optical density range of the resultant autoradiograms, to facilitate 
densitometric processing. Films were processed using a standard Kodak 
automatic processor.
1.4.3 Preparation of f125U-MK-801 Autoradiograms
At the end of the 120 min experimental period, rats were decapitated, 
their brains removed intact and frozen in isopentane at -43°C for 10 min. 
The time from decapitation to freezing did not exceed 5 min. Frozen brains 
were mounted onto swivel-headed microtome chucks with plastic embedding 
matrix (Lipshaw) over solid C0 2  and stored at -20°C (for 2 days maximum) 
before being cut into 20)im-thick coronal cryostat sections. Four sets of 
duplicate sections were collected at 5 predetermined regions of interest, at 
the levels of cerebellum hemisphere, medial geniculate body, hippocampus, 
posterior cingulate cortex, and striatum. At each coronal level, one pair of 
sections were thaw-mounted onto heated glass coverslips for immediate 
autoradiography, and the remaining pairs thaw-mounted onto gelatin-subbed 
slides for washing prior to autoradiography. Sections were dried rapidly on 
a hotplate at 60°C. Sections were washed in cold (4°C) Tris/acetate buffer 
(170mM, pH 7.2) for periods of 15, 30 or 60 min. After washing, sections 
were air dried. Coverslips and slides were then glued onto thin card and 
autoradiograms generated by exposing the brain sections along with
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precalibrated 125I standards (concentration range 1,490 - 42,000nCi/g) to 1 2 5I- 
sensitive film (Kodak GRL) in light-tight cassettes for 3-12 weeks. The 
duration of exposure was estimated from the calculated plasma integral for 
125I and the known half-life of 125I (60 days). Films were processed using a 
standard Kodak automatic processor.
1.4.4 Preparation of f3Hl-PK-11195 Binding Autoradiograms
Tissue sections labelled with [3H]-PK-11195 were mounted securely on 
card along with a set of precalibrated tritium standards (1060- 17720nCi/mg 
tissue equivalents). The brain sections and standards were apposed to 
tritium-sensitive film (Hyperfilm, Amersham) in light-tight cassettes for 14 
days. At the end of the exposure time films were manually developed in 
Kodak D-19 developer for 5 min at 17°C, with intermittent agitation. 
Development was stopped by a 30 sec rinse in deionised water at 20°C. 
After fixing for 10 min at 20°C in Kodak Kodafix, films were washed in 
running filtered water for 40 min, rinsed in deionised water, and then 
suspended in a drying cabinet overnight.
1.4.5 Quantification of Autoradierams
Analysis of resultant [14C]-2-deoxyglucose, [125I]-MK-801 and [3H]-PK- 
11195 autoradiograms was performed using a computer-assisted image analysis 
system (Quantimet 970, Cambridge Instruments). Films were analysed 
densitometrically for radioisotope content in discrete brain regions by grey 
level comparison with precalibrated standards.
Optical density measurements of autoradiograms were made under
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constant low lighting provided by four 24W lamps, the light intensity being 
computer controlled. Autoradiographic images were captured by a video 
camera fitted with a zoom lens (2.5x), and digitised into an array of image 
points (pixels), each with a grey level value in the range 0-255 (grey level = 
1 corresponds to optical density = 2.41; grey level = 255 corresponds to 
optical density = 0). The image analyser was calibrated against an opaque 
object (maximum optical density) and a Kodak neutral density filter (optical 
density = 1 .0 ) to allow grey level values of each pixel to be converted into 
optical density values, and against the film background to facilitate 
reproducible measurements.
Following calibration, the optical densities of the images produced by 
the pre-calibrated standards were measured, generating a calibration curve 
of optical density versus isotope concentration and thus allowing subsequent 
quantification of tissue isotope concentrations in discrete brain regions. 
Optical density measurements were made by placing a measuring frame over 
each anatomical region of interest. The size of the measuring frame was 
variable (9-900 pixels/frame) but was kept constant for each anatomical 
region between animals. For each anatomical region of interest, the image 
analyser calculated the mean of optical density values made in 3-6 sections 
per animal. In rat studies of systemic drug administration, optical density 
measurements were made bilaterally for each region. In ra t studies involving 
intracerebral interventions, optical density measurements were made 
separately in the ipsilateral and contralateral hemispheres for each region. 
Structures in rat brain were defined anatomically with reference to a 
stereotaxic atlas (Paxinos & Watson, 1986).
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1.4.6 Data Analysis
The statistical design to be employed in analysis of each experiment was 
decided a priori. In studies involving analysis of multiple treatment groups, 
appropriate Bonferroni correction factors were applied to significance levels 
in order to take into consideration the impact of comparing more than two 
sets of data. Due to the complexities of the statistical designs applied to 
different experiments in this thesis, statistical analysis will be addressed in 
greater detail with respect to individual experimental protocols.
:
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2. ANIMAL STUDIES I
GLUTAMATE RECEPTOR MANIPULATIONS:
IN VIVO AUTORADIOGRAPHIC STUDIES FOLLOWING SYSTEMIC 
DRUG ADMINISTRATION
2.1 General
In the following section, experiments are described in which in vivo 
autoradiographic procedures were performed after systemic administration 
of pharmacologically active agents. In two series of animals [14C]-2- 
deoxyglucose autoradiography was performed to assess the effects of 
glutamatergic agents on local rates of cerebral energy metabolism. In a third 
series of animals [125I]-MK-801 autoradiography was performed to assess the 
effect of an agent on NMDA receptor activation in vivo.
2.1.1 Animals
The subjects of these experiments were male adult Sprague Dawley rats, 
270-400g. Prior to drug administration and autoradiography the animals were 
housed 2  or 3 to a cage, in natural daylight conditions, at a room temperature 
of approximately 21°C, with food and water available ad libitum.
2.2 [14C]-2-Deoxyglucose Autoradiography
2.2.1 Drug Administration
Prior to drug administration rats were surgically prepared for [14C]-2- 
deoxyglucose autoradiography as described in section 1.1.3. The deoxyglucose 
procedure was performed according to the protocol outlined in section 1.1.4 
after intravenous administration of one of the following agents:-
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1) NBQX or LY-2935598
The AMPA receptor antagonists NBQX (10, 30 or lOOmg/kg) or LY- 
293558 (10, 30 or lOOmg/kg) were administered by intravenous injection 
via the femoral vein catheter, in a volume of 2 ml/kg at a constant rate 
over 2 min, 15 min prior to administration of [1 4C]-2-deoxyglucose. 
Control animals similarly received an intravenous injection of vehicle 
(5.5% glucose, pH 8.0 with NaOH; 2ml/kg) 15 min prior to isotope 
injection.
i
i 2) D-Cycloserine binding site on the NMDA receptor complex.
The NMDA receptor-glycine site partial agonist D-cycloserine (0.3, 3 or 
30mg/kg) was administered by intravenous injection via the femoral vein 
catheter, in a volume of lml/kg at a constant rate over 2 min, 15 min 
prior to isotope injection. Control animals similarly received 
intravenous injections of vehicle (sterile saline: lml/kg).
2.2.2 Data Analysis
NBQX and LY-293558
Local cerebral glucose utilisation (LCGU) values measured in each of 50 
CNS regions following intravenous administration of NBQX (10, 30 or 
lOOmg/kg) or LY-293558 (10, 30 or lOOmg/kg) were compared with the LCGU 
values of corresponding regions in control animals. |
One way analysis of variance (ANOVA) was used initially to identify 
anatomical regions in which significant alterations in glucose utilization 
occurred, followed by independent t-tests to identify the drug groups
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producing significant changes relative to control values in these regions. A 
Bonferroni correction factor of 6  was applied to probability values, to take 
into consideration the multiple comparisons between treatment and control 
groups.
The degree of responsiveness of each of the 50 regions investigated to 
each of the 2 drugs, NBQX (10, 30, lOOmg/kg) and LY-293558 (10, 30, 
lOOmg/kg) was then assessed by application of an arithmetic function which 
encompasses the entire dose-response data available for each region. A rank 
ordering of these regional responses was derived from the function, f  :- 
/  = e  (xc - * T i ; 2
where xc is the mean of loge (glucose use) for the control group members, 
and Xj. is the mean of log9 (glucose use) for the /th dose of the treatment 
group in question, T, i.e. either NBQX or LY-293558 (Kelly et al., 1986).
The advantage of using this method to compare drug actions is primarily 
that this arithmetic function takes into account all of the dose-response data 
generated by the 2 -deoxyglucose technique, thus removing the bias of posthoc 
selection of a single "representative” dose. In addition, the use of log data 
minimises the distortion created by differences in the magnitude of the basal 
rates of glucose use in different regions, while squaring of the function 
permits comparison of bidirectional events if applicable. The validity and 
reliability of this approach has been described previously (Kelly e t al. 1986). 
The f  values were calculated for each drug in each region. Frequency 
distribution profiles were thus generated for both drugs, and NBQX and LY- 
293558 activities were compared by application of Pearson’s correlation 
analysis.
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i>-Cycloserine
Local cerebral glucose use values measured in each of 51 CNS regions 
following intravenous administration of D-cycloserine (0.3, 3 or 30mg/kg) were 
compared with the glucose use values of corresponding regions in control 
animals. One way analysis of variance (ANOVA) was used initially to identify 
anatomical regions in which significant glucose use alterations occurred, 
followed by independent t-tests (2 -tailed) between treatment and control 
groups, with a Bonferroni correction factor of 3 for multiple comparisons.
2.3 [125I]-MK-801 Autoradiography
2.3.1 Drue Administration
Prior to drug administration animals were prepared for the 
autoradiography procedure as described in section 1.2.2. The (125I]-MK-801 
autoradiography procedure was performed according to the protocol outlined 
in section 1.2.4, isotope being injected intravenously 15 min after intravenous 
administration of a-cycloserine (3mg/kg) (lml/kg volume). Control animals 
similarly received an intravenous injection of vehicle (sterile saline; lml/kg) 
15 min prior to isotope injection.
2.3.2 Data Analysis
Total bound [125I]-MK-801 was measured in 13 discrete CNS regions from 
rat brain sections washed in buffer for 0, 15, 30 or 60 min, following 
intravenous administration of D-cycloserine (3mg) to conscious rats. Values 
were compared with total bound [125I]-MK-801 in corresponding regions of 
vehicle-injected control animals (anaesthetised and conscious). Due to the
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paucity of NMDA receptors in the cerebellum molecular layer, radioisotope 
concentration in this region served as a within animal measure of non-specific 
binding. The ratio of total [1251]-MK-801 bound in each of the 12 forebrain
1 OKstructures, relative to total [ I]-MK-801 bound in the cerebellum hemisphere
molecular layer, was calculated for each wash period. Ratios for each 
structure were then compared between all treatment groups for each wash 
time, initially using one way analysis of variance (ANOVA) to identify any 
regions in which the extent of [125I]-MK-801 binding significantly differed 
between groups, followed by independent t-tests (2-tailed) with a Bonferroni 
correction factor of 2  for multiple comparisons.
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3. ANIMAL STUDIES n
GLUTAMATE NEUROTOXICITY IN VIVO: EFFECTS OF AMPA AND NMDA 
RECEPTOR MANIPULATIONS
3.1 General
Experiments are described which utilise two models of glutamate-induced 
neuronal damage in the rat:- the middle cerebral artery (MCA) occlusion 
model of focal cerebral ischaemia, and a novel model of cortical neuronal cell 
death induced by glutamate perfusion. In the following section the surgical 
procedures involved to produce these models are described. The experimental 
routines described involved manipulation of glutamatergic receptor activities 
by two pharmacologically active agents, NBQX and o-cycloserine, which act 
at AMPA and NMDA excitatory amino acid receptor subtypes respectively, 
to analyse any modification in the pattern or extent of neuronal damage 
produced in these models.
3.1.1 Animals
The subjects of these experiments were male adult Sprague Dawley rats, 
300-400g. Prior to experiments animals were housed in cages in groups of 
2 or 3 under natural daylight conditions, at a room temperature of 
approximately 21 °C, with food and water available ad libitum. In the 24h 
survival experiments described, animals were returned to these conditions 
post-surgery, but were housed individually in cages lined with absorbent pads, 
and were regularly examined to check their post-operative recovery.
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3.2 Middle Cerebral Artery Occlusion
3.2.1 Background
Permanent occlusion of one middle cerebral artery (MCA) produces focal 
cerebral ischaemia in a discrete region of ipsilateral cerebral cortex and 
striatum, characterised 24h post-occlusion by neuronal cell death, pyknosis, 
vacuolation of the neuropil, and oedema. A typical lesion produced by MCA 
occlusion is illustrated in Figure 8 . Glutamate has been implicated in the 
production of ischaemic cell damage, as extracellular concentrations of 
glutamate are markedly elevated in ischaemic brain tissue as a consequence 
of both enhanced neuronal glutamate release, and impaired glutamate uptake 
into glia and neurones (Benveniste et al., 1984; Drejer et al., 1985; Hagberg 
e t al., 1987; Butcher et al., 1990). In addition, glutamate receptor 
antagonists have been found to markedly reduce neuronal damage in 
experimental models of ischaemic cell death (Gill et al., 1991; Park et al., 
1988b; Choi, 1990).
3.2.2 Procedure
Rats were placed in a perspex chamber and anaesthetised initially with 
5% halothane in a nitrous oxide-oxygen gas mixture (70%:30%). Anaesthesia 
was maintained thereafter with 0.5-1% halothane in the gas mixture 
administered via a plastic face mask. The surgical procedure involved, 
firstly, exposure of the skull by a longitudinal midline incision in the scalp. 
The animals then underwent subtemporal craniectomy and exposure of the left 
MCA, under an operating microscope at high magnification. The exposed 
artery was occluded from its origin to the point where it crosses the inferior
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FIGURE 8: FOCAL ISCHAEMIC LESION
A representative coronal rat brain section stained with haematoxylin and eosin, 
illustrating a typical lesion produced by permanent occlusion of the left middle 
cerebral artery (MCA), 24h post-occlusion. The region of ischaemic infarct is 
evident as an area of pallor with a discrete boundary, affecting ipsilateral striatum 
and cortex. Within this region there is histological evidence ischaemic damage, 
including cellular swelling, shrunken nuclei, vacuolisation, and neuronal loss. In 
addition, the ipsilateral hemisphere appears swollen.
cerebral vein, by microbipolar coagulation. This surgical division of the 
artery with extensive coagulation results in large, consistent ischaemic lesions 
in the cerebral cortex and basal ganglia. Body temperature was monitored 
throughout by a rectal thermometer and animals maintained normothermic 
by means of heating lamps.
Following MCA occlusion the scalp wound was sutured closed, 
anaesthesia discontinued, and the animals allowed to regain consciousness. 
Twenty-four hours after occlusion the rats were decapitated, their brains 
removed intact, frozen by immersion in isopentane at -43°C and processed 
for histological lesion assessment (see section 2.3.4).
3.2.3 Drue Administration
o-Cycloserine (3mg/kg) was administered by subcutaneous injection 
(lml/kg) 15 min after MCA occlusion, and again 3h later. Control animals 
received subcutaneous injections of sterile saline vehicle (lml/kg) at the same 
time points.
3.3 Cortical Glutamate Neurotoxicity
3.3.1 Background
Glutamate perfusion into the cortex of intact rat brain in vivo, via a 
microdialysis probe, results in the generation of a well-defined lesion around 
the probe, as illustrated in Figure 9 (Fujisawa et al., 1993a and b; Landolt et 
al., 1993). In contrast to the MCA occlusion model of ischaemic neuronal 
injury, this intervention has been shown to minimally affect cerebral blood 
flow and energy supply, and hence to produce lesions putatively due solely to
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FIGURE 9: CORTICAL GLUTAMATE LESION
A representative coronal rat brain section stained with haematoxylin and eosin, 
illustrating a typical lesion produced by perfusion of glutamate (0.5M) into the 
right cerebral cortex. Section shown is at the same plane as the dialysis probe. 
Glutamate perfusion produced a pale lesion with a clear boundary around the 
dialysis probe, in the cortex. Shrinkage of neurones and neuropil, triangulation 
of the nucleus, and swelling of perineuronal astrocytes were evident in the area of 
pallor. No histological abnormalities were evident in brain regions remote from 
the dialysis probe.
the presence of glutamate in the extracellular space. Another advantage of 
this procedure is that it is less invasive than other in vivo models of 
glutamate toxicity, such as the MCA occlusion model.
3.3.2 Surgical Preparation of Animals
Animals were placed in a perspex chamber and anaesthetised with 5% 
halothane in a nitrous oxide-oxygen gas mixture (70%:30%). Anaesthesia was 
maintained with 1 % halothane by use of a face mask while a tracheostomy 
was performed, and thereafter rats were ventilated mechanically by means 
of a pump, with a nitrous oxide-oxygen gas mix (70%:30%) containing 0.5- 
1% halothane. The femoral vessels were exposed bilaterally by blunt 
dissection via small incisions made either side of the groin. Polyethylene 
catheters (Portex: external diameter 0.96mm; internal diameter 0.58mm; 15cm 
long) containing heparinised saline (10 IU/ml) were inserted 2cm into both 
femoral arteries and one femoral vein. The catheters were tied in place with 
silk thread and the wounds sutured closed. One arterial catheter was 
connected to a pressure transducer (P231D Gould Stratham, Model 2202) for 
continuous monitoring of arterial pressure. Core temperature was monitored 
by a rectal thermometer, and animals were maintained normothermic by 
means of heating blankets and lamps. Arterial pC02, p0 2  and pH were 
monitored throughout the subsequent procedures by blood gas analysis 
(168pH/Blood Gas System, Corning). The stroke volume of the ventilator was 
adjusted to maintain arterial carbon dioxide tension at approximately 
35mmHg, and adequate arterial oxygenation (p02 > 90mmHg) throughout the 
experiment.
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3.3.3 Glutamate Perfusion
The anaesthetised and ventilated animals were mounted into a Kopf 
stereotaxic frame (Clark Electromedical, London, U.K.). The right parietal 
skull and Bregma were exposed by making a longitudinal midline incision in 
the scalp, reflecting the skin and clearing any connective tissue from the skull 
surface. The stereotaxic coordinates for placement of the microdialysis 
probe, taken from the stereotaxic atlas of Paxinos and Watson (1986), relative 
to Bregma were:- Anterior-Posterior +0.0mm; Lateral +4.0mm; Ventral 
-3.5mm below dura; incisor bar set +5mm above the interaural line. The 
position of probe placement was marked in ink on the skull surface and a burr 
hole made through the skull with a high-speed dental drill. After incising 
the arachnoid dura, a microdialysis probe (Carnegie Medicin, Sweden, 
membrane length 3mm; outside diameter 0.5mm) was lowered into the cortex 
at an angle of 15° to the sagittal plane.
Monosodium glutamate (0.5M) was dissolved in mock cerebrospinal fluid, 
CSF (NaCl, 135mM; KC1, ImM; KH2 P04, 2mM; CaCl2, 1.2mM; MgCl2, ImM; 
pH 7.4). After placement in the cortex, the microdialysis probe was perfused 
with mock CSF for bewteen 30 and 60 min and thereafter with 0.5M 
glutamate at a flow rate of 1.5pLl/min for 90 min using a Carnegie Medicin 
100 infusion pump (Biotech Instruments, Luton, U.K.). Following 90 min of 
glutamate perfusion, the microdialysis probe was removed from the cortex 
and the scalp wound closely sutured. The animals were decapitated 150 min 
later (4h after the start of glutamate perfusion), their brains dissected out 
intact, frozen by immersion in isopentane at -43°C and processed for 
histological lesion assessment (see section 3.4).
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3.3.4 Drue Administration
In two series of animals the following pharmacologically active agents 
were administered by intravenous injection via the femoral vein catheter at 
a constant rate over 2 min. Glutamate perfusion was initiated 30 min after 
drug or vehicle administration.
1) NBQX
Dual injections of NBQX were administered at a dose of 30mg/kg (2ml/kg 
volume) 30 min prior to and 30 min after the start of glutamate 
perfusion. Control animals similarly received dual intravenous injections 
of vehicle (5.5% glucose, pH 8.0 with NaOH; 2ml/kg).
2) D-Cycloserine
D-Cycloserine was administered at a dose of 3mg/kg (lml/kg volume). 
Control animals received an intravenous injection of vehicle (sterile 
saline; lml/kg).
3.4 Experimental Analysis
3.4.1 Histological Processing of Brain Tissue
The frozen brains were mounted onto swivel-headed microtome chucks 
with plastic embedding matrix (Lipshaw) and cut into 20pim-thick coronal 
cryostat sections. Three consecutive sections were picked up onto gelatin- 
subbed slides at 2 0 0 )im intervals throughout the forebrain for haematoxylin 
and eosin staining. A fourth adjacent section was similarly collected for 
cresyl-violet staining for light microscopic verification of the lesion.
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3.4.2 Quantification of Lesion/Infarct Volumes
At 24h following MCA occlusion, or 4h after glutamate perfusion, the 
region of infarcted tissue could be clearly identified in sections stained with 
haematoxylin and eosin (see Figures 8  and 9). The infarcted area could be 
defined as a sharply delineated region of pallor, bordered by normal, densely 
stained tissue. The volumes of brain damage were measured by computer- 
assisted densitometry (Quantimet 920, Cambridge Instruments, U.K.). The 
haematoxylin and eosin stained sections were placed under the video camera 
which projected the section image onto the monitor screen. The regions of 
lesion or ischaemic infarct were easily identified as areas of low optical 
density relative to the intact brain. The boundary of the lesion/ischaemic 
region was delineated manually on the screen using the computer "mouse".
The densitometer calculated the area of the delineated region. Area 
measurements were made on each of the triplicate sections at each level 
throughout the brain, and mean area calculated. Hence the total volume of 
lesion/ischaemic tissue per specimen was calculated from the area 
measurements and the known distance between each coronal level (260]im). 
In MCA occluded animals, the volumes of ipsilateral and contralateral 
hemispheres were similarly calculated from densitometric measurement of 
hemipsheric areas at each coronal level and the known distance between each 
coronal plane. Knowledge of hemispheric volume allowed analysis of any 
drug-induced swelling effect. Sections were analysed "blind", i.e. sections 
were coded by a colleague to prevent knowledge of the treatment group they 
belonged to during the densitometric analysis.
149
3.4.3 Data Analysis
MCA Occlusion - D-Cycloserine
The hemispheric volume and volume of infarcted cerebral tissue in MCA 
occluded animals after systemic administration of D-cycloserine (3mg/kg) were 
compared with hemispheric volume and infarct volume in MCA occluded 
animals after vehicle injection (controls) using Student’s unpaired t-test 
(1 -tailed for infarct comparison, 2 -tailed for hemipsheric volume comparison).
Glutamate Perfusion
1) D-Cycloserine
The volume of the glutamate-induced lesion in animals receiving 
D-cycloserine (3mg/kg) was compared with lesion volume in vehicle- 
injected control animals using one way analysis of variance (ANOVA), 
followed by an independent t-test (2 -tailed). In a contemporaneous study 
employing the same control group, the effect of another 
pharmacologically active agent on glutamate-induced cerebral damage 
was also investigated. Consequently, a Bonferroni correction factor of 
2  was applied to t-test probability values to take into consideration the 
multiple control-vehicle group comparisons.
2) NBQX
The volume of tissue damage resulting from glutamate perfusion 
of the cortex following intravenous administration of NBQX (2 x 
30mg/kg) was compared with the lesion volume produced by glutamate 
perfusion following systemic administration of vehicle, using ANOVA,
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followed by an indpendent t-test (2-tailed). In contemporaneous 
experiments, using the same group of control animals, the effects of 3 
other agents on the extent of glutamate-induced damage were also 
investigated which were not part of the present study (Fujisawa et al., 
1993a). Consequently, a Bonferroni correction factor of 4 was applied 
to the t-test probability values to take into consideration the multiple 
treatment-vehicle comparisons.
151
4. ANIMAL STUDIES m
BASAL FOREBRAIN INTERVENTIONS: EFFECTS ON LOCAL CEREBRAL 
GLUCOSE USE
4.1 General
The chronic effects of excitotoxic basal forebrain lesions, and the acute 
effects of excitatory amino acid and GABA agonist infusions into the basal 
forebrain on local cerebral glucose utilisation were investigated using the 
[14C]-2-deoxyglucose in vivo autoradiography technique. Stereotactic surgical 
procedures were employed to infuse the agonists into the nucleus basalis 
magnocellularis (NBM) region of the basal forebrain. In addition, [3H]-PK- 
11195 in vitro autoradiography was performed in sections taken from animals 
which had received basal forebrain lesions, to gain insight into the location 
and extent of glial proliferation associated with chronic excitotoxic lesions.
4.1.1 Animals
The subjects of these experiments were male, adult, hooded Lister rats, 
250-300g pre-operative weights (Olac, Bicester, U.K.). Prior to surgery 
animals were allowed to acclimatise to their surroundings for 5 days and 
nights. In holding, both prior to and following surgery, rats were individually 
housed under natural daylight conditions, with room temperature maintained 
at approximately 21°C, and food and water provided ad libitum. The animals 
weights and general physiological condition were checked daily to ensure the 
rats recovered normally from surgery.
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4.2 Surgical Preparation of Animals
4.2.1 Stereotactic Lesions of the NBM: Chronic Glucose Use Measurement
Rats were anaesthetised by an intraperitoneal injection of Avertin 
(tribromoethanol in tertiary amyl alcohol; lml/kg body weight). Once 
unconscious animals were not handled for 15 min, and were then placed in a 
stereotactic frame (David Kopf, Tujunga, CA, U.S.A.). A longitudinal midline 
incision was made into the scalp and the skin reflected to expose the skull.
Burr holes were made through the skull, bilaterally at the appropriate
stereotactic coordinates for infusion, using a high speed dental drill. 30- 
Gauge stainless steel cannulae (Cooper’s Needleworks Ltd., U.K.) attached to 
5]il microsyringes (Hamilton) were lowered through the burr holes into the 
NBM region of the basal forebrain at the following stereotactic coordinates 
(relative to Bregma):-AP + 1.0mm; L ±3.2mm; V -7.2mm from dura; incisor 
bar set +5mm above interaural line (coordinates taken from the stereotaxic 
atlas of Paxinos & Watson, 1986; see Robbins et al., 1989a and b). Quisqualic 
acid (0.09M), a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA;
0.015M), N-methyl-o-aspartate (NMDA; 0.09M) and ibotenic acid (0.09M) or 
sterile phosphate buffered saline vehicle (0.2M, pH 7.2) were then infused 
unilaterally into the NBM in a volume of 0 .5 )jl1, at a constant rate over 3 min. 
The cannula was left in place for a further 3 min to allow the infusate to 
diffuse away from the infusion site and prevent ’’back-tracking1’ up the needle 
tract. The needle placement in the contralateral hemisphere, with no 
infusion served as a ’’sham” operation. Following cannulae removal the scalp 
wound was sutured closed with silk thread and the animals allowed to recover 
from anaesthesia. Glucose/saline (5ml) was administered subcutaneously to
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compensate for loss of body fluids during recovery from anaesthesia.
Following surgery, animals survived for 21-24 days, at which time the 
rats underwent [u C]-2-deoxyglucose in vivo autoradiography according to the 
procedures outlined in sections 1.1.3 and 1.1.4. At the end of the procedure 
the rats* brains were processed for quantitative autoradiography (see section 
1.4) and [3H]-PK-11195 in vitro autoradiography (see section 1.3.2).
4.2.2 Stereotactic Agonist Infusions into the NBM: Acute Glucose Use 
Measurement
Rats were anaesthetised with Avertin (lml/kg body weight, i.p.), placed 
in a Kopf stereotactic frame and the skull exposed, as described in section 
4.2.1. Burr holes were made through the skull bilaterally, a t the appropriate 
stereotactic coordinates, using a high-speed dental drill. Stainless steel guide 
cannulae (23 gauge; Cooper’s Needleworks Ltd., U.K.) were implanted 
bilaterally into the basal forebrain, terminating 1 .2 mm above the injection 
sites. The stereotaxic coordinates for injections targeted on the NBM 
relative to Bregma were:- Anterior-Posterior (A-P) + 1.0mm; Lateral (L) ± 
3.2mm; and Ventral (V) -7.2mm from dura (guide cannulae inserted to -6.0mm 
from dura); incisor bar set +5mm above the interaural line taken from the 
stereotaxic atlas of Paxinos and Watson (1986) (Muir et al., 1992). Two 
stainless steel screws were place in the skull anterior and posterior to the 
guide cannulae and the entire assembly covered in dental acrylic. In order 
to keep the cannulae patent a stainless steel stylet, cut to the same length 
as the guide cannulae, was inserted into each. Animals were then removed 
from the frame and allowed to regain consciousness. Glucose/saline solution
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(5ml) was administered subcutaneously to compensate for loss of body fluids 
while the animals were recovering from the effects of anaesthesia. Ten to 
fourteen days were allowed for post-operative recovery prior to further 
manipulation.
The excitatory amino acid agonists AMPA (0.0015M), NMDA (0.009M) 
and the GABA agonist muscimol (0.03mM) were dissolved (lml/kg) in sterile 
phosphate buffer vehicle (2M, pH 7.2). Aliquots were made in advance and 
stored, frozen at -20°C, for a maximum of 1 week.
On the day of the agonist infusion the rats were prepared for [14C]-2- 
deoxyglucose autoradiography as described in section 1.1.3. Agonist perfusion 
was initiated at least 2 h after animals had regained consciousness following 
halothane anaesthesia. The stylets were removed from both guide cannulae 
and a 30-gauge cannula was inserted into each outer guide tube, to protrude 
1.2mm below the base of each guide cannula. Each injection cannula was 
attached to a 5pl Hamilton syringe. AMPA, NMDA or muscimol, in a volume 
of ly.1, were injected unilaterally into the right hemisphere at a constant rate 
of 0.5]il/min by means of a perfusion pump controlling the Hamilton syringes. 
In all animals, vehicle (IjjlI) was simultaneously infused into the contralateral 
hemisphere. Injection cannulae were left in place for a further 2 min before 
removal.
The [14Cj-2-deoxyglucose procedure was initiated 15 min after 
completion of agonist infusion, according to the protocol outlined in section 
1.1.4. At the end of the procedure the ra t’s brains were removed and 
processed for quantitative autoradiography (as described in section 1.4).
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4.3 Quantification of Lesion Volume and Histological Analysis
[3H]-PK-11195 binds to peripheral-type benzodiazepine binding sites 
which are situated predominantly on glial cells within the CNS. Hence the 
extent of increased [3H]-PK-11195 binding evident after an intracerebral 
intervention putatively gives insight into the location and extent of gliosis 
occurring as a result of that intervention.
The volume of brain tissue showing an increased density of [ H]-PK- 
11195 binding after excitotoxic lesions, relative to the levels of binding in the 
contralateral non-lesioned hemisphere was assessed in each animal by 
computer-assisted densitometry. [3H]-PK-11195 autoradiograms were 
positioned under the video camera and section images analysed from the 
monitor screen. In [3H]-PK-11195 binding autoradiograms, regions of 
enhanced [3H]-PK-11195 binding were easily identified due to the greatly 
increased optical density of the film relative to ’’normal” cerebral tissue in 
the non-lesioned hemisphere. The densitometric paradigm used involved 
measuring the optical density of the blackest region of ’’normal” brain tissue 
in a section outwith the infusion site, to give a maximal optical density limit 
for "background”. It was then possible to programme the densitometer to 
detect regions with an optical density greater than this value (set individually 
for each animal film) and hence quantify the area in which [3H]-PK-1195 
binding was abnormally increased. By using the computer "mouse" to 
delineate a region of the section encompassing the infusion site and lesion, 
the densitometer then calculated the area of tissue within this region with 
an optical density greater than the previously set background limit, 
corresponding to the area of [ H]-PK-11195 binding. It was important to
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exclude regions of normally high glial content from this region of 
measurement (for example, the ventricles). Mean area values were 
calculated from duplicate adjacent sections, at 2 0 0 pm intervals throughout 
the extent of the lesion. Hence the volume of tissue in which increased [3H]- 
PK-11195 binding was evident following agonist infusions could be calculated 
from the area measurements and knowledge of the distance between 
successive sections.
The position of the lesions was verified by histological analysis of cresyl- 
violet stained sections, taken at 260pm intervals throughout the brain, and 
adjacent to sections used for autoradiography.
4.4 Data Analysis
4.4.1 Chronic NBM Lesions
Local cerebral glucose use values were measured bilaterally in 49 CNS 
regions in animals which had received unilateral infusions of NMDA, ibotenic 
acid, quisqualic acid, AMPA or vehicle into the NBM region of the basal 
forebrain. A needle was inserted into the corresponding region of the 
contralateral hemisphere to provide a ’’sham-operated” control hemisphere. 
Statistical analysis involved, firstly, analysis of glucose use values for 
structures in the contralateral, sham-operated hemispheres between all 
treatment groups, (using one way analysis of variance (ANOVA), followed by 
independent t-tests with Bonferroni correction for multiple comparisons). 
No significant differences in contralateral glucose use values were evident 
between vehicle- and treatment-infused groups. Subsequent interhemispheric 
comparison of glucose utilisation values for each structure in the vehicle-
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infused (control) animals, using Student’s paired t-test, demonstrated no 
significant differences between rates of glucose use in vehicle-infused and 
sham-operated hemispheres. Consequently, glucose use values in the vehicle- 
infused (ipsilateral) hemisphere of control animals were used as control values 
for subsequent comparison with values in the ipsilateral hemisphere of agonist- 
infused animals, initially using ANOVA to identify any regions showing 
alterations in glucose use, followed by independent t-tests with a Bonferroni 
correction factor of 4 for multiple comparisons.
4.4.2 Acute NBM Infusions
Local rates of cerebral glucose utilisation were measured bilaterally in 
52 CNS regions in animals which had received unilateral infusions of AMPA, 
NMDA or muscimol into the NBM region of the basal forebrain, with 
simultaneous infusions of vehicle into the corresponding region of the 
contralateral hemisphere. The statistical analysis involved, firstly, 
comparison of glucose use values for each structure of the contralateral 
(vehicle-infused) hemisphere, between all three treatment groups, using one 
way analysis of variance (ANOVA) followed by independent t-tests. No 
significant differences in glucose use values between treatment groups were 
identified in any of the regions investigated. Therefore, subsequent analyses 
of any alterations in glucose use in the ipsilateral (agonist-infused) 
hemispheres used the contralateral hemisphere as "control” values, comparing 
ipsilateral and contralateral glucose use values within treatment groups using 
Student’s paired t-test.
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5. MATERIALS
[1 4C]-2-Deoxy-D-glucose (50-60mCi/mmol) was obtained from Amersham.
(+)-3-l125I]-MK-801 (2200Ci/mmol) and [^ l-P K -lllS S  (8 6 Ci/mmol) were 
obtained from New England Nuclear. N-Methyl-o-aspartic acid (NMDA), a- 
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), quisqualic acid, 
ibotenic acid, muscimol, PK-11195, D-cycloserine and Tris buffer base 
(Tris[hydroxymethyl]amino-methane) were all obtained from Sigma Chemical 
Company. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline (NBQX) 
was obtained from Novo Nordisk and LY-293558 from Eli Lilly.
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CHAPTER III 
RESULTS
1. EFFECTS OF AMPA RECEPTOR BLOCKADE ON CEREBRAL GLUCOSE USE
The effects of systemic administration of the AMPA receptor 
antagonists NBQX (10, 30 and lOOmg/kg) and LY-293558 (10, 30 and 
lOOmg/kg) on local cerebral glucose utilisation were assessed, in conjunction 
with measurements of physiological parameters and observation of overt 
behaviour, to gain insight into the functional consequences of AMPA receptor 
blockade.
1.1 General Observations
Intravenous administration of the AMPA-receptor antagonists NBQX (10, 
30, lOOmg/kg) and LY-293558 (10, 30, lOOmg/kg) resulted in marked 
alterations in the overt behaviour of the rats (which varied drug- and dose- 
dependently in rate of onset and duration) and changes in the measured 
respiratory parameters, but had no sustained effect on the cardiovascular 
system. All physiological measurements are presented in Table 4.
Prior to drug administration the partially restrained rats were generally 
quiescent, with intermittent periods of spontaneous head and forelimb 
movements, grooming and sniffing. All rats responded appropriately to 
noise and visual stimulation. Following the administration of NBQX 
and LY-293558 rats became heavily sedated, apparently unconscious, staring 
straight ahead with a rigid body posture, no movement of head or forelimbs, 
and signs of CNS depression characterised by loss of responsiveness to 
auditory and visual stimuli. The rate of onset of this state was slower after 
LY-293558 administration than after NBQX. Rats became sedated within 
1 min of receiving NBQX (lOOmg/kg), and 1-5 min after NBQX (10 or
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30mg/kg). Rats receiving LY-293558 (lOOmg/kg) became sedated 1-5 min 
post-administration, while the rate of onset of sedation was slower after 
lower doses of LY-293558 (4-20 min after lOmg/kg and 3-10 min after 
30mg/kg). Following NBQX (lOOmg/kg) or LY-293558 (lOOmg/kg) rats 
remained sedated for the duration of the experiment. Following lower doses, 
animals showed signs of recovery within 30 min of NBQX (lOmg/kg) or 
LY-293558 (lOmg/kg), and within 40 min of NBQX (30mg/kg) or LY-293558 
(30mg/kg). Recovery was exemplified by the return of responsiveness to 
auditory and visual stimuli, and movements of head and forelimbs. During 
recovery from sedation, animals exhibited abnormal motor activity 
characterised by intermittent periods of jerky head movements, neck arching, 
facial twitching, gnawing and grinding of teeth, which persisted for the 
remainder of the experimental period. Similar atypical movements were seen 
in all animals after LY-293558 administration, prior to the onset of sedation 
occurring. In contrast, control animals remained fully conscious, lively and 
alert throughout the experimental period.
NBQX and LY-293558 both evoked dose-dependent increases in arterial 
C0 2 tension (pC02) and decreases in arterial oxygen tension (p02) over the 
time course of the experiments (Figures 10 and 11). The respiratory 
depressant effects of LY-293558 were more marked than those of NBQX. 
Control animals showed no significant alterations in PC02 and P0 2 during the 
lh experimental period.
The cardiovascular effects of each agent were restricted to the period 
immediately following injection, with neither drug inducing a sustained 
significant change in arterial blood pressure over the 60 min experimental
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period. However, NBQX (lOOmg/kg) and LY-293558 (lOOmg/kg) had 
contrasting effects on mean arterial blood pressure acutely after injection.
NBQX (lOOmg/kg) produced a transient decrease in arterial pressure (-12 ± 
9mmHg, mean ± SEM), maximal by 1 min post-administration and persisting 
for up to 5 min. Lower doses of NBQX had negligible effects on blood 
pressure. In contrast, LY-293558 induced a dose-dependent pressor effect. 
LY-293558 (lOOmg/kg) markedly increased arterial pressure (+33 ± 9mmHg, 
mean ± SEM, p<0.05) maximal by 1 min post-injection and which returned to 
pre-injection levels within 6  min. In animals receiving lower doses of LY- 
293558, transient but non-significant increases in blood pressure occurred 
following 30mg/kg (+19 ± 6 mmHg) and lOmg/kg (+15 ± 4mmHg), evident by 
1 min post-injection and persisting for up to 6  min. In control animals, 
vehicle injection had no effect on arterial pressure.
Plasma glucose levels were significantly increased 50 min after NBQX 
(lOOmg/kg) relative to control values. In contrast LY-293558 had no 
significant effects on plasma glucose levels over the time course of the 
experiments. Trends towards reduced body temperature were evident in some 
animals following both NBQX and LY-293558, however the use of heating 
lamps throughout the experimental period makes interpretation of drug- 
related temperature effects difficult.
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1.2 Local Cerebral Glucose Utilisation
1.2.1 General
Intravenous administration of NBQX (10, 30 and lOOmg/kg) and 
LY-293558 (10, 30 and lOOmg/kg) resulted in marked, widespread, dose- 
dependent reductions in local cerebral glucose utilisation throughout the CNS. 
The glucose use alterations associated with systemic administration of NBQX 
or LY-293558 in the 50 CNS regions investigated are presented in Tables 5 - 
9 (see also Figures 12 and 13).
Following intravenous administration of NBQX (lOmg/kg), none of the 
50 regions examined displayed significant alterations in glucose use. 
Following NBQX (30mg/kg), glucose use was significantly reduced in 17 of the 
50 regions investigated, and NBQX (lOOmg/kg) significantly reduced glucose 
use in 48 of the 50 regions. In contrast, intravenous administration of LY- 
293558 (lOmg/kg) produced significant reductions in glucose use in 7 of the 
50 regions examined. Following LY-293558 (30mg/kg) glucose use was 
significantly reduced in 34 of the 50 regions investigated, while LY-293558 
(lOOmg/kg) significantly reduced glucose use in 43 of the 50 regions. No 
significant elevation in glucose use was observed in any of the brain regions 
examined following any dose of either drug.
Administration of the highest dose of either agent, NBQX (lOOmg/kg) 
or LY-293558 (lOOmg/kg), resulted in extremely large magnitude reductions 
in glucose use in several CNS regions, in particular in a number of cortical, 
auditory and limbic regions where glucose use was decreased by up to 6 8 % 
(see Figures 12 and 13). For example, in the superior olivary nucleus glucose 
use was reduced from 114 ± 6  punol/lOOg/min in control animals to 44 ± 6  and
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FIGURE 12: NBQX AND CEREBRAL GLUCOSE USE
Representative dose-response curves illustrating the effects of intravenous 
administration of NBQX (10, 30 or 100 mg/kg) or vehicle on local cerebral 
glucose utilisation. Data presented as mean ± SEM.
Note the general similarities between the dose-dependent glucose use 
reductions in the four brain regions illustrated, although glucose use was 
depressed to a proportionately greater extent by NBQX (100 mg/kg) in the 
superior olivary nucleus than in the limbic and cortical regions.
*p<0.05, **p<0.01 (ANOVA, followed by S tudent’s unpaired t- te s t with Bonferroni
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FIGURE 13: LY-293558 AND CEREBRAL GLUCOSE USE
Representative dose-response curves illustrating the effects of intravenous 
administration of LY-293558 (10, 30 or 100 mg/kg) or vehicle on local cerebral 
glucose utilisation. Data presented as mean ± SEM.
Note the general similarities between the dose-dependent glucose use 
reductions in the four brain regions illustrated, although glucose use was 
depressed to a proportionately greater extent by LY-293558 (100 mg/kg) in the 
superior olivary nucleus than in the limbic and cortical regions.
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37 ± 3 ymol/lOOg/min following NBQX (lOOmg/kg; -61%) and LY-293558 
(lOOmg/kg; -6 8 %) respectively.
In the cerebral cortex, both AMPA antagonists markedly reduced glucose 
utilisation in all regions investigated (Table 6 ). The laminar pattern of 
glucose use seen in sensory motor and frontal cortex of control animals was 
conserved following antagonist administration, layer IV exhibiting greater 
glucose use than other lamina. In neocortical and allocortical regions the 
reductions in glucose use seen after NBQX and LY-293558 were both 
qualitatively and quantitatively similar, with the exception of cingulate 
cortical regions which exhibited markedly greater glucose use reductions 
following either NBQX or LY-293558 than other cortical regions. For 
example, in the posterior cingulate cortex glucose use was reduced from 89 
± 7 pimol/lOOg/min in control animals to 31 ± 5 and 32 ± 1 punol/lOOg/min 
following NBQX (lOOmg/kg; -65%) and LY-293558 (lOOmg/kg; -64%) 
respectively. No significant elevation in glucose use was observed in any of 
the brain regions examined following any dose of either drug.
In the majority of regions investigated NBQX and LY-293558 produced 
qualitatively similar patterns of glucose use alterations, both agents inducing 
more or less uniform dose-dependent reductions in glucose use, as is 
demonstrated by the similarities between dose-response curves for glucose use 
alterations in response to NBQX and LY-293558, illustrated in Figures 12 and 
13. However, a small number of regions exhibited heterogeneous responses 
to NBQX and LY-293558. The observation of anomalous responses to NBQX 
and LY-293558 in some brain regions is underlined by the fact that NBQX 
(lOOmg/kg) produced significant reductions in glucose use in 48 out of the 50
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regions examined whereas LY-293558 (lOOmg/kg) significantly affected only 
43 regions. For example, in the olfactory tubercle NBQX (lOOmg/kg) 
produced a significant reduction in glucose use, from 99 ± 7 punol/lOOg/min 
in control animals to 52 ± 5 pmol/100g/min (-47%, p<0.01), whereas 
LY-293558 (lOOmg/kg) produced a much smaller magnitude reduction in the 
same region (to 73 ± 6>imol/100g/min, -26%, p>0.05). The insensitivity of 
the olfactory tubercle to glucose use alteration by LY-293558, relative to the 
marked reduction produced by NBQX, is readily apparent from visual 
inspection of the autoradiograms (see Figure 14).
Other brain regions examined in which glucose use was insensitive to any 
dose of LY-293558 were the superficial layer of the superior colliculus, 
olfactory amygdala, substantia nigra pars compacta and pars reticulata, 
medial habenular nucleus and cerebellar white m atter (see Tables 5, 7, 8  and 
9). Glucose use in the superior colliculus superficial layer and inferior 
olivary nucleus was insensitive to change by NBQX at any dose (see Tables 
5 and 8 ). In one region, the superficial layer of the superior colliculus, 
glucose utilisation was not significantly altered by either NBQX or LY-293558 
(controls = 72 ± 5 punol/lOOg/min; NBQX (lOOmg/kg) = 56 ± 6  jimol/lOOg/min; 
LY-293558 (lOOmg/kg) = 6 6  ± 4 ymol/lOOg/min). The lack of effect of NBQX 
(lOOmg/kg) and LY-293558 (lOOmg/kg) on glucose use in the superior colliculus 
superficial layer, relative to the marked glucose use reductions in other brain 
regions, is clearly evident from visual inspection of the autoradiograms (see 
Figure 15).
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1.2.2 Comparison of Effects of NBQX and LY-293558: Ranking Analysis
The anatomical patterns of glucose use changes produced by NBQX and 
LY-293558 were broadly similar throughout the CNS, with approximately two 
thirds of the regions investigated showing similar sensitivities to both agents 
(as illustrated in Figure 16). However, a number of regional anomalies are 
apparent between the effects of the two drugs (see Figures 17 and 18). 
Further insight into the differences between glucose use responses to NBQX 
and LY-293558 can be gained by examination of the ”/  ’’ ranking function 
values generated in each region independently for the effects of either NBQX 
(10, 30 and lOOmg/kg) and LY-293558 (10, 30 and lOOmg/kg) (as outlined in 
Methods, Section 2.2.2). Briefly, the function is an arithmetic function 
which provides an index of the degree of responsiveness of each CNS region 
investigated to each of the two drugs, taking into consideration the entire 
dose-response data available following administration of multiple drug doses 
(Kelly et al., 1986). The H/ "  ranking function:-
/  * *  (xc -  *T1 )  2
where xc is the mean of loge (glucose use) for control group members, and xTi 
is the mean of loge (glucose use) for the ith dose of the treatment group in 
question, T, i.e. either NBQX (10, 30, lOOmg/kg) or LY-293558 (10, 30, 
lOOmg/kg). /  values for each of the 50 CNS regions investigated are 
presented in Tables 5-9.
Application of the function allowed regional responses to NBQX 
or LY-293558 to be rank ordered, to compare inter-regional differences in 
responsiveness of the two drugs using an approach which takes into account 
the entire data group available. The hierarchies of regional sensitivies are 
presented in Tables 10a and 10b.
173
a) F ron tal C ortex  (layer IV )
On
2  o  - 1 0 -o3co
COOO
2
IOo
£^t-i
<DW>
§ 9J - s
<D w
U
- 20 -
-30-
-40-
-50-
-60 J
10
"T~
30 Too
•  NBQX 
O LY-293558
D o s e  o f  A n t a g o n i s t  ( m g / k g )
b ) H ip p ocam pu s (M olecu lar L ayer)
0  -i
- 10 -
- 20 -
-30-
C3o  ^
^  Pco H
£  °D o
2  fiSS oO Ihu  VM 
^  <D
5  S*
s i  - 4 0 '
2  O
fe w  -50- 
-60 J
10
T ~
30 100
•  NBQX 
O LY-293558
D o s e  o f  A n t a g o n i s t  ( m g / k g )
FIGURE 16: AMPA ANTAGONISTS AND CEREBRAL GLUCOSE USE:
HOMOGENEOUS EFFECTS OF NBQX AND LY-293558
Data presented as mean ± SEM percentage change in glucose utilisation relative to 
glucose use in control (vehicle-treated) animals. * p < 0.05, ** p < 0.01 (ANOVA, 
followed by Student’s unpaired t-test with Bonferroni correction). Note the 
similarities in the magnitudes of glucose use reductions induced by NBQX and 
LY-293558 in (a) frontal cortex and (b) hippocampus molecular layer.
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FIGURE 17: AMPA ANTAGONISTS AND CEREBRAL GLUCOSE USE :
HETEROGENEOUS EFFECTS OF NBQX AND LY-293558
Data presented as mean ± SEM percentage change in glucose utilisation relative to 
glucose use in control (vehicle-treated) animals. * p < 0.05, ** p < 0.01 (ANOVA, 
followed by Student's unpaired t-test with Bonferroni correction). Note the greater 
potency of LY-293558 than NBQX in these representative auditory (a) and limbic (b) 
regions.
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FIGURE 18: AMPA ANTAGONISTS AND CEREBRAL GLUCOSE USE :
HETEROGENEOUS EFFECTS OF NBQX AND LY-293558
Data presented as mean ± SEM percentage change in glucose utilisation relative to 
glucose use in control (vehicle-treated) animals. * p < 0.05, ** p < 0.01 
(ANOVA, followed by Student's unpaired t-test with Bonferroni correction). Note 
the relative insensitivities of (a) the olfactory tubercle and (b) the medial habenular 
nucleus to glucose use depression by LY-293558, compared to the effects of NBQX.
LEGEND TO TABLES 10a AND 10b:
HIERARCHY OF REGIONAL RESPONSIVENESS TO NBQX (10a) 
AND TO LY-293558 (10b)
The effects of NBQX and LY-293558 on local cerebral glucose use in each 
of the 50 brain regions investigated are ranked in order of decreasing 
magnitude of effect, according to the regional calculated /  values. The 
" /  " function takes into consideration all the dose-response data available for 
a given region, and hence reflects the overall sensitivity of the region to 
glucose use alteration by NBQX or LY-293558 (for derivation of the " f  " 
function, see Methods, Section 2.2.2). Regions have been arbitrarily 
classified into four groups:-
Extremelv Sensitive regions, classified as f  >0.08. The /  values for these 
regions lie outwith the normal distribution of /  values for either drug. 
Extremely sensitive regions generally displayed glucose use reductions of 
>55% after the highest dose (lOOmg/kg) of either agent.
Sensitive regions, 0.5< f  <0.8. Sensitive regions generally displayed glucose 
use reductions of >50% after the highest dose (lOOmg/kg) of either agent. 
Moderately Sensitive regions, 0.3 < /  < 0.5. Moderately sensitive regions 
generally displayed 30-50% reductions in glucose use after the highest dose 
(lOOmg/kg) of either agent.
Minimally Sensitive regions, /  <0.3. Minimally sensitive regions displayed 
glucose use reductions of <30% after the highest dose (lOOmg/kg) of either 
agent. Included in this group are regions in which glucose use was not 
significantly altered after any dose of NBQX or LY-293558, although all 
regions showed a trend towards decreased glucose use. These insensitive 
regions are identified by *.
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By examination of the *’/  " ranking hierarchies it is apparent that areas 
which were particularly sensitive to LY-293558 were, in general also highly 
sensitive to NBQX (see also Figure 16), while those least affected by 
LY-293558 were also least susceptible to NBQX. Regions in which glucose 
use was particularly sensitive to NBQX, typically displaying reductions in 
glucose use of 50% or more at lOOmg/kg and f  values in excess of 0.5 (Table 
1 0 a), included primary auditory areas, cerebral cortex, limbic regions 
(including cingulate cortex and the hippocampal formation), basal ganglia and 
thalamic regions. Regions in which glucose use was particularly sensitive to 
LY-293558, displaying glucose use reductions of 50% or more at lOOmg/kg and 
/  values in excess of 0.5 (Table 10b), included primary auditory areas, the 
cerebral cortex (in particular cingulate cortex) and thalamus.
However, examination of frequency distribution profiles of /  values for 
NBQX and LY-293558 (Figure 19) and correlation analysis of /  values (Figure 
2 0 ), reveals differences in glucose use responses to the two agents in a small 
number of regions. The regional /  values in NBQX-treated animals are 
normally distributed around the mean, reflecting the relatively homogenous 
anatomical pattern of depressant effects of NBQX on local cerebral glucose 
use (Figure 19a). This observation is supported by examination of the 
magnitudes of glucose use reductions throughout the brain (Tables 5-8). In 
contrast, the anatomical pattern of local cerebral glucose use depression 
produced by LY-293558, although widespread, was more heterogeneous than 
the pattern of effects produced by NBQX. This is evident from the skewed 
distribution of LY-293558 /  values (Figure 19b), the range of glucose use 
reductions across different brain regions (Tables 5-9), and the failure of a
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FIGURE 19: FREQUENCY DISTRIBUTIONS OF f  VALUES FOR NBQX AND 
LY-293558
"f " Function values reflect the sensitivity of individual regions to drug treatment. 
Following the administration of NBQX (a) the distribution of /  values was 
relatively regionally homogeneous, regions being normally distributed around an /  
value of 0.5. In contrast, the regional response to LY-293558 (b) was more 
heterogeneous, with a wider range of /values and a skewed distribution.
greater number of brain regions to achieve accepted statistical significance 
following LY-293558 (lOOmg/kg) than after NBQX (lOOmg/kg).
Comparison of the /  values for NBQX with those for LY-293558 in each 
region using Pearson’s product moment correlation analysis generated a 
coefficient value (r), of 0.758 reflecting a high degree of association between 
/va lues across all the CNS regions investigated (illustrated in Figure 20a). 
This correlation analysis confirms the broad similarity between regional 
responses to the two agents.
However, within a subset of regions the /  value for LY-293558 greatly 
exceeded the value for NBQX, reflecting enhanced sensitivity of these regions 
to glucose use depression by LY-293558, as illustrated in Figure 20b. This 
subset of regions was not randomly distributed in the CNS, but comprised 
mainly two functional systems - the primary auditory system and 
thalamocortical regions, including all neocortical and suprarhinal cortical 
areas (r = 0.895). The increased potency of LY-293558 relative to NBQX in 
the medial geniculate body and posterior cingulate cortex is evident from 
examination of Figure 17 .
Within all other brain areas examined, including limbic, primary visual, 
olfactory, sensory motor and extrapyramidal regions, NBQX and LY-293558 
were generally equipotent (showing a relatively low degree of correlation, 
r  = 0.5; Figure 20c) with the exception of a small number of regions which 
showed slightly greater susceptibility to NBQX than to LY-293558. These 
regions included the substantia nigra (pars reticulata and pars compacta), 
cerebellar white matter, medial habenular nucleus, olfactory amygdala and 
olfactory tubercle (see Figures 14 and 18).
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LEGEND TO FIGURE 20:
The relationship between the responsiveness of glucose utilisation in 50 brain 
regions to NBQX and LY-293558. Each data point represents the " f" value generated 
from analysis of the entire dose-response curve of a single structure in reponse to 
NBQX and LY-293558. " f" values were compared using Pearson's product-moment 
correlation analysis.
a) The overall correlation coefficient, r, for all regions investigated is 0.758, 
indicating a high degree of association between the regional effects of NBQX and 
LY-293558.
b) A subset of regions, comprising primary auditory regions, cerebral cortex and 
thalamus, showed a particularly high degree of association, with a correlation 
coefficient of 0.895 and a slope of 1.44. In these regions, glucose use was more 
susceptible to depression by LY-293558 than NBQX.
c) Residual areas exhibited a lower degree of association, with a correlation 
coefficient of 0.586 and a slope of 0.38.
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2. MANIPULATION OF NMDA RECEPTOR ACTIVITY BY d-CYCLOSERINE
Four different approaches were used to gain insight into the effects of 
putative NMDA receptor modulation by the glycine site partial agonist 
D - c y c l o s e r i n e ,  on aspects of CNS function under both normal and pathological 
conditions in the rat. The four strategies employed were:- 
(i) Investigation of the effects of systemic administration of D-cycloserine 
(0.3, 3 and 30mg/kg) on local cerebral glucose utilisation in conscious 
rats, using the [14C]-2-deoxyglucose in vivo autoradiography technique.
(ii) Investigation of the effects of systemic administration of a putative 
agonist dose of D-cycloserine (3mg/kg) on [125I]-MK-801 binding in the 
conscious rat brain, to gain insight into the consequences of putative 
glycine site stimulation on NMDA receptor activation in the CNS. 
Results were compared with levels of I IJ-MK-801 binding in both 
conscious and halothane-anaesthetised control animals.
(iii) Investigation of the effect of systemic administration of a putative 
agonist dose of D-cycloserine (3mg/kg) on lesion volume in the MCA 
occlusion model of focal cerebral ischaemia.
(iv) Investigation of the effect of systemic administration of a putative 
agonist dose of D-cycloserine (3mg/kg) on the volume of lesion produced 
by intracortical perfusion of glutamate. The effects of D-cycloserine 
were compared with the effects of a well characterised neuroprotective 
dose of the AMPA receptor antagonist NBQX (30mg/kg) on lesion size 
in the same model, assessed in a separate group of experiments.
|
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2.1 Local Cerebral Glucose Utilisation
2.1.1 General Observations
Intravenous administration of D-cycloserine (0.3, 3 and 30mg/kg) to 
conscious rats had no effect on overt behaviour, or the measured respiratory 
or cardiovascular parameters throughout the lh experimental period. All 
physiological measurements are presented in Table 11.
The partially restrained animals were generally quiescent throughout, 
with intermittent periods of spontaneous head and forelimb movements, 
grooming and sniffing following either D-cycloserine (0.3, 3 and 30mg/kg) or 
vehicle administration. Both drug and vehicle-treated rats remained 
conscious and alert during the experiments. There were no significant 
differences in the measured respiratory parameters (pC02  and p02) or plasma 
glucose concentrations between control and drug-treated animals of the time 
course of the experiments. The statistical analysis employed (ANOVA, 
followed by Student’s unpaired t-test) indicated that mean arterial blood 
pressure in the group of animals which received D-cycloserine (0.3 and 3mg/kg) 
was significantly higher at the start of the experiment than in control 
animals, while there were no significant differences between treatment groups 
50 min after drug or vehicle administration. However, from subsequent 
paired t-test analysis within treatment groups, no significant differences were 
evident within treatment groups between blood pressure levels prior to, and 
50 min after administration of vehicle or D-cycloserine (0.3, 3 or 30mg/kg) 
(Student’s paired t-test, p>0.05). This observation indicates that there is no 
evidence that D-cycloserine significantly alters mean arterial blood pressure 
over the duration of the experiment.
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2.1.2 Glucose Utilisation
The glucose utilisation values associated with the intravenous 
administration of D-cycloserine (0.3, 3 and 30mg/kg) are presented in Tables 12- 
15. Glucose utilisation was not significantly altered in any of the 51 CNS 
regions investigated following any dose of D-cycloserine, relative to values 
in the corresponding regions of control animals.
Examination of the glucose use values measured after D-cycloserine (0.3, 
3 and 30 mg/kg) indicates that the degree of variance in glucose use values 
within treatment groups is extremely low (see Figures 21 and 22, Tables 12-15). 
This observation suggests that significant dose-dependent glucose use changes 
are not being masked by intra-group variability, and supports the evidence of no 
effect of D-cycloserine (0.3, 3 or 30mg/kg) on local cerebral glucose utilisation 
in the 51 CNS regions examined. The lack of effect of D-cycloserine on 
cerebral metabolic rate in limbic (Figure 21) and cerebellar regions (Figure 22) 
is of particular interest in light of the high concentrations of NMDA receptors 
present in limbic regions (in particular in hippocampus), the marked effects of 
the non-competitive NMDA antagonist MK-801 on glucose use in regions such 
as the posterior cingulate cortex, and the previously reported stimulatory effect 
of D-cycloserine (3mg/kg) on cGMP activity in the cerebellum.
It should be noted that the statistical design adopted a priori involved 
initial identification of regions in which glucose use was altered by any dose of 
D-cycloserine by analysis of variance (ANOVA), followed by Student’s unpaired 
t-test with Bonferroni correction for multiple treatment groups. However, no 
significant glucose use alterations were detected by analysis of variance in any 
of the 51 brain regions examined. Therefore, to gain insight into regions in
ii
182
1 2 0 1
• H4
<L>
100 -
8 0
a0a
« 3
1  6 0  
£
1  4 0
2  -D
24>u 20
13o
Posterior Cingulate 
Cortex
Mammillary Body
Entorhinal Cortex
Hippocampus CA1 
(stratum radiatum)
0 J I-----
V e h i c l e
“ T" 
0 . 3
I
3 . 0 3 0 . 0
C y c l o s e r i n e  ( m g / k g )
FIGURE 21: D-CYCLOSERINE AND GLUCOSE USE I : LIMBIC REGIONS
Representative dose-response curves illustrating the effects of intravenous 
administration of D-cycloserine (0.3, 3 or 30 mg/kg) or vehicle on local cerebral 
glucose utilisation. Data presented as mean ± SEM (pmoles/lOOg/min).
Note the lack of any significant dose-dependent effects of D-cycloserine on glucose 
use in these limbic structures, in which NMDA receptor activity is thought to play an 
important role in functional activity.
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FIGURE 22: D-CYCLOSERINE AND GLUCOSE USE II
Representative dose-response curves illustrating the effects of intravenous 
administration of D-cycloserine (0.3, 3 or 30 mg/kg) or vehicle on local cerebral 
glucose utilisation. Data presented as mean ± SEM (pmoles/lOOg/min).
Note the lack of any significant dose-dependent effects of D-cycloserine on glucose 
use in the thalamus, frontal cortex and lateral geniculate body - structures in which 
ligand binding studies have previously identified high densities of NMDA receptor 
binding sites . In contrast, the cerebellum (molecular layer) contains relatively low 
levels of NMDA receptor binding sites (Monaghan and Cotman, 1986).
which glucose use showed some sensitivity towards alteration by D-cycloserine, 
a less conservative statistical approach was employed, involving application of 
independent t-tests (Student’s unpaired t-test, 2-tailed) between control and 
treatment groups, with no Bonferroni correction. Using this approach, trends 
towards reduced glucose utilisation were observed in:- cerebellar white matter 
following D-cycloserine (0.3mg/kg) (controls = 34 ± 2, D-cycloserine = 28 ± 2 
punol/lOOg/min); and following D-cycloserine (3mg/kg) in the cochlear nucleus 
(controls = 106 ± 5, D-cycloserine = 81 ± 8 pLmol/100g/min), and superior olivary 
nucleus (controls = 123 ± 5, D-cycloserine = 104 ± 5 jimol/lOOg/min).
In contrast, trends towards increased glucose use were observed in:- 
the lateral habenular nucleus after D-cycloserine (0.3mg/kg) (controls = 
87 ± 4, D-cycloserine * 100 ±4 pimol/100/min); and following D-cycloserine 
(0.3 and 30mg/kg) in hippocampus CA1 stratum oriens (controls = 46 ± 1, 
D-cycloserine (0.3mg/kg) = 52 ± 2 jimol/lOOg/min, D-cycloserine (30mg/kg) 
= 53 ± 3 pLmol/lOOg/min).
It should be emphasised that these small magnitude glucose use changes do 
not represent statistically significant alterations in cerebral metabolic rate 
following systemic administration of D-cycloserine.
TABLE 12
GLUCOSE UTILISATION FOLLOWING d-CYCLOSERINE ADMINISTRATION: 
PRIMARY VISUAL AND AUDITORY REGIONS
D-CYCLOSERINE (mg/kg)
STRUCTURE CONTROL 0. 3 3. 0 30
Primarv Visual Svstem
Visual Cortex, Layer IV 69 ± 2 77 i 4 71 ± 4 72 ± 3
Dorsal Lateral Geniculate 
Body 64 ± 4 66 ± 3 67 ± 4 68 ± 4
Thalamus: Lateral Posterior 81 ± 3 74 ± 3 80 ± 6 84 ± 4
Superior Colliculus:
Superficial Layer 69 i 3 76 i 5 67 ± 4 71 ± 3
Deep Layer 70 i 2 73 i 3 69 ± 5 71 ± 2
Primarv Auditorv Svstem ■
Auditory Cortex, Layer IV 102 ± 8 121 t 7 120 ± 6 108 ± 5
Medial Geniculate Body 99 ± 7 99 i 5 99 ± 5 94 ± 3
Inferior Colliculus 136 i 7 140 ± 8 134 ± 8 141 ± 8
Superior Olivary Nucleus 123 ± 5 111 ± 10 104 ± 5 108 ± 6
Cochlear Nucleus 107 ± 5 88 i 13 81 i 8 88 ± 14
n = 6 n = 6 n = 6 n = 6
Data are presented as mean ± SEM (jjunol/1 OOg/min.) There were no significant 
differences between treatment groups relative to control values (ANOVA, 
p>0.05).
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TABLE 13
GLUCOSE UTILISATION FOLLOWING d-CYCLOSERINE ADMINISTRATION:
CEREBRAL CORTEX
D-CYCLOSERINE (mg/kg)
STRUCTURE CONTROL 0. 3 3.0 30
Sensory Motor Cortex:
Layer I-III 76 ± 5 79 ± 5 79 ± 4 76 ± 3
Layer IV 87 ± 4 88 ± 6 88 i 5 85 ± 3
Layer V-VI 74 ± 4 65 ± 4 67 ± 3 66 ± 4
Parietal Cortex:
Layer IV 81 ± 3 81 ± 3 79 ± 4 84 ± 4
Frontal Cortex:
Layer I-III 76 t 4 78 i 4 75 ± 2 75 ± 2
Layer IV 89 ± 4 89 t 4 85 ± 4 85 ± 3
Layer V-VI 70 ± 3 64 ± 4 67 ± 4 67 ± 3
Posterior Cingulate Cortex 90 ± 5 98 ± 5 90 ± 5 91 ± 3
Anterior Cingulate Cortex 88 ± 4 93 ± 4 92 t 4 84 ± 7
Prefrontal Cortex:
Layer IV 81 ± 3 82 ± 7 82 ± 3 81 ± 3
n = 6 n = 6 n = 6 n = 6
Data are presented as mean ± SEM (ymol/1 OOg/min.) There were no significant 
differences between treatment groups relative  to control values (ANOVA, 
p>0.05).
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TABLE 14
GLUCOSE UTILISATION FOLLOWING d-CYCLOSERINE ADMINISTRATION: 
LIMBIC AND OLFACTORY REGIONS
D--CYCLOSERINE (mg/kg)
STRUCTURE CONTROL 0. 3 3. 0 30
Hippocampus:
Molecular Layer 61 ± 3 65 ± 3 64 ± 5 65 ± 3
CA1 Stratum Radiatum 44 ± 2 44 i 2 48 ± 2 46 i 3
CA1 Stratum Oriens 46 ± 2 52 ± 2 47 ± 4 53 * 3
CA3 45 ± 2 46 ± 3 45 1 3 50 ± 3
Dentate Gyrus 48 i 3 50 ± 2 48 1 3 51 ± 2
Median Raphe Nucleus 77 i 2 79 ± 3 82 ± 3 76 ± 3
Dorsal Raphe Nucleus 74 ± 3 74 ± 3 71 ± 3 71 ± 3
Lateral Habenular Nucleus 87 ± 4 100 i 4 82 ± 7 96 ± 4
Medial Habenular Nucleus 62 ± 2 65 ± 3 56 ± 4 62 ± 3
Mamillary Body 79 ± 4 87 i 3 82 1 5 81 ± 3
Hypothalamus 39 i 1 41 i 3 38 ± 3 41 ± 2
Olfactory Amygdala 37 ± 2 40 ± 5 35 ± 2 38 ± 2
Primary Olfactory Cortex 54 ± 3 57 ± 3 55 ± 4 58 ± 3
Entorhinal Cortex 48 ± 4 52 ± 4 49 ± 4 52 ± 3
n = 6 n = 6 n = 6 n  = 6
Data are presented as mean ± SEM (vunol/1OOg/min.) There were no significant 
differences between treatment groups relative  to control values (ANOVA, 
p<0.05).
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TABLE 15
GLUCOSE UTILISATION FOLLOWING M3YCLOSERINE ADMINISTRATION: 
EXTRAPYRAMIDAL AND SENSORY-MOTOR AREAS
D--CYCLOSERINE (mg/kg)
STRUCTURE CONTROL 0 . 3 3. 0 30
Striatum:
Dorsolateral 82 ± 5 88 ± 5 87 ± 6 87 ± 5
Ventromedial 81 ± 4 81 ± 5 77 ± 5 83 ± 5
Globus Pallidus 43 ± 1 45 ± 3 43 ± 3 45 i 2
Nucleus Accumbens 65 i 2 71 ± 4 60 i 4 72 ± 5
Substantia Nigra:
Pars Compacta 55 ± 3 60 ± 3 54 ± 2 57 ± 2
Pars Reticulata 37 i 2 43 t 2 42 ± 1 40 ± 2
Thalamus:
Mediodorsal 87 ± 2 86 ± 3 87 ± 6 91 ± 3
Ventrolateral 63 ± 1 62 i 2 60 i 4 65 ± 3
Ventromedial 9 1 t 4 86 t 5 88 ± 6 98 ± 5
Anteriodorsal 87 i 6 80 i 3 87 ± 4 84 i 4
Anteriomedial 92 i 5 87 1 7 87 ± 5 -H0000 3
Subthalamic Nucleus 62 i 4 64 ± 3 64 ± 3 67 ± 3
Inferior Olivary Nucleus 63 ± 4 67 ± 6 59 i 3 65 ± 4
Cerebellar Nucleus 98 ± 6 102 1 6 94 ± 3 94 ± 5
Cerebellar Hemisphere:
Granular Layer 51 t 2 5 5 ± 4 48 ± 2 50 ± 2
Molecular Layer 46 ± 3 4 4 1 3 42 ± 2 43 ± 2
Cerebellar White Matter 34 ± 2 28 1 2 31 ± 2 30 ± 2
n = 6 n = 6 n = 6 n = 6
Data are presented as mean ± SEM (junol/1OOg/min.) There were no sign ificant 
differences between treatment groups relative to control values (ANOVA, 
p<0.05).
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2.2 [125I]-MK-801 In Vivo Autoradiography
2.2.1 General Observations
The physiological variables in the conscious and anaesthetised 
(ventilated) rats, measured immediately prior to intravenous administration 
of D-cycloserine (3mg/kg) or vehicle, are presented in Table 16. The 
measured respiratory parameters (p02 and pC02), temperature, and mean 
arterial blood pressure were deemed to be within acceptable limits at the 
commencement of experiments, indicating that rats were not adversely 
stressed. Within each of the three treatment groups, mean arterial blood 
pressure did not significantly alter over the 1 2 0  min experimental period.
2.2.2 f125I1-MK-801 Binding
Total bound (125I]-MK-801 was measured in 13 CNS regions from coronal 
ra t brain sections washed for 0, 15, 30 or 60 min to remove unbound ligand. 
Data are presented in Tables 17-20. Within each of the treatment 
groups (anaesthetised vehicle, conscious vehicle (controls), and conscious 
D-cycloserine), there were no significant differences between levels of [1 2 5I]- 
MK-801 bound in any of the 13 brain regions examined. Hence, D-cycloserine 
(3mg/kg) had no apparent significant effect on the extent of [125I]-MK-801 
binding to the NMDA receptor-associated channel, in vivo.
Washing the brain sections revealed regional heterogeneity in the 
densities of [125I]-MK-801 binding sites, with highest levels present in the 
hippocampus CA1 (in conscious controls after a 60 min wash, [125I]-MK-801 
bound = 1.74 ± 0.38 pmol/g tissue). Relatively high levels of binding were 
found in hippocampus, CA3, dentate gyrus, thalamus (ventrolateral), cortex
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(sensory motor, auditory and cingulate) and the medial geniculate body. 
Lowest levels of binding were seen in the hypothalamus and cerebellar 
hemisphere (in conscious controls after a 60 min wash, [125I]-MK-801 bound 
= 0.49 ±0.15 pmol/g tissue). The effects of washing on [125I]-MK-801 binding 
are illustrated in the autoradiograms in Figure 23. By washing the brain 
sections it is evident that a much higher proportion of the [125I]-MK-801 
measured in unwashed sections represents total bound [125I]-MK-801 in 
hippocampus CA1 than in cerebellar hemisphere:- conscious control rats, CA1: 
unwashed = 3.34 ± 0.90, 60 min wash = 1.74 ± 0.38 pmol/g tissue; cerebellar 
hemisphere; unwashed = 1.73 ± 0.51, 60 min wash = 0.49 ±0.15 pmol/g tissue.
Since the cerebellar hemisphere contains few NMDA receptors, 
comparison of levels of [125I]-MK-801 binding in brain regions relative to 
levels in the cerebellar hemisphere, gives a clearer indication of the 
heterogeneous distribution of [125I]-MK-801 binding sites in vivo. The 
calculated ratios of [125I]-MK-801 bound in each structure relative to 
cerebellar levels, are presented in Tables 21-24. Figures 24-26 illustrate the 
effect of washing on the [125I]-MK-801 binding ratios in four representative 
structures. These figure underline the high concentration of [125I]-MK-801 
binding sites in hippocampus CA1 region, which indicates a high level of 
NMDA receptor activation in this region relative to other brain regions. 
D-Cycloserine (3mg/kg) had no significant effect on the [125Il-MK-801 binding 
ratios, relative to cerebellar levels, in any of the brain structures examined.
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FIGURE 23: r125Il-MK-801 BINDING IN VIVO
Representative autoradiograms illustrating [125I]-MK-801 in rat brain, at the level 
of the cerebellum (A, B, C and D), and hippocampus (E, F, G and H), in serial 
sections washed for 0 (A, E), 15 (B, F), 30 (C, G) and 60 min (D, H). Note the 
gradual reduction in optical density of the cerebellar sections with increased 
duration of wash, reflecting elution of the radioligand (A - D). The level of [125I] 
-MK-801 also declines with washing in cortex, thalamus and hypothalamus, but 
is relatively conserved in hippocampus CA1 region (E-H).
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FIGURE 24: EFFECTS OF WASHOUT ON f125H-MK-801 BINDING RATIOS: 
ANAESTHETISED CONTROLS
Data represent ratios of the concentrations of [125I]-MK-801 detected in hippocampus 
CA1, posterior cingulate cortex and striatum relative to levels in the cerebellar 
hemisphere, following intravenous administration of vehicle to conscious rats. Tissue 
sections were washed for 0,15, 30 or 60 min. Data presented as mean ± SEM.
The marked increase in the ratio of [125I]-MK-801 in hippocampus CA1 region with 
increased duration of wash, reflects the greater density of MK-801 binding sites in CA1 
relative to the cerebellum. In contrast, [125I]-MK-801 ratios for striatum and posterior 
cingulate cortex indicate that these regions contain moderate levels of MK-801 binding 
sites compared to levels in CA1, but approximately 2-fold greater binding site densities 
than in the cerebellum.
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FIGURE 25: EFFECTS OF WASHOUT ON r125Il-MK-801 BINDING RATIOS: 
CONSCIOUS CONTROLS
Data represent ratios of the concentrations of [125I]-MK-801 detected in hippocampus 
CA1, posterior cingulate cortex and striatum relative to levels in the cerebellar 
hemisphere, following intravenous administration of vehicle to conscious rats. 
Tissue sections were washed for 0,15,30 or 60 min. Data presented as mean ± SEM.
There were no significant differences between the calculated [125I]-MK-801 binding 
ratios in conscious and anaesthetised control animals, for any of the CNS regions 
examined.
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FIGURE 26: EFFECTS OF WASHOUT ON r125Il-MK-801 BINDING RATIOS: 
D-CYCLOSERINE IN CONSCIOUS RATS
Data represent ratios of the concentrations of [1251]-MK-801 detected in 
hippocampus CA1, posterior cingulate cortex and striatum relative to levels in the 
cerebellar hemisphere, following intravenous administration of D-cycloserine (3 
mg/kg) to conscious rats. Tissue sections were washed for 0, 15, 30 or 60 min. 
Data are presented as mean ± SEM.
D-Cycloserine had no effect on [125I]-MK-801 binding ratios, relative to ratios in 
conscious or anaesthetised control animals, in any of the regions examined.
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2.3 Focal Cerebral Ischaemia - MCA Occlusion
Following permanent MCA occlusion, ischaemic damage was observed 
within the territory of the occluded MCA in the ipsilateral dorsolateral cortex 
and neostriatum, as illustrated in Figure 8  (Methods). These areas showed 
the morphological characteristics of infarction (vacuolisation of the 
cytoplasm, swelling of the neuropil, and nuclear pyknosis). The 
histopathological appearance of the ischaemic brain tissue in rats treated with 
D-cycloserine was similar to that in vehicle-treated animals.
The effects of D-cycloserine on infarct volume and hemisphere volume 
24h after permanent MCA occlusion are presented in Table 25. The volumes 
of ischaemic damage in both vehicle- and D-cycloserine-treated rats were 
calculated from densitometric measurement of the area of infarct at 
predetermined coronal levels throughout the brain, and knowledge of the 
distance between coronal levels. Hemisphere volumes ipsilateral and 
contralateral to MCA occlusion were similarly calculated. Areas of infarct 
and hemispheric areas at each of the coronal brain levels examined are 
illustrated in Figure 27. Intravenous administration of D-cycloserine (3mg/kg) 
15 min and 255 min after MCA occlusion did not significantly alter the 
volume of ischaemic damage in the cerebral hemisphere (volumes of
o
ischaemic tissue in vehicle- and D-cycloserine-treated rats were 191 ± 30mm 
and 189 ± 40mm , respectively). In both vehicle- and D-cycloserine-treated 
animals there was no significant change in hemisphere volume following MCA 
occlusion, although after D-cycloserine administration there was a trend 
towards increased ipsilateral hemisphere volume (760 ± 19mm vs. 642 ± 
11mm for hemispheres ipsilateral and contralateral to MCA occlusion, 
respectively, p>0.05).
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FIGURE 27: D-CYCLOSERINE AND MCA OCCLUSION
Data represent the volume of the ischaemic infarct produced by permanent 
middle cerebral artery (MCA) occlusion in the rat brain, and the volumes of the 
hemispheres ipsilateral and contralateral to MCA occlusion, following 
intravenous administration of D-cycloserine (3 mg/kg) or vehicle. Data 
presented as mean ± SEM.
D-Cycloserine had no significant effect on the volume of the ischaemic infarct, 
relative to vehicle-treated (control) animals. A slight tendancy towards 
increased hemispheric volume is evident in the hemisphere ipsilateral to 
occlusion in both control animals, and, more markedly, in D-cycloserine-treated 
rats, although there was no statistical evidence of a significant effect on 
hemispheric volume in either group.
TABLE 25
THE EFFECT OF d-CYCLOSERINE ON THE VOLUME OF ISCHAEMIC 
DAMAGE FOLLOWING MCA OCCLUSION
VEHICLE
(n=6)
D-CYCLOSERINE (3mg/kg) 
(n=6)VOLUME (mm3)
Infarct 191 ± 30 189 ± 40
Hemisphere:
Ipsilateral 691 ± 28 760 ± 19
Contralateral 623 ± 22 642 ± 11
Swelling +67 ± 12 +118 ± 21
Data are presented as mean ± SEM volume (mm'3). Data represent the 
volume of infarct produced by permanent MCA occlusion, and cerebral 
hemisphere volume ipsilateral and contralateral to MCA occlusion. D- 
cycloserine (3mg/kg) or vehicle were administered by sub-cutaneous 
injection 15 and 255 min after MCA occlusion. The volume of 
hemispheric swelling in vehicle-(controls) and D-cycloserine-treated 
animals is the difference between ipsilateral and contralateral 
hemisphere volumes within treatment groups. There were no significant 
differences in volumes of infarct or swelling between vehicle- or 
D-cycloserine-treated animals (p>0.05, Student's unpaired t-test).
TABLE 26
THE EFFECTS OF d-CYCLOSERINE AND NBOX ON LESION VOLUME 
FOLLOWING CORTICAL PERFUSION OF GLUTAMATE
LESION VOLUME 
( m m 3 )
Vehicle (Saline) 
(n=8)
20.3 ± 1.3
D-Cycloserine (3mg/kg) 
(n=5)
20.3 ± 2.1
Vehicle (5.5% Glucose) 
(n=10)
14.4 ± 0.7
N B Q X  (30mg/kg) 
(n=5)
11.1 ± 0.7*
Data are presented as mean ± SEM volume (mm3). Data represent the 
volumes of lesions measured 4h after onset of intracortical 
glutamate (0.5M) perfusion. *p<0.05, **p<0.01, significant
difference relative to contemporaneous vehicle controls (ANOVA, 
followed by Student's unpaired t -test with Bonferroni correction).
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2.4 Cortical Glutamate Neurotoxicity
2.4.1 General Observations
All physiological measurements are presented in Table 27. Intravenous 
administration of NBQX (30mg/kg x 2; 30 min before and 30 min after onset 
of glutamate perfusion) or D-cycloserine (3mg/kg; 30 min prior to glutamate 
perfusion) to halothane-anaesthetised rats had no significant effects on the 
measured respiratory parameters (arterial carbon dioxide tension, pC02, and 
oxygen tension, p0 2), or plasma glucose levels over the 4jh duration of the 
study. Rectal temperature was significantly increased following D-cycloserine 
administration, although the use of heating lamps during the experiment 
makes interpretation of drug-related temperature effects difficult. NBQX 
had no significant effect on temperature. Vehicle-treated control animals 
showed no alterations in these parameters over the experimental period.
In the anaesthetised animals, NBQX (30mg/kg) induced a moderate, 
sustained increase in mean arterial blood pressure throughout the period of 
glutamate perfusion and in the post-perfusion period, relative to levels 
in control animals which remained constant throughout the experiment. 
D-Cycloserine (30mg/kg) did not significantly alter mean arterial blood pressure 
during the experimental period, relative to levels in control animals.
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2.4.2 Assessment of Histological Damage
Perfusion of 0.5M glutamate in vehicle-treated animals produced a 
discrete cortical lesion, as illustrated in Figure 9 (Methods). The glutamate- 
induced lesion in vehicle-treated animals extended approximately 2.00mm 
anterior and posterior to the perfusion site.
The effects of D-cycloserine (3mg/kg) and NBQX (30mg/kg) on the size 
of the glutamate-induced lesion are presented in Table 26. Pretreatment 
with D-cycloserine (3mg/kg) 30 min prior to glutamate perfusion did not 
significantly alter the volume of damage produced by intracortical glutamate 
perfusion (20.3 ± 2.1mm and 20.3 ± 1.3mm in D-cycloserine and vehicle- 
treated rats respectively). Intravenous administration of NBQX (30mg/kg) 
30 min prior to, and 30 min after the start of glutamate perfusion 
significantly reduced the volume of glutamate-induced damage by 
approximately 23% (11.1 ± 0.7mm3 and 14.4 ± 0.7mm3 in NBQX- and vehicle- 
treated rats respectively (p<0.05). Figure 28 illustrates the areas of damaged 
tissue at each of the coronal brain levels examined, from which lesion 
volumes were calculated by knowledge of the distance between coronal levels.
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FIGURE 28: EFFECTS OF NBQX AND D-CYCLOSERINE ON GLUTAMATE- 
INDUCED CORTICAL DAMAGE
Graphs illustrating the effects of intravenous administration of D-cycloserine (3 mg/kg) 
and NBQX (30 mg/kg) on the extent of damage produced by intracortical perfusion of 
glutamate (0.5M) in rat brain. Points represent areas of damage in serial coronal brain 
sections at 200 fim intervals from the dialysis probe (0mm). Data are presented as 
mean ± SEM. Areas under the curves represent lesion volumes. NBQX significantly 
reduced the volume of glutamate-induced lesions, relative to lesion size in 
vehicle-treated rats (p < 0.05, ANOVA and t-test). D-Cycloserine did not significantly 
alter lesion volume.
EFFECTS OF INTRACEREBRAL BASAL FOREBRAIN MANIPULATIONS ON 
CEREBRAL GLUCOSE USE
The cerebral metabolic consequences of manipulating neuronal activity 
within the basal forebrain were investigated to gain insight into the 
contributions of basal forebrain neuronal populations, and in particular 
cholinergic neurones of the nucleus basalis magnocellularis (NBM), to 
integrated cerebral functional activity. Two different strategies were 
employed to manipulate neuronal activity:-
(i) Excitotoxic lesions of the NBM region: to assess the chronic effects 
of lesioning NBM efferents, including cholinergic projections to 
neocortex, on glucose use throughout the brain. The cerebral 
metabolic consequences of lesions produced by four different 
excitatory amino acid receptor agonists - ibotenic acid, NMDA, 
quisqualic acid and AMPA -were compared in the light of previous 
reports that of these excitotoxins AMPA shows the greatest 
selectivity for cholinergic magnocellular neurones. In addition, 
[ H]-PK-11195 in vitro autoradiography was used to gain insight into 
the extent of gliosis occurring in response to excitatory amino acid 
lesions.
(ii) Agonist stimulation of neurones within the NBM region: to
investigate the acute effects of receptor activation on cerebral 
glucose use. The effects of infusions of the excitatory amino acid 
receptor agonists NMDA and AMPA into the NBM region were 
compared with the cerebral metabolic consequences of infusion of 
the GABAa agonist muscimol.
3.1 Chronic Excitotoxic Basal Forebrain Lesions
3.1.1 General Observations
Local cerebral glucose utilisation was assessed in conscious rats 21-24 
days after they had undergone unilateral infusion of ibotenic acid (0.09M), 
NMDA (0.09M), quisqualic acid (0.09M), AMPA (0.015M) or vehicle (saline) 
into the NBM region of the basal forebrain. All animals showed a reduction 
in body weight in the initial 24h post-operative period, but recovered to pre­
operative weights within 7 days.
On the day of the [14C]-2-deoxyglucose autoradiography procedure, all 
animals exhibited apparently normal behaviour. The partially restrained rats 
were lively and alert, with spontaneous exploratory behaviour, grooming and 
sniffing. The measured physiological parameters (pC02, p02, mean arterial 
blood pressure and plasma glucose concentration) were within acceptable 
limits, indicating no adverse levels of stress in the lesioned rats. 
Physiological measurements are presented in Table 28.
Lesion placement in the NBM region was verified in cresyl violet-stained 
sections from each animal. Four animals were subsequently excluded from 
the study on the basis of poor lesion placement.
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3.1.2 Local Cerebral Glucose Utilisation 
General
The effects of ibotenic acid, NMDA, quisqualic acid and AMPA basal 
forebrain lesions on cerebral glucose use 21-24 days post-lesion are presented 
jin Tables 29-32 (see also Figures 29, 30 and 31). The statistical design adopted 
a priori involved initial comparison between treatment groups of glucose use 
levels in structures in the sham-operated (contralateral) hemisphere. There 
were no apparent significant differences in contralateral hemisphere glucose use 
values between treatment groups in any of the 49 CNS regions investigated. 
Glucose use values in structures in the vehicle-infused (ipsilateral) and sham- 
operated (contralateral) hemispheres of control animals were then compared. 
There were no apparent statistically significant interhemispheric differences in 
glucose use values in control animals in any of the brain regions examined. 
These findings suggest that there were no trans-hemispheric effects on glucose 
use following excitotoxic basal forebrain lesions, and indicate that vehicle 
infusion had no effects on cerebral glucose use. Subsequently, glucose use 
values in structures in the ipsilateral (lesioned) hemisphere of excitatory amino 
acid-infused rats were compared with values in the corresponding region of the 
ipsilateral (vehicle-infused) hemisphere of control animals.
Following ibotenic acid infusion, glucose utilisation was significantly 
increased in the NBM, but was not significantly altered in any of the other 48 
brain regions examined. Following NMDA infusion, glucose use was significantly 
increased in the hypothalamus, relative to levels in control animals, but was not 
significantly altered in any other region examined. Local rates of glucose 
utilisation were not significantly altered in any of the 49 CNS regions examined
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AMPA
FIGURE 29: GLUCOSE USE DEPRESSION IN MEDIAL PREFRONTAL
CORTEX AFTER AMPA BASAL FOREBRAIN LESIONS
Note the reduction in glucose use in the ipsilateral (left) prefrontal cortex 
(arrowed) after unilateral AMPA-induced lesion of the NBM region of basal 
forebrain, relative to cortical glucose use in the non-lesioned (right) hemisphere, 
and in vehicle-infused (sham) animals.
following infusions of AMPA or quisqualic acid.
It should be noted that the statistical analysis employed in the current 
study was extremely conservative as a consequence of the large number of 
treatment groups involved, involving initial analysis of variance (ANOVA) 
followed by independent t-tests with Bonferroni correction for multiple 
comparisons. However, insight into regions in which glucose use showed a 
tendency to change in response to excitotoxic lesions may be gained by 
examination of structures in which the analysis of variance "F" value exceeded 
the critical 5% probability level. Regional trends evident from such analysis 
are highlighted below.
Regions Distal to Infusion Site
Since the NBM provides the major cholinergic innervation of neocortex, 
any glucose use alterations in cortical regions in response to NBM lesions are 
of particular interest. Although there were no significant alterations in glucose 
utilisation in any of the cortical regions examined following infusion of any of 
the excitatory amino acid agonists (Table 29), a trend towards reduced glucose 
use was evident in frontal cortical regions following AMPA infusions. In 
particular, glucose use was reduced in medial prefrontal cortex, layer IV 
(-19%), in dorsolateral frontal cortex, layer IV (-18%) and sensory motor cortex 
(-19%) following AMPA lesions, as illustrated in Figures 29 and 30.
In subcortical regions, a trend towards reduced glucose use was evident 
in the lateral habenular nucleus following AMPA lesions (Table 31). Following 
NMDA infusion, glucose use was significantly increased in the hypothalamus 
(+20%), while a trend towards elevated glucose use was evident in the globus
208
pallidus in NMDA (+13%) and quisqualic acid (+19%) lesioned animals. Glucose 
utilisation rates in representative CNS regions are illustrated in Figures 30 and 
31.
Infusion Site
Excitatory amino acid agonist-induced NBM lesions had marked effects 
on glucose use at the infusion site. Infusions of all the agonists resulted in 
increases in glucose utilisation in the NBM, which varied between agents in the 
volume of tissue in which glucose use was elevated. Volumes of tissue showing 
increased glucose use following each excitotoxin are presented in Table 33. The 
pattern of glucose use around the infusion site following AMPA, ibotenic acid 
and vehicle infusions is illustrated in Figure 32.
Following vehicle, quisqualic acid and NMDA infusions the volume of tissue 
in which glucose use was increased was negligible, being visible in only a very 
small area of the basal forebrain on the autoradiographic image. Increased 
glucose use occurred in a slightly larger volume of tissue following AMPA (0.25 
± 0.19mm ), evident as a diffuse pattern of increased optical density in the 
region of the NBM and ventromedial globus pallidus. In contrast, glucose use 
was increased in a much larger volume of tissue following ibotenic acid than 
following any of the other agents (0.83 ± 0.37mm ), producing a relatively 
homogenous region of elevated glucose use extending dorsally from the NBM to 
the striatal/pallidal border (see Figure 32). The rank ordering of agents 
according to the volume of tissue in which glucose use was:-
Ibotenic acid >> AMPA > NMDA > Quisqualic acid = Vehicle.
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FIGURE 30: EFFECTS OF EXCITOTOXIC LESIONS ON CEREBRAL 
GLUCOSE USE: I
Glucose use in representative cortical, sensory and cerebellar regions (control 
and lesioned hemispheres) following excitotoxic lesions of the NBM. Data 
presented as mean ± SEM. None of the excitotoxins investigated significantly 
altered glucose use, but note the trend towards reduced glucose use in prefrontal 
cortex after AMPA lesions. Abbreviations: Ibo, ibotenate; Quis, quisqualate.
S t r i a t u m
o 60
■  Control 
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T h a l a m u s  ( V e n t r o l a t e r a l )
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FIGURE 31: EFFECTS OF EXCITOTOXIC LESIONS ON CEREBRAL 
GLUCOSE USE: II
Glucose utilisation in representative extrapyramidal regions (control and lesioned 
hemispheres) following excitotoxic lesions of the NBM. Data presented as mean 
± SEM. None of the excitotoxins investigated significantly altered glucose use 
in any of these regions. Abbreviations: Ibo, ibotenate; Quis, quisqualate.
LEGEND TO FIGURE 32:
Representative autoradiograms illustrating levels of [ 14C]-2-deoxyglucose 
(indicative of local rates of glucose utilisation) in coronal rat brain sections 
21-24 days ater vehicle ("sham"), AMPA or ibotenate infusion into the NBM 
region of the left hemisphere. The anatomical localisation of the infusion site 
is illustrated in the line diagram as the area of dark hatching, while the light 
hatching delineates the largest volume of tissue in which [3H]-PK- 11195 
binding increased after ibotenate infusion (see Figure 34).
Following ibotenate-induced lesions, glucose use was markedly increased in an 
area of tissue extending from the NBM into globus pallidus and striatum. In 
contrast, glucose use was increased in a small area of tissue, confined to the 
immediate vicinity of the infusion site, following AMPA lesions. Vehicle 
infusion had no apparent effect on glucose use in the basal forebrain, compared 
to levels in the non-infused hemisphere (right). Abbreviations: NBM, nucleus 
basalis magnocellularis; GP, globus pallidus.
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LEGEND TO TABLES 29. 30. 31 AND 32
Data are presented as mean ± SEM local cerebral glucose utilisation 
(jimol/lOOg/min) for structures in treatment-infused (ipsilateral) and sham- 
operated (contralateral) hemispheres, 21-24 days after infusions of NMDA 
(0.09M), AMPA (0.015M), ibotenic acid (0.09M), quisqualic acid (0.09M) or vehicle 
into the NBM region of the ipsilateral basal forebrain. *p<0.05 Significant 
difference between glucose use values in the corresponding hemispheres of 
agonist- and vehicle-infused animals (ANOVA, followed by Students unpaired 
t-test with Bonferroni correction for multiple treatment-control group 
comparisons).
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TABLE 33
VOLUMES OF BRAIN TISSUE 
EXHIBITING INCREASED LOCAL CEREBRAL GLUCOSE USE 
AND INCRFASFD f a l - P f C - l l ^  BINDING. 
FOLLOWING EXCITOTOXIC BASAL FOREBRAIN LESIONS
VOLUME / (mm3)
LCGU [*H]-PK-11195 n
Ibotenic Acid 0.83 ± 0.37 6.76 ± 1.52 5
AMPA 0.25 ± 0.19 4.64 ± 1.66 5
NMDA 0.20 ± 0.16 2.02 ± 1.29 3
Quisqualic Acid 0.17 ± 0.05 1.71 ± 0.33 5
Vehicle 0.16 ± 0.13 0.99 ± 0.55 5
Data are presented as mean ± SEM volume (mm3) of brain tissue in 
the hemisphere ipsilateral to excitatory amino acid or vehicle 
infusion into the basal forebrain, exhibiting the following 
characteristics:
LCGU: Local cerebral glucose utilisation (LCGU)
increased above the normal glucose utilisation 
level observed in vehicle-infused control 
animals.
[^I-PK-11195: [ ] —PK—11195 binding above the "normal" level
of binding observed in the corresponding region 
of vehicle-infused animals.
The excitatory amino acids infused are tabulated in decreasing 
order of tissue volume affected.
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3.1.3 I^ l-P K - Im s  Binding
[T1]-PK-11195 binds to peripheral-type benzodiazepine receptors. In the 
CNS these receptors are located predominantly on glial cells. Hence the 
pattern of [^J-PK-lllQS binding in rat brain sections gives an indication of 
the distribution of glial cells. The pattern of total and non-specific [ H]-PK- 
11195 binding in adjacent sections from an ibotenic acid lesioned rat is 
illustrated in Figure 3. Following unilateral infusions of ibotenic acid, 
NMDA, quisqualic acid or AMPA into the NBM region, [3H]-PK-11195 binding 
was increased at the infusion site relative to the corresponding region in the 
non-infused contralateral hemisphere, as illustrated in Figure 34. The volume 
of tissue showing increased [3H]-PK-11195 binding following infusion varied 
markedly between the agents infused, as shown in Table 33. Following 
vehicle infusion, [3H]-PK-11195 binding was evident only in a small volume 
of tissue in the NBM region (0.99 ± 0.55mm ). Similarly, after quisqualic acid 
and NMDA infusions, [3H]-PK-11195 binding was restricted to small volumes 
of tissue around the infusion site (1.71 ± 0.33, and 2.02 ± 1.29mm3 
respectively). In contrast, [3H]-PK-11195 binding was evident in considerably 
larger volumes of tissue following AMPA and ibotenic acid infusions (AMPA, 
4.64 ± 1.66mm3; ibotenic acid, 6.76 ± 1.52mm3). AMPA infusion produced 
a diffuse pattern of ( Hj-PK-11195 binding in the basal forebrain, with small 
regions of high optical density scattered throughout the NBM and the 
medioventral border of the globus pallidus and the substantia innominata. 
In contrast, ibotenic acid infusion resulted in dense [3H]-PK-11195 binding in 
a large region extending dorsally from the NBM to include the globus pallidus 
and medial striatal regions (see Figure 34). Therefore, of the excitatory
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FIGURE 33: f 3H1-PK-11195 BINDING IN LESIONED BRAIN
Adjacent, representative brain sections illustrating A: Total, and B: 
Non-specific [ 3H]-PK-11195 binding following unilateral ibotenate lesion of 
the NBM region of basal forebrain. Note the markedly increased [3H]- 
PK-11195 binding around the lesion site (arrow, left), compared to levels in the 
non-lesioned hemisphere. In addition, high levels of [ 3H]-PK-11195 binding 
are evident in the ventricles (arrow, right). These observations correspond with 
the known localisation of peripheral-type benzodiazepine receptors in the CNS, 
on glial cell and endothelial cell membranes (Benvenides et al., 1984). In 
contrast, non-specific [ 3H]-PK-11195 binding is homogeneous. It should be 
noted that the slightly darker appearance of section B is due to a longer 
exposure period.
LEGEND TO FIGURE 34:
Representative autoradiograms illustrating [3H]-PK-11195 binding in coronal rat 
brain sections 21-24 days ater vehicle ("sham"), AMPA or ibotenate infusion into 
the NBM region of the left hemisphere. The anatomical localisation of the 
infusion site is illustrated in the line diagram as the area of dark hatching, while 
the light hatching delineates the largest volume of tissue in which [3H]-PK-11195 
binding increased after ibotenate infusion. In vehicle-infused animals,[3H]- 
PK-11195 binding was restricted to the position of the needle tract, putatively 
indicative of mechanical tissue damage. Following AMPA infusion, a diffuse 
pattern of [3H]-PK-11195 binding was evident around the infusion site in the left 
hemisphere. In contrast, increased levels of [3H]-PK-11195 binding were evident 
in a large area of tissue around the infusion site following ibotenate, including 
NBM, globus pallidus and medial striatum. Abbreviations: NBM nucleus
basalis magnocellularis; GP: globus pallidus.
The sections shown are adjacent to those in Figure 32, illustrating glucose use in 
basal forebrain - lesioned rats.
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amino acid agonists infused, ibotenic acid produced tissue damage furthest 
from the infusion site, while quisqualic acid infusion affected the smallest 
volume of tissue of any of the excitatory amino acids infused. Rank ordering 
of the volume of tissue affected by agonist in terms of volume of l3H]-PK- 
11195 binding:-
Ibotenic acid > AMPA > NMDA > Quisqualic acid > Vehicle.
3.2 Acute Agonist Stimulation of the Basal Forebrain
3.2.1 General Observations
Local cerebral glucose utilisation was assessed in conscious rats 15 min 
after unilateral infusion of AMPA (0.0015M), NMDA (0.09M) or muscimol 
(0.03M) into the NBM region of the basal forebrain, with simultaneous vehicle 
infusion into the corresponding region of the contralateral hemisphere.
Intracerebral infusions of AMPA, NMDA or muscimol did not markedly 
alter the overt behaviour of the rats. The partially restrained rats remained 
lively and alert, showing normal exploratory behaviour, grooming and sniffing 
throughout the lh experimental period. There were no significant alterations 
in the measured physiological parameters (pC02, p02, mean arterial blood 
pressure and plasma glucose concentration) following intracerebral infusions.
All physiological measurements are presented in Table 34.
3.2.2 Local Cerebral Glucose Utilisation 
General
Intracerebral infusions of NMDA, AMPA and muscimol unilaterally into 
the NBM region of the basal forebrain produced marked alterations in glucose
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utilisation in a number of discrete brain regions. Local rates of glucose 
utilisation in each of the 50 CNS regions investigated are presented in Tables 
35-37.
The statistical analysis adopted a priori involved initial comparison of 
glucose use values in vehicle-infused (contralateral) hemispheres between 
treatment groups. Glucose use values in the vehicle-infused hemispheres did 
not differ significantly between the treatment groups in any of the structures 
investigated. Hence, statistical analysis of the effects of agonist infusions 
on glucose use was subsequently made by comparing glucose use values in the 
ipsilateral and contralateral hemispheres within each treatment group.
Cerebral Cortex
AMPA infusion produced significant reductions in glucose utilisation in 
ten of the 17 cortical regions investigated, 9 of which corresponded to 
primary projection targets of NBM efferents (medial and dorsolateral 
prefrontal cortex, medial frontal cortex (see Figure 35), sensory motor cortex, 
parietal cortex, hindlimb cortical area, anterior and posterior cingulate and 
retrosplenial cortex). Glucose use was also reduced in the agranular insular 
cortex.
NMDA infusion only significantly altered glucose utilisation in two 
cortical regions. Glucose use was reduced in ipsilateral medial prefrontal 
cortex (-18%). In contrast, a significant increase in glucose use was observed 
in medial frontal cortex, layers V-VI (+18%). Other cortical regions showed 
trends towards decreased glucose utilisation (with ANOVA "F” values 
exceeding the level required for 5% significance, but failing to reach 5% 
significance in the subsequent independent t-test with Bonferroni correction).
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These regions were medial frontal, anterior cingulate and hindlimb area 
cortex (see Figure 35).
Muscimol produced significant, although very small magnitude reductions 
in glucose use in two cortical regions, retrosplenial (-7%) and agranular 
insular cortex (-4%). No other cortical regions showed any significant 
interhemispheric asymmetries following muscimol infusion.
Sub-Cortical Regions
AMPA induced heterogeneous alterations in glucose use in a number of 
sub-cortical areas (see Tables 36 and 37). Reduced glucose utilisation was 
observed in areas of dorsolateral and ventromedial striatum (outwith the 
hypermetabolic ring around the infusion site, see below) whereas in striatal 
and pallidal regions infringing on this hypermetabolic zone glucose use was 
increased. Glucose use was also altered in other sub-cortical regions which 
were primary or secondary projection targets of striatal/pallidal efferents. 
Structures showing increased functional activity included the entopeduncular 
nucleus (+29%), substantia nigra pars compacta (caudal, +19%) and pars 
reticulata (rostral +38%, caudal +39%) (see Figures 36 and 37). In contrast, 
glucose use was reduced in mediodorsal thalamus and nucleus accumbens (- 
9%). Further, AMPA infusion reduced glucose use in the ventrolateral 
thalamus (-15%), and produced small magnitude elevations in glucose use in 
the hippocampus molecular layer (+4%) and cerebellar hemisphere (+7%) (see 
Figures 36 and 37).
NMDA infusions resulted in increased glucose utilisation in a number of 
sub-cortical regions, including striatum, pallidum and their projection targets:-
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FIGURE 37: GLUCOSE USE CHANGES IN STRIATO-PALLIDAL PROJECTION 
TARGETS FOLLOWING AGONIST NBM INFUSIONS
Cerebral glucose utilisation in the rat acutely after unilateral AMPA, NMDA or 
muscimol infusions into the basal forebrain. Data are presented as mean ± SEM, in 
treatment-infused (■) and vehicle-infused (□) hemispheres. Agonist infusions 
increased glucose use in the ipsilateral hemisphere, in regions which are primary or 
secondary components of striato-pallidal projection pathways. * p < 0.05, ** p <
0.01, significant difference relative to glucose use in vehicle-infused hemispheres.
entopeduncular nucleus (+45%), substantia nigra pars compacta (rostral, +36%) 
and pars reticulata (rostral, +19%), subthalamic nucleus (+25%), ventromedial 
thalamus (+19%), and the lateral habenular nucleus (+16%) and in the nucleus 
accumbens (see Tables 30 and 31, Figures 36 and 37).
In contrast to AMPA and NMDA, muscimol infusion into the NBM region 
induced a reduction in glucose utilisation in the external segment of the 
globus pallidus, but did not significantly alter glucose utilisation in other 
pallidal or striatal regions. However, elevations in glucose use were evident 
in some regions corresponding to striatal/pallidal projection targets, although 
alterations were smaller in magnitude than those elicited by AMPA and 
NMDA. Increased glucose use was observed in substantia nigra pars compacta 
(caudal, +37%; rostral +9%) and pars reticulata (caudal +37%; rostral, +16%), 
(see Figures 36 and 37), subthalamic nucleus (+5%) and ventromedial thalamus 
(+13%). In other CNS regions, muscimol significantly elevated glucose use 
in the medial geniculate body (+12%), inferior colliculus (+8%) and internal 
capsule (+7%).
Infusion Site
Infusions of AMPA and NMDA into the NBM resulted in marked increases 
in glucose utilisation around the infusion site clearly visible from the 
autoradiograms in Figure 38. AMPA and NMDA produced massive increases 
in glucose utilisation in the NBM itself (+76% and +83%, respectively), and 
in a ring of tissue surrounding the infusion site which extended dorsally from 
the NBM to affect the striatum and globus pallidus. The extent of this zone 
of hypermetabolic tissue could be traced in successive brain sections,
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LEGEND TO FIGURE 38:
Representative autoradiograms illustrating levels of [ 14C]-2-deoxyglucose 
(indicative of local rates of cerebral glucose use) in the rat brain acutely after 
unilateral infusions of AMPA, NMDA or muscimol into the NBM region of the 
right hemisphere. The anatomical localisation of the infusion site is illustrated 
in the line diagram. AMPA and NMDA infusions produced marked increases in 
glucose use in a ring of tissue around the NBM in the ipsilateral hemisphere, 
extending into striatum and globus pallidus ("hypermetabolic" zone). Note also 
the reduction in glucose use in ipsilateral medial cortex following AMPA and 
NMDA infusions, relative to levels in the cortex of the contralateral, 
vehicle-infused hemisphere. In contrast, muscimol increased glucose use in 
only a small area within the NBM / ventromedial globus pallidus region and had 
no apparent effect on glucose use in cortex.
High concentrations of the [14C] radiolabel are evident bilaterally in the 
dorsolateral globus pallidus of all animals. The anatomical localisation of these 
regions correspnds with the position of the tips of the chronically implanted 
guide cannulae, suggesting that the concentration of [14C]-2-deoxyglucose in 
these areas results from local tissue damage caused by insertion of the injection 
cannulae.
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extending to affect tissue ± 1.6mm and ± 1.3mm rostral and caudal to the 
locus of the infusion site in the NBM after infusions of NMDA and AMPA, 
respectively. An area of increased glucose use was also evident in the cortex 
around the position of the needle placement in NMDA-infused animals (see 
Figure 38), suggesting the possibility of NMDA back-flow up the needle tract. 
In contrast to the excitatory amino acid agonists, muscimol induced only a 
slight increase in glucose use in the NBM, restricted to a small area at the 
infusion site (see Figure 38).
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LEGEND TO TABLES 35. 36 AND 37
Data are presented as mean ± SEM local cerebral glucose utilisation 
(punol/lOOg/min) for structures in ipsilateral and contralateral hemispheres, 
acutely after unilateral infusion of NMDA (0.009M) (n=5), AMPA (0.0015M) 
(n=6) or muscimol (0.03mM) (n=5) into the NBM region of the ipsilateral basal 
forebrain. Vehicle was simultaneously infused into the corresponding region 
of the contralateral hemisphere. *p<0.05, **p<0.01 Significant
interhemispheric differences within each treatment group (ANOVA, followed 
by Student’s unpaired t-test with Bonferroni correction for multiple 
comparisons).
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CHAPTER IV 
DISCUSSION
1. FUNCTIONAL CONSEQUENCES OF AMPA RECEPTOR BLOCKADE
The cellular functions and energy requirements of cerebral tissue 
components are intimately related. Since neuronal energy requirements are 
met by oxidative catabolism of glucose, measurements of local rates of 
glucose utilisation provide direct insight into regional levels of functional 
activity within the CNS.
Glutamate is the major excitatory neurotransmitter within the CNS, its 
neurotransmitter action being mediated by a group of post-synaptic excitatory 
amino acid receptors of which four classes - NMDA, AMPA, kainate and 
metabotropic have been characterised to date. Glutamate also possesses 
neurotoxic properties, which has led to the implication of a role for glutamate 
in the pathogenesis of a number of neurodegenerative disorders. 
Consequently, the contributions of glutamate receptor subtypes to cerebral 
functional activity in normal and pathological conditions are of great interest. 
[14C]-2-Deoxyglucose autoradiography provides a means to map in vivo 
functional events following manipulations of specific glutamate receptor 
populations, as these are reflected by alterations in local rates of cerebral 
glucose utilisation. In the past, studies involving inhibition of receptor 
activity have been particularly fruitful in revealing anatomical pathways 
associated with certain receptor populations. Alterations in rates of glucose 
metabolism in discrete brain regions after systemic administration of 
competitive and non-competitive NMDA antagonists have shed light on the 
polysynaptic pathways modulated by NMDA receptor activity, and on the 
modes of action of different NMDA antagonist classes (Nehls et al., 1988; 
Chapman et al., 1989; Kurumaji e t al., 1989; McCulloch and Iversen, 1991).
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The NMDA receptor has to date been the most intensively studied of the 
glutamate receptor subtypes due to the availability of several potent NMDA 
antagonists, while research into non-NMDA receptor subtypes has until 
recently been restricted by the lack of selective, centrally active antagonists. 
In the present thesis, the [14C]-2-deoxyglucose in vivo autoradiography 
technique has been used to assess the effects of two recently developed 
potent AMPA receptor antagonists, NBQX and LY-293558, on cerebral glucose 
utilisation.
Systemic administration of both NBQX (10, 30 and lOOmg/kg) and 
LY-293558 (10, 30 and lOOmg/kg) produced marked, anatomically widespread, 
dose-dependent reductions in glucose utilisation throughout the brain. The 
metabolic depressant effects observed after administration of the highest 
doses of NBQX and LY-293558 (lOOmg/kg) were so great that cerebral glucose 
use was reduced by up to 68% in a number of brain regions, with reductions 
of greater than 50% seen predominantly in auditory, cortical and limbic 
structures. No elevations in glucose use were observed in the fifty regions 
investigated following any dose of either agent.
In view of the known pharmacologies of these two agents, the metabolic 
depression induced by NBQX and LY-293558 appears to be attributable to 
blockade of glutamatergic AMPA receptors (Sheardown et al., 1990; Ornstein 
et al., 1993). NBQX and LY-293558 both potently inhibit [3H]-AMPA binding 
in rat cortical membranes (ICgg values of 0.15jjlM and 1.35yM, respectively) 
and reduce AMPA-evoked depolarizations in the rat cortical slice 
preparations. In addition, both exhibit markedly higher affinity for AMPA 
rather than kainate receptors (approximately 30-50 fold), but have minimal
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affinity for the NMDA receptor subtype. While NBQX has negligible affinity 
for the NMDA receptor in vitro or in vivo, LY-293558 does show low affinity 
for the NMDA receptor recognition site in vitro, but has been found to have 
no effect on NMDA-induced lethality in vivot even at concentrations up to 
100 fold greater than the ED^ for AMPA-mediated effects (Sheardown et al., 
1990; Ornstein et al., 1993). The essentially similar effects of NBQX and 
LY-293558 on local cerebral glucose use observed in the present study, in 
terms of the nature, magnitude and anatomical pattern of responses, 
therefore appear to reflect the comparable pharmacologies of these two 
agents.
Despite the broad similarity in regional responses to NBQX and 
LY-293558, results indicated subtle differences in sensitivity in the effects 
of the two agents on glucose use in certain CNS regions (evident from visual 
inspection of the autoradiograms (see Figures 14 and 15) and corroborated 
by marked differences in the values of the ranking function, " /  ", for the two 
agents in a small number of regions). The use of the " /  " ranking function 
(for arithmetic derivation see Methods, Section 2.2.2) provides a means of 
assimilating all the information available from the dose-response relationships 
for each agent in each of the 50 regions investigated, and provides a valuable 
approach for comparing and contrasting the anatomical patterns of glucose 
use alterations evoked by different drug treatments. The pharmacological 
utility of the " /  " ranking function has previously been illustrated by its 
ability to separate the cerebral functional effects of the benzodiazepine 
diazepam, from those of the GABA agonists muscimol and THIP (Kelly et al. 
1986). In the present study, correlation analysis of regional f  values for
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NBQX and LY-293558 indicates that glucose use in thalamo-cortical and 
primary auditory systems is more sensitive to LY-293558 than NBQX 
(illustrated in Figure 20). In other CNS regions LY-293558 and NBQX appear 
to be more or less equipotent, or regions exhibit marginally greater 
susceptibility to NBQX. The clustering of the ”/  ” function data into two 
well accepted functional systems (thalamo-cortical and primary auditory 
areas) suggests that this phenomenon is not a random numerical artefact, but 
implies that functional heterogeneity may exist between different AMPA 
antagonists. Due to the reported high specificity of both NBQX and 
LY-293558 for the AMPA receptor subtype, and low affinity for other 
excitatory amino acid receptor subtypes, it appears unlikely that this 
heterogeneity reflects actions on other receptor populations. While 
pharmacological studies have not as yet provided strong support for the 
existence of AMPA receptor subtypes, recent molecular biological evidence 
of multiple non-NMDA glutamate receptor subunits (Keinanen et al., 1990) 
indicates there is undoubtedly diversity amongst AMPA receptors which might 
underly the observed heterogeneous functional consequences of NBQX and 
LY-293558.
In one of the 50 regions investigated, the superficial layer of the 
superior colliculus, glucose use was not significantly altered by any dose of 
either NBQX or LY-293558 (see Figure 15), despite reports of moderate levels 
of AMPA receptors in this region (Chalmers and McCulloch, 1991). The 
reason for this lack of response to AMPA blockade is unclear, but may reflect 
contributions of other transmitter systems to functional activity in this 
region.
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At first sight, the overall patterns of glucose use reductions seen 
throughout the brain following either NBQX or LY-293558 administration 
appear to reflect the distribution of receptors in the CNS, since areas in 
which glucose use was markedly depressed following AMPA receptor blockade, 
including cortical, hippocampal and thalamic regions, largely correspond to 
regions in which high densities of AMPA binding sites have been demonstrated 
in previous autoradiographic and in situ hybridization studies (Monaghan et 
al., 1984; Rainbow et al., 1984; Olsen et al., 1987; Sato et al., 1993). 
However, closer inspection reveals a number of discrepancies which contradict 
this view. Firstly, the laminar pattern of glucose use seen in the cortex of 
control animals, with highest glucose use in layer IV (which is conserved 
following both NBQX and LY-293558 administration), does not correspond with 
the reported topography of AMPA binding sites which are located 
predominantly in outer cortical layers. Most notably, the greatest magnitude 
reductions in glucose use seen in the present study occurred in auditory 
regions, despite reports of only relatively moderate AMPA binding site 
densities in these areas. However, electrophysiological evidence indicates 
that non-NMDA receptors mediate most of the excitatory input to auditory 
nuclei (Zhou and Parks, 1991), perhaps explaining the massive impact AMPA 
receptor blockade has on functional activity in these regions. Further, 
comparison of the f  values generated in the present study for 16 discrete 
brain regions, with the corresponding reported concentrations of AMPA 
binding sites (taken from Monaghan et al., 1984) indicates that there is no 
correlation between the concentration of AMPA receptors in a given region 
with that region’s glucose use response to AMPA blockade by either
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LEGEND TO FIGURE 39:
The relationship between the responsiveness of glucose utilisation in 16 brain 
regions to NBQX or LY-293558, and pH]-AMPA binding site concentrations in the 
same regions. Each data point represents the " f1 value generated from analysis of the 
entire dose-response curve of a single structure in reponse to NBQX or LY-293558, 
and specific pH]-AMPA binding site densities reported in an autoradiographic ligand 
binding study by Monaghan et al. (1984). Values were compared using Pearson's 
product-moment correlation analysis. Examination of the respective correlation 
coefficients, r, indicates that in the regions studied there is litde or no evidence of an 
association between the concentrations of AMPA receptors and the observed metabolic 
response to either NBQX (r = 0.286) or LY-293558 (r = 0.0).
The regions examined were : parietal cortex, frontal cortex (layers I-III, IV and 
V-VI), lateral and medial geniculate bodies, globus pallidus, dorsolateral striatum, 
hippocampus CA1, dentate gyrus, entorhinal cortex, lateral habenular nucleus, 
hypothalamus, olfactory tubercle, cerebellar hemisphere (molecular layer) and 
cerebellar white matter.
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FIGURE 39: RELATIONSHIP BETWEEN r3Hl-AMPA BINDING SITE DENSITIES 
AND f  VALUES FOR GLUCOSE USE AFTER NBQX OR LY-293558
NBQX or LY-293558 (see Figure 39). It therefore appears that the 
topography of cerebral glucose use alterations produced by NBQX or 
LY-293558 more likely reflect the distribution of regions functionally 
associated with AMPA receptor-mediated activity.
It should be noted that, in a small number of regions, the alterations in 
glucose use seen in the present study following NBQX (10 and 30mg/kg) 
contrast with a previous report of the cerebral metabolic effects of this drug. 
Suzdak and Sheardown (1992) reported selective increases in rates of glucose 
use in the lateral habenular nucleus, raphe nuclei, superior and inferior 
colliculus 75 min after systemic administration of NBQX (3-30mg/kg) to 
conscious rats, whereas in the present study glucose use was either 
significantly decreased, or showed a trend towards a reduction in these 
regions. An explanation for these discrepancies is not immediately obvious 
although a number of factors may contribute, such as the experimental 
protocol employed, and the timing of the procedure in view of the extremely 
short plasma half life of NBQX (t^ = 30 min; Gill, 1992).
The extent of the metabolic depression seen following LY-293558 and 
NBQX is similar, both in magnitude and in the widespread anatomical 
distribution, to glucose use reductions previously reported following 
administration of other CNS depressants, such as barbiturates (Crane et al., 
1978; Hodes et al., 1985), GABA agonists (Kelly and McCulloch, 1982: Kelly 
et al. 1986), and certain inhalation anaesthetics including chloral hydrate, 
thiopental and halothane (Sokoloff et al., 1977; Shapiro et al., 1978; Grome 
and McCulloch, 1983). However, although many pharmacological 
interventions produce reductions in glucose use, the magnitude of the effects
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seen with AMPA antagonists in the present study has only been observed 
previously following doses of barbiturates which produce complete 
electrocortical silence (Crane et al., 1978). Despite the general similarities 
between glucose use alterations produced by AMPA antagonists and other CNS 
depressants, some dissimilarities exist. For example, whereas AMPA 
antagonists markedly reduce glucose use in limbic regions, barbiturates have 
been reported to induce only moderate reductions in these areas (15-30%) at 
doses which maximally depress glucose use in thalamocortical areas (by 50 - 
60%). These observations are particularly pertinent in light of reports that 
barbiturates putatively have an inhibitory action at AMPA receptors in the 
CNS (Simmonds and Horne, 1988), but the anomalies may be explained by 
recent reports that the barbiturates thiopental, phenobarbital and 
pentobarbital exert their actions at the kainate, rather than AMPA, non- 
NMDA receptor subtype (Frandsen et al., 1990; Zeman and Lodge, 1991).
Examination of the " /  " ranking analysis has also highlighted anomalies 
between the effects of AMPA antagonists and GABA agonists. Comparison 
of f  values following AMPA antagonist administration with previously 
reported /  values generated from a dose-response study of the effects of the 
GABAa agonist muscimol (Kelly et al., 1986), suggest inter-regional disparities 
between the consequences of AMPA receptor blockade and stimulation of 
inhibitory GABAergic systems within the CNS. The differences between the 
two classes of CNS depressants are highlighted by the lack of association 
between f  values for muscimol and either NBQX (r = 0.164) or LY-293558 
(r = 0.224) treated rats, as illustrated in Figure 40.
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LEGEND TO FIGURE 40:
The relationship between the responsiveness of glucose utilisation in 36 brain 
regions to NBQX or LY-293558 and muscimol. Each data point represents the "/" 
values generated from analysis of the entire dose-response curve of a single structure in 
reponse to NBQX or LY-293558, and to muscimol. The "/ " values for the dose- 
dependent effects of the GABA^ agonist muscimol were taken from a previous 
[14C]-2-deoxyglucose autoradiographic study by Kelly et al. (1986). ”f " values were 
compared using Pearson's product-moment correlation analysis. Examination of the 
respective correlation coefficients, r, indicates that in the regions studied there is a low 
degree of association between the observed metabolic responses to muscimol and those 
to either NBQX (r = 0.164) or LY-293558 (r = 0.224)
The regions examined were : cortical regions (frontal and sensory motor (layers 
I-m, IV and V-VI), prefrontal, parietal, visual, auditory and posterior and anterior 
cingulate), lateral geniculate body, superior colliculus (superficial and deep layers), 
globus pallidus, substantia nigra pars compacta and pars reticulata, hippocampus 
molecular layer, dentate gyrus, entorhinal cortex, lateral and medial habenulae, 
mammillary body, median raphe nucleus, ventrolateral and mediodorsal thalamus, 
subthalamus, hypothalamus, inferior colliculus, superior olivary nucleus, cochlear 
nucleus, medial geniculate body, cerebellar nuclei, cerebellar hemisphere (molecular 
layer) and cerebellar white matter,.
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FIGURE 40: RELATIONSHIP BETWEEN f  VALUES FOR CNS DEPRESSANTS
Following the observations in the present study of marked respiratory 
depression after administration of both NBQX (30 and lOOmg/kg) and 
LY-293558 (30 and lOOmg/kg), concomitant with the widespread depression 
in glucose utilisation, the possibility arises that the physiological effects of 
the drugs may affect cerebral energy metabolism resulting in altered glucose 
utilisation. However, from examination of the effects of hypoxic and 
hypercapnic conditions on cortical glucose utilisation reported by Borgstrom 
et al. (1976), it seems unlikely that the alterations in arterial oxygen tension 
(p02) and carbon dioxide tension (pC02) in the present study are of a large 
enough magnitude to account for the massive reductions in glucose use. 
Borgstrom and colleagues (1976) reported that hypoxia producing an 80% 
reduction in arterial p02 for 15 min did not significantly alter the cerebral 
metabolic rate for glucose. In contrast, hypercapnia producing an increase 
in arterial pC02 from 38 ± 1 to 85 ± 2mmHg resulted in an approximate 30% 
reduction in cortical glucose use. In the present study, the highest doses of 
NBQX or LY-293558 (lOOmg/kg) increased arterial pC02 by only 
approximately 25% of the increase reported by Borgstrom et al. (1976), 
from 40 ± 1 to 50 ± 1 and 56 ± 4mmHg following NBQX and LY-293558, 
respectively. Therefore, the respiratory depressant effects of NBQX and LY- 
293558 do not appear to be responsible for the glucose use reductions in the 
present study.
In view of the capacity of AMPA antagonists to inhibit neuronal 
excitation, NBQX and LY-293558 might have been predicted to induce global 
glucose use depression throughout the CNS. Dynamic alterations in glucose 
use reflect predominantly energy-demanding activity in axonal terminals of
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polysynaptic neuronal pathways. Since non-NMDA receptor activation is 
thought to mediate glutamate-induced neuronal excitation under normal 
conditions (see MacDermott and Dale, 1987), blockade of AMPA-mediated 
excitatory events should result in decreased energy demanding activity in 
axonal terminals of polysynaptic neuronal pathways (see McCulloch, 1982). 
Thus, the ubiquity of glutamate-excitable neurones and widespread distribution 
of AMPA receptors throughout the CNS (Monaghan et al., 1984; Rainbow et 
al., 1984; Cotman et al., 1987; Collingridge and Lester, 1989) may explain the 
extensive functional depression seen following NBQX and LY-293558. 
However, as is illustrated in Figure 41, the patterns of glucose use alterations 
seen in the present study contrast strikingly with those induced by NMDA 
receptor antagonists which might also, at the most simplistic level, have been 
expected to reduce neuronal excitability and hence depress function. Instead, 
systemic administration of competitive and non-competitive NMDA 
antagonists has been found to produce heterogeneous alterations in glucose 
use. Non-competitive NMDA antagonists such as MK-801 and 
phencyclidine (PCP) markedly increase glucose use in anatomical components 
of the limbic system (in particular posterior cingulate and entorhinal cortices, 
hippocampus, mamillary body, substantia nigra pars compacta and pars 
reticulata), while moderately reducing glucose use in neocortex and the 
inferior colliculus (Weissman et al., 1987; Nehls et al., 1988; Kurumaji e t al., 
1989; McCulloch and Iversen, 1991). In contrast, while non-competitive 
NMDA antagonists produce largely similar patterns of altered glucose use, 
competitive antagonists display heterogeneous effects on glucose use. For 
example, CPP and AP7 induce few overt glucose use changes, whereas CPP-
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ene reduces glucose use in sensory regions including auditory and visual 
structures, while not markedly affecting glucose use in limbic regions 
(Chapman et al., 1989; Kurumaji et al., 1989; Inglis e t al., 1992). In addition, 
the AP7 analogue CGP-39551 (2-amino-4-methyl-5-phosphono-3-pentanoic acid 
1-ethyl ester), a potent orally active competitive NMDA antagonist, induces 
large increases in glucose use in limbic, extrapyramidal, and olfactory regions, 
but does not affect sensory regions (Chapman et al., 1991).
The basis for the differences in metabolic responses to NMDA and 
AMPA receptor blockade are not yet fully understood, although differences 
appear to reflect divergent mechanisms of actions between the drug classes. 
For example, the hypermetabolic sequelae of non-competitive NMDA 
antagonists such as MK-801 are thought to reflect the use-dependent nature 
of non-competitive receptor inhibition, which leads to potentiation of 
blockade in areas of high glutamatergic activity (Kurumaji e t al., 1989). In 
contrast, competitive NMDA and AMPA receptor antagonists will be 
competitively and readily displaced by the endogenous agonist during intense 
glutamatergic activity.
The contrasting patterns of glucose use alterations produced by NMDA 
antagonists and the AMPA antagonists NBQX and LY-293558 may have some 
bearing on the clinical utility of these drugs as anti-ischaemic agents. 
Overwhelming evidence that NMDA antagonists are potent neuroprotectants 
led to a role in the management of ischaemic injury being proposed (for 
review see McCulloch and Iversen, 1991). However, observations of marked 
focal increases in glucose utilisation in components of the limbic system after 
administration of NMDA antagonists such as MK-801, PCP and CGS-19755
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have led to major concern about the safety of these drugs, since metabolic 
changes in areas such as the posterior cingulate cortex following NMDA 
antagonist administration have been shown to precede (and may contribute 
to) the appearance of pathomorphological changes in neurones, such as 
cytosolic swelling and vacuolisation (Olney et al., 1989, 1991; Hargreaves et 
al., 1993). In addition, hypermetabolic sequelae in limbic regions have been 
suggested to be involved in the psychotomimetic properties of NMDA 
antagonists such as PCP. The absence of any focal elevations in glucose use 
following systemic administration of AMPA antagonists, as demonstrated in 
the present study, therefore suggests that the morphological changes 
associated with NMDA antagonists are an unlikely consequence of AMPA 
antagonist administration.
In the present investigation the dose range studied encompassed the 
range over which the AMPA antagonists NBQX and LY-293558 have been 
demonstrated to be neuroprotective against glutamate-mediated excitotoxicity 
and ischaemic cell death both in vitro (Choi, 1991) and in vivo. Significant 
reductions in the size of ischaemic lesions produced by middle cerebral artery 
(MCA) occlusion in the rat have been seen after dual administration of NBQX 
(30mg/kg) pre- and post-occlusion up to 60 min apart (Buchan et al., 1991; Gill 
et al., 1992), while in experimental models of global ischaemia 3 injections 
of NBQX (30mg/kg) within 30 min are typically required to significantly 
reduce neuronal injury (Sheardown et al., 1990, 1993; Buchan et al., 1991; 
Diemer et al., 1992). In addition, NBQX (30mg/kg) is neuroprotective against 
the delayed neuronal death seen in the hippocampus following transient 
forebrain ischaemia even when administered up to 24h after the initial insult,
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and under circumstances in which NMDA antagonists are ineffective (Buchan 
et al., 1991; Buchan and Pulsinelli, 1991; Diemer e t al., 1992; Nellgard and 
Wieloch, 1992; Sheardown et al., 1993). It should be noted that this 
neuroprotective dose of NBQX (30mg/kg) was the lowest dose found to 
significantly depress glucose use in any of the CNS regions investigated in the 
present study.
The impact of the novel AMPA antagonist LY-293558 on ischaemic 
neuronal death has not yet been investigated as extensively as NBQX. 
However, an initial study in a model of focal cerebral ischaemia in the cat 
indicates that LY-293558 (15mg/kg) is neuroprotective at lower doses than 
NBQX (Bullock et al., 1993). In corollary, in the present thesis LY-293558 
(lOmg/kg) significantly reduced glucose use in seven of the 50 regions 
examined, whereas NBQX (lOmg/kg) did not significantly alter glucose use in 
any regions.
In conclusion, the observations of almost global reductions in glucose 
utilisation following AMPA receptor blockade by systemic administration of 
NBQX and LY-293558, taken together with previous reports of their 
neuroprotective properties under conditions of ischaemia and glutamate- 
induced excitotoxicity, indicate that the use of AMPA antagonists as potential 
therapeutic agents for the management of cerebral ischaemia in man is 
unlikely to be complicated by concerns over adverse hypermetabolic CNS 
sequelae, in contrast to the effects of NMDA antagonists. However, it should 
be noted that there are a number of factors which may restrict the clinical 
utility of NBQX and LY-293558. These include the low solubility of NBQX 
in aqueous media and its poorly defined penetration of the blood-brain barrier
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(Gill, 1992), reports of precipitation of NBQX in renal tubercles, together with 
the evidence from the present study of CNS and respiratory depression 
following systemic administration of neuroprotective doses of NBQX (30 and 
lOOmg/kg) and LY-293558 (30 and lOOmg/kg).
2. NMDA RECEPTOR MANIPULATION
The NMDA subtype of excitatory amino acid receptors is believed to 
play an important role in processes of learning and memory. Activation of 
NMDA receptors has been linked with the mechanism of long-term 
potentiation (LTP) which is hypothesised to be intrinsic to learning and 
memory (Collingridge and Bliss, 1987). Competitive and non-competitive 
NMDA receptor antagonists have been found to block induction of LTP in both 
the hippocampus and cortex, while the competitive NMDA antagonist AP5 has 
been shown to impair learning of cognitive tasks in rats (Morris e t al., 1986; 
Danysz et al., 1988). It has therefore been suggested that compounds which 
enhance glutamatergic transmission at the NMDA receptor, such as agonists 
interacting with the NMDA receptor-associated glycine site, may facilitate 
learning and memory in pathological conditions involving impaired cognitive 
function, such as Alzheimer’s disease (AD). This proposal has gained further 
support following a report that glycine stimulation of l3H]-MK-801 binding at 
the NMDA receptor channel site is reduced in the cerebral cortex of 
Alzheimer’s disease patients (Procter et al., 1989). Observations that full 
NMDA transmitter site agonists and glycine site agonists may exacerbate 
NMDA receptor-mediated neurotoxicity, and can produce convulsions, have 
led to glycine site partial agonists such as D-cycloserine being proposed as
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putative cognitive enhancers.
D-Cycloserine is a partial agonist at the strychnine-insensitive glycine 
regulatory site on the NMDA receptor (Hood et al., 1989; Watson et al., 1990; 
Emmett e t al., 1991). This compound, which has been in clinical use as an 
antibiotic for a number of years, was initially identified as a potential 
cognitive enhancer following observations that it readily crosses the blood- 
brain barrier and is centrally active (Mandell and Sardt, 1990). D-Cycloserine 
has subsequently been found to improve performance of learning and memory 
tasks in rodents (Handelman et al., 1988; Monahan et al., 1989; Flood et al., 
1992), and has been shown in rats to reverse the impairments produced in 
learning tasks by hippocampal lesions (Schuster and Schmidt, 1992), or by 
treatment with the muscarinic antagonist scopolamine (Sirvio e t al., 1992). 
In postmortem studies, Chessell and colleagues (1991) have demonstrated that 
D-cycloserine can potentiate NMDA receptor activation, which has been shown 
to be impaired in cortical neurones of AD patients (Procter et al., 1991). 
Consistent with the partial agonist profile of D-cycloserine, Chessel e t al. 
(1991) reported that D-cycloserine (O.l-lOOpM) enhanced [3H]-MK-801 binding 
in AD cortex homogenates, producing a maximal stimulation of 64% of the 
response induced by glycine alone. At higher concentrations (>100jjlM), 
D-cycloserine exhibited antagonist properties, producing a marked reduction 
in [3H]-MK-801 binding.
In the current thesis, experiments have been performed in rats to try 
to further characterise the actions of D-cycloserine in vivo. Quantitative 
[u C]-2-deoxyglucose and [125I]-MK-801 autoradiographic techniques were 
employed to investigate the dose-dependent effects of D-cycloserine on local
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cerebral glucose use, and the effects of a putative agonist concentration of 
D-cycloserine (3mg/kg) on NMDA receptor activation, respectively. In 
addition, the effects of D-cycloserine (3mg/kg) on glutamate-induced 
neurotoxicity were investigated in models of focal cerebral ischaemia (MCA 
occlusion), and in a model of cortical glutamate neurotoxicity. The proposed 
agonist dose of D-cycloserine (3mg/kg), employed in these studies was 
determined from previous reports of potentiation of NMDA receptor-mediated 
responses in vivo, including observations of enhanced learning in behavioural 
tests (Handelman et al., 1988; Monahan et al., 1989), and increased NMDA 
receptor-mediated cGMP turnover in mouse cerebellum (Emmett e t al., 1991).
Local Cerebral Glucose Utilisation
D-Cycloserine (0.3, 3 or 30mg/kg) had no significant effects on cerebral 
glucose use in conscious rats, in any of the 51 CNS regions investigated. 
Since behavioural and biochemical studies have previously indicated enhanced 
functional activity within the brain following systemic administration of 
D-cycloserine within the range of l-10mg/kg (Handelman et al., 1988; Monahan 
et al., 1989b; Wood et al., 1989; Emmett et al., 1991), the results of the 
present study suggest that the [u C]-2-deoxyglucose technique is insensitive 
to any subtle effects on cerebral metabolism which may be associated with 
the functional consequences of D-cycloserine, within the dose range examined. 
However, examination of the dose-response curves for D-cycloserine (Figures 
21 and 22) reveals a striking degree of similarity, within regions, between 
glucose use values for each concentration investigated, with very few regions 
showing any trends towards alterations in glucose use, and a small degree of
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variance at each dose. This observation suggests that it is unlikely that any 
insensitivity in the [u C]-2-deoxyglucose method is masking biologically 
relevant glucose use alterations evoked by D-cycloserine. It should be taken 
into consideration that regional glucose use values reflect overall rates of 
glucose utilisation in a given structure, but do not allow spatial resolution at 
the cellular level. Hence, dynamic metabolic changes in one neuronal 
population within a structure may be counterbalanced by opposite changes in 
another population within the same region, resulting in no apparent glucose 
use change overall. Another factor which may influence outcome is the 
timing of the glucose utilisation measurement relative to drug administration. 
In the present study, the [u C]-2-deoxyglucose procedure was initiated 15 min 
after intravenous injection of D-cycloserine. The profile of [u C]-2- 
deoxyglucose uptake from circulating plasma into brain tissue, as described 
by Sokoloff and colleagues (1977), indicates that [14C]-2-deoxyglucose is 
rapidly extracted from plasma in a concentration-dependent manner, so that 
the bulk of the injected bolus is taken up from the plasma within the first 15 
min after intravenous injection (as illustrated in Figure 42). Hence glucose 
use measurements reflect predominantly [14C]-2-deoxyglucose uptake in the 
first 15 min of the 45 min measurement period. In the behavioural studies 
of the effects of D-cycloserine, learning tasks were assessed over the initial 
30 min period post-drug administration (Handelman et al. 1988; Monahan et 
al., 1989b). Hence the period over which [14C]-2-deoxyglucose uptake was 
measured after D-cycloserine administration is consistent with the 
experimental period employed in behavioural tests, and with measurements 
of cerebellar cGMP activity assayed 30 min post-drug (Emmett et al., 1991).
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FIGURE 42: r14Cl-2-DEOXYGLUCOSE UPTAKE FROM ARTERIAL PLASMA
Graphical representation of the time courses of [14C]-2-deoxyglucose ([14C]-DG) 
concentrations in arterial plasma and grey matter, and [14C]-2-deoxyglucose-6- 
phosphate ([14C]-DG-6-P) concentration in grey matter, over the 45 min experimental 
period following an intravenous pulse of 50 pCi [14C]-2-deoxyglucose at time 0 min 
(after Sokoloff et al., 1977). The plasma curve was derived from measurements of 
plasma [14C]-2-deoxyglucose concentrations. Tissue concentrations are average 
levels calculated from the plasma curve and the mean values of the rate constants for 
the operational equation for the procedure, k j *, k2* and kj*,  for 15 grey matter 
regions in the conscious rat (see Sokoloff et al., 1977).
Note the rapid extraction of [14C]-2-deoxyglucose from the circulating arterial blood 
over the first 15 min after intravenous injection. In excess of 75% of the isotope has 
been taken up from the plasma within 15 min of injection.
It therefore appears unlikely that the timing of the experimental protocol 
in the present study would mask any cerebral metabolic effects of d-  
cycloserine.
Although the [u C]-2-deoxyglucose in vivo autoradiography technique has 
previously proved to be a potent tool for investigating the cerebral metabolic 
consequences of numerous pharmacological and physiological manipulations, 
there are examples of pharmacological agents with known actions on function 
which do not markedly affect cerebral glucose utilisation. For instance, 
intravenous administration of the prostaglandin synthesis inhibitor 
indomethacin has previously been shown to have no significant effect on 
glucose use in the CNS, despite evidence that corresponding doses of 
indomethacin significantly reduce cerebral blood flow and inhibit cerebral 
prostaglandin synthesis (McCulloch e t al., 1982a). Since neurochemical and 
electrophysiological evidence indicates that prostaglandins are involved in 
synaptic transmission, affecting adenylate cyclase activity and cell firing 
rates in a number of brain regions, it is of interest that modulation of their 
functional activity by indomethacin is not reflected by changes in glucose use. 
These observations further support the implication from the present study 
that assessment of cerebral glucose utilisation by [14C]-2-deoxyglucose 
technique does not adequately reflect the cerebral functional sequelae of d- 
cycloserine administration.
[ ' 25U-MK-801 Binding
The density and distribution of [ IJ-MK-801 binding sites in vivo is
thought to reflect the extent of NMDA receptor activation, since MK-801 can
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only gain access to its binding site when the NMDA channel is open, during 
receptor activation. McCulloch e t al. (1992) have previously demonstrated 
that the use of [125I]-MK-801 technique to map the distribution of activated 
NMDA receptors in the brain is optimally exploited under circumstances of 
abnormal NMDA receptor activation, such as during an ischaemic insult when 
extracellular glutamate levels are markedly elevated. Hence, it was 
hypothesised that an agonist dose of D-cycloserine (3mg/kg) might potentiate 
NMDA receptor activation, resulting in elevated levels of [125I]-MK-801 
binding in the CNS. [125I]-MK-801 binding site densities were predicted to be 
highest in CNS regions rich in NMDA receptors, in particular hippocampal 
regions CA1 and CA3 (Monaghan et al., 1985). In the present study, the 
effect of D-cycloserine (3mg/kg) on [125I]-MK-801 binding in conscious rats was 
compared with levels of I125I]-MK-801 binding in conscious and halothane- 
anaesthetised control (vehicle-treated) rats. D-Cycloserine did not 
significantly alter [125!]-MK-801 binding densities in any of the 13 brain 
regions examined, relative to either control group. The pattern of [125lj- 
MK-801 binding measured by this in vivo autoradiographic technique was 
similar to the previously reported distribution of NMDA receptors determined 
in in vitro autoradiographic methods, with highest levels in hippocampal 
regions, in particular CA1, and lowest levels in the hypothalamus and 
cerebellum.
Glutamate-Induced Neurotoxicity
Following the apparent lack of effect of a putative agonist dose 
of D-cycloserine (3mg/kg) on I3H]-MK-801 binding in vivo and the
245
ineffectiveness of D-cycloserine (0.3, 3 and 30mg/kg) on local cerebral glucose 
use, it was decided to further investigate the effects of D-cycloserine 
(3mg/kg) on glutamate-mediated events under pathological conditions. Two 
experimental models were used to investigate glutamate excitotoxicity in 
vivo: permanent middle cerebral artery (MCA) occlusion, and intracortical 
perfusion of glutamate. In the light of previous in vivo demonstrations of 
agonist properties of this dose of D-cycloserine (3mg/kg) (Handelman et al., 
1988; Monahan et al., 1989b; Emmett e t al., 1991), and reports of the intrinsic 
involvement of NMDA receptor activity in the neurotoxic actions of 
glutamate (see Choi, 1987), D-cycloserine might have been predicted to 
exacerbate the effects of glutamate, via potentiation of NMDA receptor 
activity, in both models of neurotoxic damage. However, neither the volume 
of ischaemic damage produced by permanent MCA occlusion or the volume 
of neuronal damage produced by cortical glutamate perfusion, were 
significantly altered following systemic administration of D-cycloserine.
The MCA occlusion experimental model of focal cerebral ischaemia 
allows assessment of drug actions on glutamate-mediated neurotoxic events 
in vivo, in a model closely resembling the effects of stroke injury in the CNS. 
Using this model, the in vivo neuroprotective properties of a number of 
excitatory amino acid receptor antagonists, such as MK-801 and NBQX, 
have previously been demonstrated. The lack of efficacy of D-cycloserine 
in this model m a y  simply reflect the concentration of D-cycloserine, or 
alternatively, the experimental protocol employed (D-cycloserine was 
administered 15 min and 255 min after onset of ischaemia). However, 
perhaps the most likely explanation for the lack of efficacy of D-cycloserine
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in this model is the possibility of saturation of the glycine site in vivo by 
endogenous glycine, which will be discussed in greater detail later.
In contrast to the MCA occlusion model, the cortical glutamate 
perfusion model of glutamate-induced neuronal damage facilitates 
investigation of the effects of systemic drug administration on the neurotoxic 
actions of glutamate in a model which is uncomplicated by factors which may 
contribute to the mechanism of ischaemic injury, such as reduced blood flow. 
Retrograde dialysis of glutamate (0.5M) into the cerebral cortex in rats 
produces a discrete, well-defined and reproducible lesion within the cortex. 
In the present study, systemic administration of D-cycloserine (3mg/kg) had 
no effect on the size of the glutamate-induced lesion. There are a number 
of possible explanations for this lack of response to D-cycloserine. The first 
concerns the integrity of the procedure. In order to verify the utility of the 
glutamate perfusion model as a representative model of excitatory amino acid 
receptor-mediated events in vivo, the effects of the AMPA antagonist NBQX 
were investigated in the same model. NBQX has previously been shown to 
ameliorate glutamate-mediated neuronal damage in both global and focal 
models of ischaemic damage (minimum neuroprotective dose: 30mg/kg) 
(Buchan et al., 1991a; Gill et al., 1992). Consequently, NBQX (30mg/kg) was 
found to significantly reduce the volume of neuronal damage in the glutamate 
perfusion model by approximately 25% (see Figure 28).
The effects of other agents which putatively modulate glutamatergic 
activity have also been investigated previously in this model of cortical 
neurotoxicity, summarised in Figure 43 (see also Fujisawa et al., 1993). 
Systemic administration of the non-competitive NMDA antagonist MK-801,
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Vehicle MK-801 NBQX L-NAME CI-977 Vehicle DCS BW
1003c87
FIGURE 43: THE EFFECTS OF GLUTAMATERGIC MANIPULATION ON 
CORTICAL NEURONAL DAMAGE
The effects of systemic administration of previously reported neuroprotective doses of 
MK-801 (0.5mg/kg; NMDA antagonist), NBQX (2 x 30mg/kg; AMPA antagonist), 
L-NAME (lOmg/kg; nitric oxide synthase inhibitor) and CI-977 (2 x 0.3mg/kg; kappa 
opioid antagonist) on the extent of neuronal damage produced by intra-cortical glutamate 
(0.5M) perfusion, were investigated relative to the lesion volume in vehicle (5.5% 
glucose) - treated rats . In a separate study, the effects of D-cycloserine (3mg/kg; 
NMDA receptor glycine site partial agonist) and BW-1003c87 (20mg/kg; sodium 
channel blocker) were investigated in the same model, relative to vehicle (saline) - 
treated animals. Data are presented as mean ± SEM, * p < 0.05, ** p < 0.01 statistical 
difference relative to the appropriate vehicle group (ANOVA, followed by Student's 
unpaired t-test).
Agents which modify glutamate-mediated events via post-synaptic actions (ie. MK-801, 
NBQX, L-NAME and possibly BW-1003c87) produced marked reductions in the volume 
of neuronal damage in the cortex. In contrast, neither the pre-synaptic glutamate release 
inhibitor CI-977 or the putative agonist dose of D-cycloserine significantly altered lesion 
volume (see also Fujisawa et al., 1993).
or the nitric oxide synthase inhibitor L-nitroarginine methyl ester (l-NAME), 
significantly reduced lesion volume in this model. In contrast, two agents 
which putatively inhibit presynaptic release of endogenous glutamate, the 
kappa opioid agonist CI-977 (enadoline) and the sodium channel blocker BW- 
1003c87, had conflicting effects on lesion volume. CI-977 did not alter the 
volume of the lesion induced by exogenous glutamate, as might have been 
predicted from the proposed presynaptic site of action of this drug. 
However, BW-1003c87 significantly reduced the volume of glutamate-induced 
damage by approximately 50%. These results suggest that although the 
neuroprotective actions of both CI-977 and BW-1003c87 against ischaemic 
neuronal injury have been proposed to be mediated by presynaptic inhibition 
of glutamate release, a post-synaptic component of BW-1003c87 activity may 
contribute to its neuroprotective effect. Overall, these results indicate that 
the cortical glutamate neurotoxicity model is sensitive to compounds acting 
at post-synaptic excitatory amino acid receptors.
Lack o f Efficacy of  d-Cycloserine In Vivo
A number of factors may contribute to the apparent lack of effect of 
D-cycloserine in the in vivo experimental paradigms investigated in this thesis, 
including the concentrations of D-cycloserine employed, possible saturation of 
the glycine regulatory site in vivot or the statistical design of the 
experiments.
The concentrations of D-cycloserine employed in the present studies were 
selected on the basis of doses previously reported to have agonist properties 
in vivo. Handelman et al. (1988) and Monahan et al. (1989b) reported that
248
intraperitoneal injection of D-cycloserine injections of 3mg/kg, and 0.3, 3 and 
lOmg/kg respectively, enhanced performance in behavioural tests of learning. 
Further, Emmett et al. (1991) have demonstrated agonist effects of d- 
cycloserine (1.25, 5 and lOmg/kg) on the rate of NMDA receptor-mediated 
cGMP turnover in mouse cerebellum, following sub-cutaneous administration. 
Consequently, in the present thesis, the investigation of the effects of d- 
cycloserine on local cerebral glucose use employed a dose range of 0.3 - 
30mg/kg (incorporating putative agonist doses of D-cycloserine), while d- 
cycloserine (3mg/kg) was used to study the effects of agonist stimulation of 
the NMDA receptor on [125I]-MK-801 binding in vivo, and on glutamate- 
induced neurotoxicity in vivo. It is therefore of interest that these 
functionally active doses of D-cycloserine had no effect on the parameters 
measured in this thesis. However, it should be noted that the route of drug 
administration and timing of the measurement period may influence the 
detected effects of the drug. In addition, that concentrations of D-cycloserine 
which possess agonist properties seem to vary according to the experimental 
paradigm involved. With reference to this last point, three studies of dose- 
dependent behavioural effects of D-cycloserine have recently been reported 
which describe differential agonist doses of D-cycloserine. Flood et al. (1992) 
reported that subcutaneous administration of 10, 20 and 30mg/kg D-cycloserine 
significantly improved memory retention in a cognitive test in mice, while 
doses of 2.5, 5, 40 and 50mg/kg were ineffective. In a water maze task 
assessing cognitive function in mice, D-cycloserine (0.3 and lmg/kg) improved 
the learning deficit induced by scopolamine, but D-cycloserine (3mg/kg) had 
no effect (Sirvio et al., 1992). Further, Schuster et al. (1992) demonstrated
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that D-cycloserine (12mg/kg) enhanced performance in a spatial learning task 
in hippocampus-lesioned rats, following intraperitoneal administration (no 
other doses were investigated in this study). Therefore, it is possible that 
the concentration range of D-cycloserine employed in the present thesis were 
inadequate to optimally reflect the effects of D-cycloserine in the 
experimental paradigms investigated.
A critical factor influencing the efficacy of D-cycloserine in vivo is the 
extent of occupancy of the NMDA glycine site by endogenous glycine. 
Glycine site saturation could account for the lack of effect of D-cycloserine 
on cerebral glucose use, [125I]-MK-801 binding, and on glutamate-induced 
lesions. Previous microdialysis studies have indicated that concentrations of 
endogenous glycine in extracellular fluid within the brain are sufficient to 
saturate the glycine site (Butcher e t al., 1990), which might explain the 
inability of exogenously added D-cycloserine to potentiate NMDA receptor 
activity. However, evidence of enhanced performance in behavioural tests 
by D-cycloserine (Monahan et al., 1989b) suggests that there is some capacity 
for potentiation of NMDA receptor activity in vivo. In addition, the 
distribution of a recently cloned neurone-specific glycine transporter in the 
brain indicates that this transporter is expressed in regions with a high density 
of NMDA receptors, including the cortex and hippocampus (Smith et al., 
1993). Therefore, since this transporter putatively regulates extracellular 
glycine levels, it has been suggested that there may be some capacity for 
modulation of NMDA-receptor mediated synaptic transmission within regions 
containing high concentrations of the transporter, including hippocampal 
regions (for review see Kemp and Leeson, 1993).
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Another complicating factor in the analysis of D-cycloserine^ central 
action in vivo is that, as a consequence of its partial agonist properties, 
D-cycloserine may antagonise ligand binding at the glycine site in 
circumstances of glycine site saturation by an endogenous ligand (Hood et al., 
1989). Thus, under conditions in which extracellular glycine concentrations 
are elevated, such as during MCA occlusion, the systemic administration of 
a putative agonist dose of D-cycloserine may conversely antagonise NMDA 
receptor-mediated events. It is therefore possible that the lack of effect 
of D-cycloserine on infarct size in the MCA occlusion model may be due to 
an overall "cancelling out" of agonist and antagonist effects of the drug. 
Alternatively, the massive release of glutamate into the extracellular space 
during ischaemia may be so great that its effects are largely unaffected by 
a relatively trivial modulation of the NMDA receptor. Similarly, attempting 
to enhance NMDA receptor activity by D-cycloserine stimulation of the 
glycine site during cortical glutamate perfusion may also be futile, in view 
of reports that excessive NMDA receptor stimulation provokes glycine release 
to above saturating levels (Fadda et al., 1988; Hood et al., 1990).
The overwhelming impression gained from the studies performed in this 
thesis to investigate the in vivo actions of D-cycloserine is that the 
experimental paradigms employed are insensitive to the cerebral functional 
effects of this agent. In order to gain further insight into the sensitivities 
of the four approaches used, post hoc power analysis was used to calculate 
the magnitude of effect which would be detected as a statistically significant 
alteration in each of the four studies. The calculated detectable effect for 
each paradigm is presented in Table 38, based on the group sizes and variance 
of measurement in representative regions within control groups.
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TABLE 38
d-CYCLOSERINE STUDIES: METHODOLOGICAL ASSESSMENT
VARIABLE PARAMETER MEAN ± SEN (n) DETECTABLE EFFECT
Glucose Use 
(Frontal Cortex) 89 ± 4 (6) 18%
[125I1-MK-801
Binding
(Hippocampus CA1) 1.74 ± 0.38 (6) 86%
MCA Occlusion 
(Infarct Size) 1.91 * 30 (6) 62%
Cortical Lesion 
(Lesion Size) 20.3 ± 1.3 (5) 25%
Post hoc power analysis, based on group size (n) and variance within 
control groups, using representative data from studies reported in this 
thesis. "Detectable effect" is the minimum change required to elicit 
a statistically significant response in a 2-tailed analysis of the 
parameters outlined, employing the simplest experimental design of 1 
control group and 1 treatment group. a = 5%, 3 = 80%.
ICohen (1977)
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Power analysis assesses the likelihood of Type 2 (false negative) errors 
occurring within a statistical analysis. Post hoc power analysis of the data 
set generated in a given experiment gives an indication of the magnitude of 
change which would be detected as a statistically significant alteration, the 
"detectable effect" calculated in Table 38 is based on the change required to 
achieve a probability value of p<0.05 with 80% power in a simple statistical 
comparison between two groups, such as an independent t-test, using the 
experimental designs employed in the studies outlined in this thesis. The 
results indicate that local cerebral glucose use is the most sensitive of the 
measures which were used to assess the in vivo effects of D-cycloserine, 
capable of detecting small magnitude (18%) changes. Similarly, the cortical 
glutamate perfusion model is sensitive to relatively small magnitude effects. 
In contrast, in the MCA occlusion model, and especially in the [125I]-MK-801 
autoradiography procedure, power is very weak with the group sizes used (62% 
and 86% respectively), indicating a realistic possibility of false negative 
results which must be considered when assessing the experimental results. 
However, in order to be able to detect any significant effects of D-cycloserine 
using these two techniques (set arbitrarily at 20% changes), power analysis 
based on the variance observed in the present studies indicates that group 
sizes of 59 for MCA occlusion and 115 for [125I]-MK-801 autoradiography 
should be used.
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3. BASAL FOREBRAIN INTERVENTIONS
Cholinergic neurotransmission in the cerebral cortex and hippocampus 
is implicated in processes of learning and memory. In Alzheimer’s disease 
(AD), in which mnemonic function is impaired, learning and memory deficits 
have been correlated with depleted levels of cholinergic markers in the 
cerebral cortex (Bartus et al., 1982; Fibiger, 1991; Price et al. 1991). The 
nucleus basalis of Meynert (nbM), within the basal forebrain, has been 
identified as the primary extrinsic source of acetylcholine (ACh) in the 
cerebral cortex (Lehmann et al., 1980; Johnston e t al., 1981; Bigl et al., 1982). 
Hence, reports of neuronal loss in the NBM of AD patients (Whitehouse et 
al., 1982) have resulted in the proposition that nbM cholinergic dysfunction 
is critically involved in the etiology of AD (Richardson and Delong 1988).
The contribution of cortical cholinergic deafferentation to memory 
impairment has been investigated experimentally in the rat, by lesioning 
efferent projections arising from the nucleus basalis magnocellularis (NBM, 
homologous to the nbM in man). In the absence of a specific cholinergic 
neurotoxin, excitatory amino acid agonists have been widely used to produce 
axon-sparing lesions of basal forebrain neurones, including NBM projections. 
However, there are a number of problems inherent to the use of excitotoxins. 
Primarily, due to the diffuse distribution of magnocellular cholinergic 
neurones of the NBM throughout the basal forebrain (and in particular in 
dorsal globus pallidus), excitatory amino acids will destroy both cholinergic 
and non-cholinergic neurones in the basal forebrain, provided they have 
receptors for these agonists. Ibotenic acid, in particular, induces widespread 
cell death throughout the basal forebrain.
254
Investigations of the effects of basal forebrain lesions on cognitive 
function have, to date, centred on assessment of altered behaviour in tests 
of learning, memory and attention. In conjunction with observations of 
differential reductions in cortical cholinergic markers, such as choline acetyl 
transferase (ChAT) activity, these behavioural studies provide evidence of a 
dissociation in the effects of NMDA and non-NMDA receptor agonists on NBM 
neurones (Dunnett e t al., 1987; Etherington et al., 1987; Robbins et al. 1989 
a and b; Connors and Thai, 1991; Page et al., 1991). The AMPA receptor 
agonists quisqualic acid and, in particular, AMPA appear to be much more 
selective for cholinergic NBM neurones than NMDA ibotenate or KA (see 
Table 3; for review see Dunnett et al., 1991). In view of these reports, and 
in the light of PET studies which have demonstrated glucose use and oxygen 
use depression in the cortex of AD patients (Frackowiak et al., 1981; McGeer 
e t al., 1986), the effects of excitotoxic basal forebrain lesions on local 
cerebral glucose use in the conscious rat have been assessed in the conscious 
rat, as an alternative index of functional activity in the brain.
In the present study, the consequences of ibotenic acid, NMDA, 
quisqualic acid and AMPA-induced NBM lesions on cerebral glucose use were 
compared. In contrast to behavioural and neurochemical studies, 
autoradiographic assessment of glucose use by the [14C]-2-deoxyglucose 
technique provides a non-subjective method for analysing functional changes, 
as these are reflected by alterations in the cerebral metabolic rate for 
glucose, in all components of the CNS simultaneously. Previous [14Cj-2- 
deoxyglucose studies have investigated the effects of ibotenic acid and KA- 
induced NBM lesions on glucose use in the rat (London et al., 1984; Lamarca
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and Fibiger, 1984; Orzi et al., 1988), however the effects of AMPA and 
quisqualic acid-induced lesions have not previously been reported. In addition, 
the acute cerebral metabolic effects of NMDA and AMPA infusions into the 
NBM region were also assessed.
Chronic Effects of  Excitotoxic Lesions
Local rates of cerebral glucose utilisation were assessed 21-24 days after 
unilateral injections of ibotenate, NMDA, quisqualate or AMPA into the NBM 
region of the basal forebrain. The agonist concentrations, injection volumes, 
and stereotactic coordinates of the injection sites employed in the present 
study reflected the injection protocols used by Dunnett and colleagues in 
previous lesioning studies, in which deficits in cognitive or attentional 
function have been reported at a similar time point post-lesion (Dunnett et 
al., 1987; Robbins et al., 1989 a and b; Page et al., 1991). Due to the 
cryostat processing of cerebral tissue in the present study, necessitated by 
the [14Cl-2-deoxyglucose technique, it was not possible to assess cortical 
ChAT levels in the same animals in which glucose use was measured. 
However, evidence from previous studies using the same lesioning paradigms 
indicates marked cortical ChAT deficits at this time point (-30-40% after 
unilateral ibotenate and NMDA infusions, approximately -50% after 
quisqualate, and -70% after AMPA) (Dunnett et al., 1987; Robbins et al., 
1989a and b; Page et al., 1991).
In spite of reports from numerous studies of sustained functional 
depression 3 weeks after excitotoxic lesions (i.e. cortical ChAT depletion and 
behavioural impairments), significant alterations in glucose use were observed
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in only 2 of the 51 CNS regions investigated after infusions of any of the 
agonists into the NBM region. Glucose use was increased relative to control 
levels in ipsilateral NBM after ibotenate, and ipsilateral hypothalamus after 
NMDA (although the glucose use increase seen in the hypothalamus of NMDA- 
treated rats was slight and there was no evidence of interhemispheric glucose 
use differences in these animals, questioning the biological significance of this 
apparent change). It should be noted that the statistical approach employed 
in the present study was extremely conservative, due to the application of a 
Bonferroni correction factor to compensate for the large number of 
vehicle/treatment group comparisons. This approach largely rules out the 
possibility of Type I (or ’’false positive”) statistical errors, but increases the 
chance of Type II or ’’false negative” errors. Setting a significance level of 
p<0.05 in any statistical analysis represents setting an arbitrary cut off point 
for putatively ’’real” biological changes, and means that 1 in 20 statistical 
comparisons might be wrongly assigned. Due to the large number of 
comparisons involved in the present study, with 5 treatment groups, a 
Bonferroni correction factor was employed in the statistical analysis to 
reduce the number of random false positive results. However, this 
conservative approach risks masking some small magnitude, but potentially 
biologically relevant, changes in glucose use. Therefore, it is of interest to 
examine the trends in glucose use alterations observed after ibotenate, 
NMDA, quisqualate and AMPA lesions. In order to do this it was decided to 
scrutinise the data with regard to regions in which glucose use changes 
generated a probability value of p<0.05 in the independent t-test analysis prior 
to application of the Bonferroni correction factor.
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The most striking alterations in glucose use were seen at the infusion 
site in the NBM region of the basal forebrain, where all four excitatory amino 
acid agonists studied induced increases in glucose utilisation. These 
hypermetabolic effects were most marked following ibotenate and AMPA 
lesions, which produced massive increases in glucose use in sub-cortical 
regions in close proximity to the NBM (i.e. in striatum and globus pallidus). 
In contrast, glucose use was marginally increased in only a small volume of 
tissue after NMDA and quisqualate infusions. The reason for this increased 
metabolic activity at the lesion site is not certain, however it is possible that 
elevated levels of glucose use may be due to the energy-demanding processes 
of reactive gliosis. Examination of the pattern of l3H]-PK-11195 binding 
around the lesion site (which labels peripheral-type benzodiazepine receptors, 
predominantly associated with glial cells in brain tissue) indicates marked 
glial proliferation in a large volume of tissue around the infusion site 
following ibotenate and AMPA lesions. However, the contribution of 
increased metabolism in glial cells cannot be conclusively linked with 
increased glucose use at the infusion site, in view of the fact that there was 
no evidence in any animals of increased glucose use in the vicinity of the 
needle tract through the cortex, despite increased [3H]-PK-11195 binding in 
the same region (see Figures 32 and 34). Moreover, comparison of [14C]-2- 
deoxyglucose autoradiograms with [3H]-PK-11195 binding patterns in adjacent 
sections indicates that the regions in which glucose use was markedly elevated 
were restricted to the core of the gliotic tissue, as is evident from 
examination of Figures 32 and 34 . However, observations that astrocytes 
initially accumulate around the periphery of lesioned tissue and gradually
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infiltrate into the core (see Logan and Berry, 1993) support the suggestion 
that reactive gliosis may still be occurring in the lesion core 3 weeks post­
lesion. Alternatively, the increased glucose use in the lesion core may 
reflect the consequences of tissue damage on the kinetic parameters of 
deoxyglucose uptake in the NBM region.
Cholinergic neurones of the NBM region project topographically to 
neocortex. Hence, lesioning NBM efferents might be predicted to result in 
reduced metabolic activity in the terminal projection zones in cortex. In the 
present study, glucose utilisation in frontal cortical regions innervated by 
NBM efferents was not significantly altered by any of the excitotoxic lesions. 
However, metabolic depression was evident in ipsilateral prefrontal cortex 
following AMPA lesions and trends towards glucose use reductions were also 
seen in frontal and sensory motor cortex after AMPA. Reductions in glucose 
use in prefrontal and sensory motor cortex were also evident following NMDA, 
although of smaller magnitude than AMPA-induced decrements. Although 
these cortical glucose use changes failed to reach statistical significance with 
the statistical analysis employed in this study, these observations are 
particularly pertinent in view of the biochemical and behavioural evidence 
that AMPA receptors appear to show a much greater degree of co-localisation 
with cholinergic NBM neurones than NMDA receptors. The results of this 
study also highlight the lack of selectivity of ibotenic acid for cholinergic 
neurones within the basal forebrain, ibotenic acid lesions having no effect on 
cortical glucose use despite consistently producing the largest volumes of 
tissue damage of the four excitotoxins investigated. This observation is 
consistent with reports that ibotenic acid lesions produce cognitive deficits
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which can be replicated by disruption of cholinergic innervation of the 
hippocampus and cortical regions outwith the NBM projection field, which 
originate from more rostral segments of the basal forebrain cholinergic 
system (i.e. the medial septum and diagonal band of Broca (Dunnett et al., 
1991).
This study demonstrates that chronic excitotoxic lesions of the NBM 
region of the basal forebrain only minimally affect integrated functional 
activity in the CNS, as assessed by the measurement of local rates of cerebral 
glucose use. Although cortical glucose use measurements hint at a separation 
in the effects of AMPA-induced lesions from those of ibotenate, NMDA and 
quisqualate, the results from this study provide no conclusive evidence to 
support suggestions of differential contributions of excitatory amino acid 
receptor subtypes to cholinergic activity in the NBM. In the light of evidence 
of sustained cortical cholinergic dysfunction and cognitive impairment after 
excitotoxic basal forebrain lesions (Bartus et al., 1982; Arendash et al., 1987; 
Dunnett et al., 1987; Etherington et al., 1987; Robbins et al., 1989a), the lack 
of cerebral metabolic changes 3 weeks post-lesion may be accounted for by 
compensatory functional adaptation within both cholinergic and non- 
cholinergic neuronal populations in the brain. Therefore, in order to further 
investigate whether glucose use measurements provide any insight into the 
putative dissociation between NMDA and non-NMDA receptor-mediated 
events in the basal forebrain, it was decided to investigate the cerebral 
metabolic consequences of stimulating cholinergic neurones in the NBM via 
pharmacological modulation of excitatory amino acid receptor activity.
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Acute Agonist Stimulation in the Basal Forebrain
Local rates of glucose use were mapped throughout the brain acutely 
after stimulation of NMDA or non-NMDA receptor subtypes within the basal 
forebrain by NBM infusions of NMDA or AMPA, respectively. The acute 
metabolic consequences of putatively inhibiting cholinergic neuronal activity 
in the NBM region were also investigated, following manipulation of the 
GABAergic input to cholinergic NBM neurones by the GABAa agonist 
muscimol.
Unilateral infusions of NMDA and AMPA into the basal forebrain NBM 
region induced widespread, heterogeneous alterations in cerebral glucose use 
in a number of regions in the ipsilateral hemisphere. The anatomical patterns 
of glucose use changes seen after agonist infusions into the basal forebrain 
revealed activity in well-organised anatomical pathways, involving changes 
in discrete brain regions which could be grouped largely into three areas: 
the infusion site, anatomically associated cortical regions, and a number of 
anatomically or functionally related sub-cortical regions. In contrast, glucose 
use alterations following muscimol were largely restricted to ipsilateral sub- 
cortical regions.
In the vicinity of the infusion site at the NBM, NMDA and AMPA 
induced a massive increase in glucose use in a band of tissue forming a ring 
of "hypermetabolism", approximately 1.5mm radius around the NBM region. 
This area of markedly enhanced metabolic activity affected a region of tissue 
extending dorsally from the NBM into striatum and globus pallidus, and 
rostally and caudally from the infusion site, as is illustrated following NMDA 
infusion in Figure 44. At the centre of the hypermetabolic ring, a region of
261
Re
pr
es
en
ta
tiv
e 
au
to
ra
di
og
ra
m
s, 
fro
m 
the
 
sam
e 
an
im
al
, 
ill
us
tra
tin
g 
gl
uc
os
e 
use
 
ac
ute
ly 
aft
er 
un
ila
te
ra
l 
in
fu
sio
n 
of 
NM
DA
 
int
o 
the
 
NB
M 
ba
sa
l 
fo
re
br
ain
 
re
gi
on
 
(ri
gh
t 
he
m
isp
he
re
). 
Ex
ce
ss
iv
el
y 
in
cr
ea
se
d 
gl
uc
os
e 
us
e, 
re
lat
iv
e 
to 
lev
els
 i
n 
the
 
ve
hi
cl
e-
in
fu
se
d 
(le
ft)
 h
em
isp
he
re
, 
is 
ev
id
en
t 
in 
bra
in 
re
gi
on
s 
ro
str
al
 (
+1
.8
2 
and
 
+ 
0.
78
m
m
) 
and
 
ca
ud
al
 (
-0
.7
8m
m
) 
to 
the
 
in
fu
sio
n 
site
 
(N
BM
 
± 
0m
m
). 
No
te 
the
 
in
cr
ea
se
d 
gl
uc
os
e 
use
 
aro
un
d 
the
 
ne
ed
le 
tra
ct 
in 
the
 
co
rte
x 
(+
1.
82
m
m
).
unaltered glucose use (relative to the contralateral hemisphere) was evident 
in each animal examined. It is postulated that the perimeter of the 
hypermetabolic zone reflects the extent of spread of AMPA and NMDA over 
the 60 min period post-injection. The extent of spread of a given infusate 
within the brain depends on a number of factors, including the infusate’s 
molecular weight, valency and lipophilicity, and is therefore difficult to 
estimate. However, the position of the hypermetabolic ring in the present 
study is reasonably consistent with the extent of spread of dyes following 
intracerebral injection, previously reported by Myers (1966).
The patterns of glucose use around the infusion site appear to reflect 
the concentration profile of the excitotoxins, with the highest concentration 
a t the core of the infusion site, and the lowest at the periphery. Under 
normal conditions, dynamic alterations in glucose utilisation predominantly 
reflect changes in metabolic activity in neurone terminals (see Kurumaji e t 
al., 1993). Therefore, the fact that glucose use is unaltered at the core of 
the infusion site does not necessarily mean that neuronal activity in this 
region is unaffected by the infusates. Conversely, the marked glucose use 
reductions seen in the cerebral cortex following AMPA and NMDA infusions 
imply a marked reduction in energy demand in the cortex due to reduced 
terminal activity. Since the NBM provides the major extrinsic cholinergic 
innervation of the neocortex, it appears likely that the metabolic depression 
seen in cortex may be due to desensitization of cell bodies at the infusion 
site, as a result of overstimulation of NMDA or AMPA receptors by 
excessively high concentrations of the excitatory amino acids. In contrast, 
it is unlikely that the hypermetabolic response in the striatum and globus
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pallidus following NMDA and AMPA infusions reflects increased activity in 
NBM projection terminals, since, while trivial projections from the NBM 
cannot be ruled out, there is no evidence to date from anatomical or 
physiological studies of a biologically important projection from the NBM to 
these regions.
It is of interest that the massive increase in glucose use observed in the 
hypermetabolic zone closely resembles the glucose use elevations seen in the 
ischaemic penumbra following MCA occlusion, and at the perimeter of 
cortical lesions produced by glutamate perfusion (Ginsberg, 1990; Landolt et 
al. 1992). Two possible explanations for this hypermetabolic response are, 
firstly, massively enhanced presynaptic terminal activity (in an attempt to 
remove the excitotoxins from the synaptic cleft), or alternatively, abnormally 
high levels of metabolic activity in neuronal cell bodies. Therefore, at the 
perimeter of the region of excitotoxin spread, neurones appear to be exposed 
to concentrations of excitotoxins sufficient to stimulate metabolic activity 
to abnormal levels, but insufficient to desensitize cells within the period of 
exposure.
At first sight the fact that AMPA reduced glucose use in 10 of the 17 
cortical regions examined, in contrast to the 2 cortical regions in which 
glucose use was depressed by NMDA, suggests that AMPA is much more 
selective for cholinergic NBM neurones than NMDA. However, examination 
of the absolute rates of glucose use in NMDA-treated rats reveals that in a 
number of other ipsilateral frontal cortical regions, such as frontal and 
parietal cortex, glucose use levels closely resemble those seen in the 
corresponding regions of AMPA-infused animals (for example, see Figure 35).
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However, further investigation suggests that the apparent paucity of 
statistically significant glucose use changes in cortex following NMDA- 
infusion may reflect the statistical design employed in this study. The 
statistical analysis, determined a priori, initially involved comparison of 
glucose use values in the contralateral (vehicle-infused) hemisphere between 
treatment groups, to try to identify any interhemispheric drug effects. 
Trends towards reduced glucose use following NMDA were evident in a 
number of contralateral cortical regions, including frontal and parietal cortex, 
although no statistically significant differences were identified between 
glucose use levels in the three treatment groups in any of the 50 contralateral 
regions investigated. The effects of NMDA, AMPA and muscimol infusions 
on glucose use in the ipsilateral hemisphere were then analysed by comparison 
of glucose use values in ipsilateral and contralateral hemispheres within 
treatment groups. Therefore, although the observed trends towards reduced 
glucose use in contralateral frontal cortical regions following NMDA infusion 
were not large enough to reach statistical significance, they may have been 
sufficient to mask ipsilateral glucose use reductions in the subsequent inter­
hemispheric statistical analysis.
The cause of the apparent glucose use depression in the contralateral 
cortex after NMDA infusion is not clear. However, the observation that no 
glucose use alterations were evident in the contralateral hemisphere of 
AMPA- or muscimol-treated animals implies that this effect is not associated 
with vehicle infusion into the basal forebrain. In addition, changes in 
contralateral glucose use in NMDA-infused rats were confined to frontal 
cortical areas, suggesting that these alterations do not reflect global
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functional depression by NMDA, but rather are directly associated with the 
local effects of NMDA infusion, possibly due to cortico-cortical 
communication or trans-callosal spread of the infusate. These hypotheses 
are supported by visual inspection of the autoradiograms which indicate an 
area of hypermetabolism around the needle tract in ipsilateral cortex of 
NMDA-treated rats, suggesting the possibility of back flow of NMDA up the 
needle tract which may have influenced cortical neuronal activity (see Figure 
44).
In contrast to NMDA and AMPA, muscimol did not markedly alter 
glucose use at the infusion site, in regions around the infusion site such as 
the striatum or globus pallidus, or in any cortical regions directly innervated 
by NBM efferents. These results suggest that muscimol has no effect on 
cholinergic neurones in the NBM. This apparent lack of responsiveness to 
muscimol could be interpreted to reflect an inadequate dose of muscimol, 
although the concentration of muscimol employed in this study has previously 
been found to alter cognitive and attentional function following unilateral 
infusion into the basal forebrain (Muir et al., 1992b). In addition, muscimol 
infusion altered glucose use in other brain regions, for example reducing 
glucose use in cingulate cortex and agranular insular cortex. These metabolic 
alterations may result indirectly from the stimulatory effects of muscimol 
on neuronal activity in thalamic nuclei, such as the ventromedial thalamus 
which sends afferent projections to the agranular insular cortex (Guildin and 
Markowitsh, 1983), and cingulate cortex (Vogt et al., 1981).
Increased glucose use was observed in a number of subcortical regions 
acutely after infusions of AMPA, NMDA and muscimol into the basal
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forebrain. Regions affected included the substantia nigra pars compacta 
and reticulata, the subthalamic nucleus, the entopeduncular nucleus and the 
ventromedial thalamic nucleus. The common factor between these regions, 
which are not directly innervated by NBM projections, is that all are primary 
or secondary components of polysynaptic projection pathways originating in 
the globus pallidus or striatum, as is illustrated in Figure 45. Thus, 
subcortical regions in which glucose use is altered correspond with regions 
receiving efferent projections arising from the zone of hypermetabolism 
induced by NMDA and AMPA infusions (see Figure 46). The effects of 
muscimol, in contrast, are less clear cut. Glucose use was largely unaltered 
in the vicinity of the infusion site and no elevations in glucose use were 
observed in striatum or pallidum following muscimol. In spite of these 
observations, and the fact that there is no evidence to date of a major 
GABAergic subcortical projection from the basal forebrain, glucose use was 
increased in striato-pallidal projection targets following muscimol infusions 
into the NBM. These effects of muscimol are reminiscent of the 
consequences of muscimol injection directly into the striatum (Kelly and 
McCulloch, 1984).
Muscimol is postulated to indirectly modulate cholinergic neuronal 
activity in the NBM via activation of inhibitory GABAergic neurones which 
synapse on magnocellular NBM neurones (Muir et al., 1992b). The inhibitory 
nature of GABAergic neurones may, superficially, suggest that stimulation of 
GABAergic pathways will inhibit functional activity in target structures, and 
hence reduce glucose use. However, synaptic transmission in inhibitory 
pathways still requires terminal activity, and therefore the increases in
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FIGURE 46: SUMMARY OF AGONIST EFFECTS IN THE STRIATOPALLIDAL 
PROJECTION FIELD
Schematic representation of the effects of agonist NBM infusion of AMPA, NMDA or 
muscimol on cerebral glucose use in sub-cortical regions of the ipsilateral hemisphere. 
Symbols correspond to regions as illustrated in Figure 45. Shading indicates regions in 
which glucose use was significantly increased ( ^ ) or decreased ( t ).
glucose use seen in sub-cortical regions after muscimol may simply be 
indicative of activity in GABAergic projection pathways. The lack of a 
hypermetabolic response in the striatum and pallidum following muscimol 
does not rule out the possibility of muscimol spread to affect striato-pallidal 
regions, but suggests that concentrations of muscimol in these regions are 
insufficient to abnormally affect the metabolic rate in cell bodies. However, 
the concentrations of muscimol in striatum and globus pallidus may still be 
sufficient to enhance terminal activity in striato-pallidal efferents. An 
alternative hypothesis is that muscimol may overstimulate GABAergic 
neurones around the infusion site, resulting in desensitization of GABAergic 
neurones and subsequent disinhibition of sub-cortical projection pathways in 
which activity is normally suppressed by GABAergic input.
It should be noted that the experimental protocol employed, including 
the concentration, volume and stereotactic placement of infusions, will 
greatly influence the outcome of studies involving intracerebral interventions. 
This point is underlined by the disparities in reports of cortical ChAT 
depletion following NBM lesions by different experimenters, outlined 
previously in Table 3. Since the aim of the present study, to compare the 
effects of different basal forebrain manipulations on cerebral glucose use, 
arose from observations of a dissociation in the effects of different excitatory 
amino acid receptor agonists in behavioural studies reported by Muir and 
colleagues, the experimental design used in the present study closely 
resembled that of Muir et al. (1992b, and personal communication). In 
investigations of the acute effects of unilateral basal forebrain infusions on 
acquisition of a conditional visual discrimination task (a learning test), and
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on a five-choice serial reaction time task (an attention test), Muir and 
colleagues have found that NMDA (0.09M) and AMPA (0.0015M) impaired 
performance in the attentional task (but not the learning task), while doses 
10 fold lower did not affect performance in the same task (Muir, personal 
communication). Similarly, muscimol (0.03mM) was the lowest dose found 
to impair performance in both the attentional and learning tasks. Therefore, 
the same concentrations were used in the present study of local cerebral 
glucose use (10 fold lower than the minimum doses found to chronically impair 
performance in the same behavioural tests, performed by the same 
investigators, 3 weeks post-lesion). In addition, the measurement period in 
the [u C]-2-deoxyglucose study was selected to reflect the assessment period 
employed in the behavioural tests.
The present study has demonstrated overwhelmingly that the acute 
cerebral metabolic consequences of NBM infusions of NMDA, AMPA and 
muscimol are not restricted solely to the NBM and functionally associated 
areas, but also have a profound effect on activity in sub-cortical regions not 
directly associated with the infusion site. Rather, sub-cortical glucose use 
changes appear to reflect an action of the infusates on neurones in the 
striatum and globus pallidus. These observations have important consequences 
for the interpretation of deficits seen in behavioural tests of cognitive 
function following agonist infusions, since it is evident that the behavioural 
deficits reported after NMDA, AMPA and muscimol cannot be attributed to 
an action solely on cholinergic NBM neurones. Further, the effects of the 
infusates on striato-pallidal neurones, with concomitant alterations in 
metabolic activity in a number of thalamic nuclei associated with movement
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control, suggest that deficits in performance of behavioural tasks following 
NBM manipulations are not necessarily representative of cognitive or 
attentional impairments, but may also reflect impaired ability to perform a 
given task.
Functional Plasticity Following Basal Forebrain Interventions
The acute and chronic effects of basal forebrain manipulations on 
glucose use imply that although metabolic activity in the brain is strikingly 
altered immediately after excitatory amino acid infusions into the basal 
forebrain, the cerebral metabolic sequelae are transient - glucose use 
returning to basal levels within 3-4 weeks in areas distal to the infusion site. 
Since the cortex is the primary projection target for cholinergic NBM 
efferents, the metabolic recovery seen in cortex after excitotoxic basal 
forebrain lesions is of particular interest, in view of the concomitant neuronal 
loss in the NBM, reports of persistent deficits in neurochemical cholinergic 
markers in the cortex, and sustained learning the memory impairment 
(Arendash et al., 1987; Orzi e t al., 1988; for review see Dunnett et al., 1991). 
In addition, a number of other studies have also reported biphasic effects of 
NBM lesions on glucose utilisation, with initial reductions in cortical glucose 
evident 3 or 4 days post-lesion, recovering to basal levels within 4 weeks 
despite sustained ChAT deficits (ibotenate lesion: London e t al., 1984; 
Lamarca and Fibiger, 1984; KA lesion: Orzi e t al., 1988; electrocoagulation: 
Kiyosawa et al., 1989; Yamaguchi et al., 1990).
A number of mechanisms may contribute to metabolic recovery, all of 
which implicate compensation or adaptation to deafferentation. One possible
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explanation is cholinergic reinnervation of the cortex by neuronal sprouting, 
either from residual intact neurones in the NBM, from the contralateral NBM, 
or from other cholinergic neuronal populations such as intrinsic cortical 
neurones. However, evidence of sustained long-term depression in cortical 
ChAT activity following unilateral NBM lesions in rat and baboon studies 
makes cholinergic reinnervation appear unlikely (London et al., 1984; 
Kiyosawa et al., 1989). Nevertheless, this possibility cannot be ruled out in 
the light of reports that deficits in other biochemical markers of cholinergic 
function, such as acetylcholinesterase (AChE) activity, do not necessarily 
parallel the long-term ChAT deficits (Bartus e t al, 1985).
Other mechanisms which may contribute to metabolic recovery include 
possible adaptation within cholinergic projection fields to increase the 
sensitivity of intact neurones to AChE, or alternatively to increase the 
densities of post-synaptic receptors (McKinney and Coyle, 1982). Alterations 
in other neurotransmitter systems in the cortex have also been reported 
following basal forebrain lesions in the rat, including GABA, 5-HT and 
peptidergic systems (Arendash et al., 1987), suggesting the possibility of 
transynaptic reorganization in damaged tissue. Further hypotheses include 
the possibility of indirect compensatory effects of NBM lesions on cortical 
metabolic activity via NBM-thalamic connections, or recovery of damage to 
non-cholinergic neurones in the NBM (for review see Kiyosawa et al., 1989). 
Metabolic recovery appears to be a general phenomenon in deafferentated 
cortex, cortical glucose use recovery has also been observed for example 
after orbital enucleation (Chalmers and McCulloch, 1991). In addition, 
metabolic recovery has been witnessed following unilateral sub-cortical
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lesions, for example hippocampal glucose use recovery following medial 
septum lesions in rats despite a persistent decrease in AChE activity (Harrell 
and Davis, 1984). In contrast, Motohashi et al., (1986) have reported that 
deafferentation of the dorsal raphfc by habenula lesions does not result in 
metabolic recovery. These observations infer that the capacity of a region 
for functional recovery will be inherently dependent on the magnitude and 
specificity of the denervation involved, and on the nature of the extrinsic 
innervation of the deafferented region.
The results presented in this thesis suggest that the [14C]-2-deoxyglucose 
autoradiographic method is insensitive to subtle functional changes at chronic 
time points post-lesion, putatively due to the masking of altered metabolic 
activity in one transmitter system by compensation in another. This leads to 
the suggestion that perhaps only pharmacological or behavioural challenge will 
be able to shed light on the long-term functional consequences of excitatory 
amino acid receptor manipulations in the basal forebrain. In addition, these 
results of apparent functional plasticity contrast with the reported chronic, 
sustained deficits in cortical metabolic activity in Alzheimer’s patients 
(Frackowiak et al., 1981; McGeer et al., 1986), leading to speculation that 
decreased cortical glucose utilisation in AD is not related to degeneration 
of the nbM-cortical projection.
The investigations into the effects of different basal forebrain 
manipulations on local cerebral glucose use in this thesis were prompted by 
suggestions of a dissociation in the effects of NMDA and non-NMDA agonists 
on basal forebrain cholinergic neurones. However, the proposition that 
AMPA receptors are co-localised with basal forebrain cholinergic neurones
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to a greater extent than other glutamatergic receptor subtypes is supported 
only to a limited extent by the results of the present glucose use studies. The 
most obvious observation from these studies is that excitatory amino agonist 
infusions into the basal forebrain acutely alter glucose utilisation in numerous 
brain regions, which are not restricted solely to the NBM and its cortical 
projection targets. The nature and magnitude of the effects of NMDA, 
AMPA and muscimol on metabolic activity in sub-cortical regions suggest that 
functional alterations in these areas may influence animals* performances in 
behavioural tasks, thus complicating interpretation of behavioural studies of 
the effects of basal forebrain interventions on cognitive function.
4. OVERVIEW
The 2-deoxyglucose autoradiography technique has been proved to be a 
potent tool in neuroscience research, providing a unique opportunity to 
localise and quantify alterations in metabolic demand associated with CNS 
challenge (Sokoloff, 1981; Kurumaji et al., 1993). The utility of this 
procedure is based on the close coupling which has been demonstrated to exist 
between functional activity and energy consumption in the CNS, and is 
enhanced by the capacity of the technique to measure local rates of glucose 
utilisation simultaneously in discrete regions throughout the CNS in conscious 
animals. Consequently, [14C]-2-deoxyglucose in vivo autoradiography has 
been widely used to investigate the cerebral metabolic consequences of 
pathological, physiological and pharmacological challenge in experimental 
animals, and the technique has been adapted to allow non-invasive metabolic 
mapping in man using positron emission tomography (PET). Cerebral glucose
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use studies have been found to be particularly beneficial in mapping the global 
patterns of dynamic metabolic alterations, such as the acute action of drugs 
in the brain, or the massive functional disturbances occurring in acute 
pathological states, such as during an ischaemic insult (see Ginsberg, 1990). 
As a result, the contributions of numerous neurotransmitter systems within 
the brain to cerebral functional activity have been investigated using the 
[14Cl-2-deoxyglucose technique in combination with a variety of techniques 
to manipulate receptor activity, such as systemic drug administration, direct 
intracerebral administration of receptor agonists or antagonists, or lesioning 
specific projection pathways within the brain.
Due to glutamate’s critical role in the CNS as the major excitatory 
neurotransmitter, and it’s involvement in excitotoxic processes within the 
brain, the effects of glutamate receptor manipulations on local rates of 
glucose use have been extensively investigated (for review see Kurumaji et 
al., 1993). Studies have revealed that antagonist manipulation of excitatory 
amino acid receptor subtypes generally yields more information about the 
location of glutamate-mediated events within the CNS than agonist 
administration, exemplified by the selective nature of glucose use responses 
to intravenous administration of kainic acid, (Cellik e t al., 1979), compared 
to the widespread effects of NMDA or AMPA receptor blockade (Kurumaji 
et al., 1989a and the present study). These discrepancies appear to reflect 
both the ubiquitous distribution of glutamate in the CNS and the importance 
of its role as an excitatory neurotransmitter in integrated functional 
activity,and suggest that exogenous agonist stimulation of an excitatory amino 
acid receptor subtype will have little or no dynamic impact on neuronal
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activity under normal conditions, whereas inhibition of transmission at post- 
synaptic glutamatergic receptors has a dramatic effect on functional activity 
in polysynaptic pathways. This is supported by the results of the present 
studies, in which putative agonist stimulation of NMDA receptors by 
o-cycloserine had no effect on cerebral glucose use, while the AMPA receptor 
antagonists NBQX and LY-293558 produced almost global metabolic 
depression.
In other excitatory transmitter systems the metabolic responses to 
systemic agonist and antagonist administration appear to be more 
heterogeneous. For example, enhancement of central cholinergic 
transmission by systemic administration of oxotremorine, a muscarinic 
receptor agonist, results in pronounced elevations in glucose use in a number 
of brain regions, and principally in structures involved in motor function such 
as motor cortex, the globus pallidus, subthalamic nucleus, nigro-striatal 
system and cerebellum (see Kurumaji et al., 1993). In contrast, inhibition 
of cholinergic activation by the muscarinic antagonist scopolamine selectively 
alters glucose use, resulting in metabolic depression in a small number of 
regions, while increasing glucose metabolism in the cerebellar vermis and the 
reticular formation (Hel6n and London, 1984). Manipulations of inhibitory 
neurotransmitter systems have also indicated diversity amongst different 
transmitter systems in terms of the localisation and nature of their effects 
on functional activity in the brain. For instance, whereas manipulation of 
dopaminergic systems by both agonists or antagonists produce extremely 
highly regionally-specific glucose use alterations, responses to GABA receptor 
stimulation are widespread, as has been discussed previously (see Introduction,
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Section 3.1.1; see also McCulloch, 1982).
The pattern of dynamic events acutely following intracerebral injection 
of agents is generally markedly different from the cerebral metabolic 
consequences of systemic administration. This is highlighted by the 
pronounced glucose use alterations seen, in the present study, following 
infusion of excitatory amino acid agonists into the NBM region of the basal 
forebrain. Local rates of cerebral glucose utilisation were altered in regions 
corresponding to the projection fields of the NBM, and of striatum and globus 
pallidus. Hence, following administration of agents which are capable of 
modifying dynamic neuronal activity, assessment of alterations in local rates 
of glucose utilisation provides insight not only into the location of specific 
receptor subtypes within the brain, but moreover into functional pathways in 
which activity is influenced by specific receptor manipulations.
In contrast to the acute effects of basal forebrain receptor 
manipulations, chronic excitotoxic NBM lesions appear to have no effect on 
cerebral glucose use, putatively due to functional plasticity in deafferentated 
regions (London et al., 1984; Orzi et al., 1988; Kiyosawa et al., 1989; and 
present study). However this lack of effect of chronic lesions on glucose 
metabolism is not characteristic of all lesion paradigms. For example, 
following chronic, unilateral excitotoxic lesions of the striatum with kainic 
acid, resulting in interruption of predominantly GABAergic striatofugal 
projections, pronounced increases in glucose use have been observed in the 
primary projection targets of striatal efferents - the ipsilateral globus pallidus 
and substantia nigra pars reticulata (Kelly et al., 1982). In these structures 
the striatal projection represents the major afferent input. Therefore, the
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chronic metabolic sequelae of neuronal lesions appear to depend on the region 
lesioned and its structural and functional association with other brain regions.
In conclusion, the results of the present local cerebral glucose use 
studies in ra t brain have highlighted some of the strengths and weaknesses of 
using the [14C]-2-deoxyglucose technique to gain insight into functional events 
in vivo. It is clear from the cerebral metabolic sequelae of the excitatory 
amino acid receptor-mediated events outlined in these studies that this 
autoradiographic technique is maximally exploited in situations in which there 
is capacity for dynamic modulation of neuronal activity, such as during 
excitatory amino acid receptor blockade. However, meaningful 
interpretation of local alterations in rates of cerebral glucose utilisation 
following receptor manipulations critically requires consideration of the 
anatomical distribution of receptors, in conjunction with an appreciation of 
functional pathways within the CNS in which activity is influenced by these 
receptor populations. The development of quantitative in vitro ligand binding 
autoradiography techniques has provided a means of mapping the distributions 
of receptors and receptor subtypes within the CNS, while in vivo ligand 
binding procedures, such as [125I]-MK-801 in vivo autoradiography, facilitate 
enhanced characterisation of the functional status of receptor populations in 
the normal brain, and under conditions of CNS challenge. Therefore, the 
application of other techniques in parallel with assessment of cerebral glucose 
use, such as quantitative in vitro and in vivo binding autoradiography, or 
biochemical, electrophysiological or histological investigation of the 
consequences of receptor manipulation, augments understanding of the 
contribution of neurotransmitter systems to integrated functional activity 
within the CNS.
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